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ABSTRACT 
YUAN ZHANG: Systemic Delivery of Phosphorylated Nucleoside Analogues and siRNA 
via LCP Nanoparticles for Cancer Therapy 
(Under the direction of Leaf Huang, Ph.D.) 
     Nucleoside analogues are a significant class of anticancer agents. As prodrugs, 
they terminate the DNA synthesis upon transforming to their active triphosphate metabolites. 
However, several in vivo delivery hurdles compromise their application in clinical settings. 
To address these delivery problems, we encapsulated the phosphorylated nucleoside 
analogues (i.e. gemcitabine triphosphate (GTP), or gemcitabine monophosphate (GMP)) into 
a novel Lipid/Calcium/Phosphate nanoparticle (LCP) platform. The therapeutic efficacy of 
drug loaded LCPs was evaluated in a panel of human non-small-cell lung cancer (NSCLC) or 
human pancreatic cancer xenograft models. Drug-loaded LCPs induced cell death and 
arrested the cell cycle in the S phase. In vivo efficacy studies in mice showed that 
intravenously injected drug-loaded LCPs triggered effective apoptosis of tumor cells, 
significant reduction of tumor cell proliferation and cell cycle progression, leading to 
dramatic inhibition of tumor growth, with little in vivo toxicity. Additionally, LCPs 
significantly prolonged the blood circulation of the entrapped GTP as compared to the free 
drug. The current study offers preclinical proof-of-principle that many active nucleotide or 
phosphorylated nucleoside analogues could be encapsulated in the LCP nanoplatform for 
systemic delivery. 
In order to suppress the tumor progression more effectively, gene therapy by RNAi 
was combined with gemcitabine chemotherapy, by formulating multiple therapeutic agents 
into one single nanoparticle. LCP encapsulating both VEGF siRNA and GMP, or LCP 
encapsulating both c-Myc siRNA and GMP were constructed. In vivo responses of combined 
 iv 
therapies were compared with individual monotherapies in NSCLC xenograft model or 
NSCLC orthotopic model. In vivo efficacies of LCP formulations were evaluated by caspase 
activation, apoptosis induction and proliferation reduction, as well as tumor growth 
inhibition. Anti-angiogenic effects and in vivo toxicities were also evaluated. The current 
studies demonstrated the plausibility of incorporating multiple nucleic acid molecules and 
phosphorylated small molecule drugs, targeting to different pathways, into a single 
nanoparticle formulation for profound therapeutic effect. 
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1.0  RNA DRUG DELIVERY APPROACHES  
1.1 INTRODUCTION 
siRNA has a high potential in therapeutic applications. siRNAs are noncoding for 
proteins and they induce a sequence specific mRNA degradation. Since they do not 
interact with DNA transcription, there is a reduced concern about possible adverse gene 
alteration
1
. siRNA can be utilized as a therapeutic drug for gene silencing for a wide 
range of target proteins to potentially treat various diseases
2
. The drug siRNA molecule 
can target any mRNA of interest, regardless of their cellular location of the translated 
proteins. Furthermore, siRNA is very potent, as only a few siRNA molecules per cell are 
enough to produce effective gene silencing
3, 4
.  
1.2  RNA MOLECULES WITH POTENTIAL FOR CANCER TREATMENT 
RNA interference (RNAi) is a process that a specific messenger RNA (mRNA) is 
targeted for degradation to inhibit the synthesis of the encoded protein. Two types of 
small RNA molecules – microRNA (miRNA) and small interfering RNA (siRNA) – are 
central to the RNAi function. It is known that both miRNA and siRNA participate in 
carcinogenesis, either inhibiting suppressor genes, or stimulating oncogenes. 
The initiation step of RNAi pathway is that the double strand (ds) RNAs are 
processed into 21-23 nucleotide small interfering RNAs (siRNA) by an RNase III-like 
enzyme called Dicer. Then, the siRNA assemble into endoribonuclease-containing 
complexes known as RNA-induced silencing complexes (RISCs). RISC uses the siRNA 
as a template for recognizing complementary mRNA. The proteins in RISC unwind 
siRNA, keep the antisense strand and degrade the sense strand. The antisense strand in 
the RISC recruits the corresponding mRNA in a sequence-specific manner, at which time 
a protein component of RISC called Slicer cuts the mRNA in the middle of the binding 
region. The cut mRNA is recognized by the cell as being abnormal and is subsequently 
destroyed, resulting in gene silencing (Fig. 1.1). As RNAi relies on the sequence-specific 
interaction between siRNA and mRNA, siRNA can be tailored to silence almost any 
gene. Besides naturally generated siRNA from a long dsRNA, siRNAs that have been 
chemically synthesized or created by in vitro transcription systems can also induce gene 
silencing. Moreover, the multiple administration of synthetic siRNAs achieved long-term 
silencing effect of the target gene without disrupting the endogenous miRNA pathways
5
. 
In the case of miRNA, a miRNA-induced silencing complex (miRISC) associates with 
the mature miRNA, and the complex binds to the 3’ untranslated region of mRNA and 
blocks translation. Many miRNAs form imperfectly complementary stem-loop structures 
on the target sense strand of mRNA, as opposed to siRNA, which require near-perfect 
match.  
 2 
 
Figure 1.1 The mechanism of RNAi (Adapted from Hannon GJ, Nature 418, 
244-251, 2002) 
1.3 CHEMICAL MODIFICATION STRATEGIES 
Although a double-stranded RNA is more stable than a single stranded RNA, unprotected 
siRNA can be quickly degraded in and outside the cells. In order to improve the stability 
of siRNA for prolonged circulation, chemical modification of siRNA has been attempted 
without compromising its potency. Various positions within the siRNA duplex have been 
chemically modified in a wide variety of ways to confer nuclease resistance.  
As increasing requirements for effective RNAi, chemical modifications can also be used 
to optimize potency as well, via features such as target-binding affinity by modulating 
hybridization on-rate and off-rate, conformational preorganization (A-form helical 
structure) and duplex flexibility. Part of the increase in potency may be due to the 
increased nuclease stability of the chemically modified siRNA.  
 3 
Chemical modifications can also be used to reduce the immunostimulatory properties of 
siRNAs
6
, which is considered a potentially dangerous off-target effect. 
1.3.1  Sugar modification 
The most widely used siRNA modifications are on the sugar moiety. Early studies 
showed that A-form duplex structure is important, the 2’-OH is not required for active 
siRNA
7. So the 2’ position has been extensively modified. For example, 2’-O-
methylation of RNA increases binding affinity and nuclease stability. Bulky 2’-
substituents are not well-tolerated in the siRNA duplex. The 2’-OH groups of siRNA in 
both strands can be converted at random into 2,4-dinitrophenyl ethers (2’-O-DNP), which 
shows improved binding affinity, nuclease resistance and potency. Fluorine substituent at 
the 2’-position can be functional and active throughout the sense and antisense strands. 
The 2’F-RNA-modified siRNA duplex can increase serum stability and the duplex 
binding affinity. Capodici et al
8
 incorporated fluorinated CTP and UTP modifications 
into siRNA, and these fluorine-derivatized siRNAs yielded equivalent activity to 
unmodified siRNA. The modification could protect the siRNA from RNase A and could 
be delivered without the transfection reagent in the presence of serum. A fully modified 
siRNA composed of 2’-O-Me and 2’F-RNA modified nucleotides showed 500 times 
more potency than the unmodified RNA
9
, and significantly reduced immunostimulatory 
activity
10
.  
Locked Nucleic Acid (LNA) is an RNA mimic in which the ribose sugar moiety is locked 
by an oxymethylene bridge connecting 2’-C and 4’-C. LNA modification possesses high 
binding affinity and excellent specificity toward complementary DNA or RNA 
oligonucleotides. In addition, LNA modified oligonucleotides improve the resistance to 
 4 
enzymatic degradation and show high stability in biological system
11, 12
. Introduction of 
LNA nucleotides in siRNA, namely, LNA-modified siRNA or siLNA, could substantially 
increase the thermal stability of the modified RNA duplex without compromising the 
efficacy of RNAi
13
, and reduce the off-target gene regulation comparing to the 
corresponding unmodified siRNA
14
.  
1.3.2 Nucleobase modification 
Some modified bases can be used to stabilize A-U base pairs, although the activity of the 
modified RNA may be somewhat reduced. Examples are 5-Br-Ura and 5-I-Ura instead of 
uracil, diaminopurine instead of adenine. 2-thiouracil, 4-thiouracil, dihydrouracil and 
some uracil analogs are also used, which could increase binding affinity, potency and 
specificity if placed appropriately within the duplex. For example, 2-thiouracil base at the 
3’-end of the antisense stand and a dihydrouracil base at the 3’-end of the sense strand 
make the modified siRNA duplex more active
15
. 
1.3.3 Terminal modification 
The terminal end of each strand can be modified by 5’-end chemical phosphorylation. 
Antisense strand phosphorylation helps to ensure high potency, especially when the 
strand is modified. Furthermore, various groups can be conjugated to the ends of a siRNA 
duplex, especially the terminal end of the sense strand. Fluorescent dyes or biotin are 
conjugated to the RNA terminal ends to allow biochemical studies. Cell penetrating 
peptides (CPPs) are short peptides that facilitate cellular uptake of various cargos. 
Conjugation of cell penetrating peptides (CPPs) via disulfide bond and lipophilic groups 
such as steroids and lipids may help with siRNA delivery through improving its stability, 
facilitating penetration and cellular uptake. Abes et al
16
 and Moulton et al
17
 conjugated 
 5 
arginine-rich CPPs and penetratin to oligonucleotides for efficient delivery of nucleic 
acid cargos. Generally, the 5’-end of the antisense strand is most sensitive to 
modifications
18. Attaching a group to an antisense 5’-phosphate does not necessarily 
eliminate RNAi activity
19
.  
1.4 CHALLENGE IN RNA DELIVERY 
1.4.1 Chemical stability and structure modification  
Naked siRNAs are highly susceptible to nuclease degradation especially in vivo. In order 
to allow siRNA to survive long enough to maintain an acceptable level in tissues, its 
degradation must be minimized or at least significantly delayed. Chemical modifications 
of siRNA have been extensively used to achieve enhanced resistance to nuclease-induced 
degradation
20. Chemical modifications can be induced to the 5’- or 3’- terminus, 
backbone, sugar and nucleobase of siRNA, which could increase the stability of siRNA 
duplex and retain or enhance their gene-silencing activity, and in some cases, 
significantly reduce the immunogenicity as well. Effective design and modification of 
siRNA can also allow minimization of the potential sequence-dependent off-target 
effects. For example, 2’-O-methyl ribosyl group substitution at position 2 in the sense 
strand could reduce silencing of most off-target transcripts
21
. 
 
 
 
 
 6 
Table 1.1 Some structures of siRNA modifications 
Sugar modification 2’-O-Me-RNA 
 
2’-O-DNP-RNA 
 
2’F-RNA 
 
LNA 
 
Nucleobase modification 5-Br-Ura 
 
5-I-Ura 
 
2-thiouracil 
 
4-thiouracil 
 
diaminopurine 
 
dihydrouracil 
 
Terminal modification Cholesterol conjugates 
 
CPP conjugates 
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1.4.2 Extracellular delivery stage 
The most important challenge in siRNA therapy is the issue of delivery. siRNA is 
negatively charged hydrophilic molecules so that it has difficulty in passing through 
negatively charged hydrophobic cellular membranes by passive diffusion. In vivo 
delivery of naked siRNA to appropriate disease sites remains a considerable obstacle 
because of rapid enzymatic digestion in the plasma and renal elimination. Limited 
penetration across the tumor capillary endothelium and inefficient cellular uptake by 
cancer cells further limit the use naked siRNA as a drug formulation
3
. Thus, developing 
effective in vivo delivery systems is critical to overcome these difficulties. The delivery 
vectors should be biocompatible, biodegradable, nonimmunogenic, and can provide 
target tissue-specific distribution after systematic administration, avoiding rapid hepatic 
or renal clearance. Generally, nanoparticles with a mean size around 100-200 nm are 
ideal for tumor targeting, because they can accumulate in the tumor leaky vasculature via 
the enhanced permeability and retention (EPR) effect after i.v. administration. However, 
the circulating nanoparticles are prone to the capture by the reticuloendothelial system 
(RES), such as the liver Kupffer cells and the splenic macrophages, causing a major loss 
of the injected dose (>50%) within a few hours after i.v. injection. So the nanoparticles 
need to have a prolonged circulation half-life and the ability to escape the surveillance of 
RES, in order to encounter the leaky tumor vasculature before they are cleared from the 
in vivo circulation
22
. For the sake of improve the pharmacokinetic properties of delivery 
vectors after intravenous administration mentioned above, poly(ethylene glycol) (PEG) 
was introduced to modify the surface of nanoparticles. This hydrophilic polymer imparts 
a steric barrier on the surface of nanoparticles and minimizes the opsonization effect. 
 8 
PEGylation on the surface of the nanoparticles exhibit stealth properties, shielding the 
nanoparticles and help them escape the surveillance of RES.  
1.4.3 Target-cell specificity and uptake via targeting ligands  
The delivery vectors need to interact with cell membrane, internalize and localize in the 
intracellular compartment before releasing the nucleic acid cargo. Though PEGylation 
mentioned above can largely facilitate the accumulation of nanoparticles in the tumor 
leaky vasculature and confer stability in the systemic circulation, it hinders the uptake of 
the nanoparticles by the tumor cells once they extravasate
22
 because of its steric 
configuration coating on the outer surface of the nanoparticles. In order to solve the PEG 
dilemma, promote the interaction with target cells and prevent side effects by avoiding 
non-specific binding to non-diseased cells, many cell specific targeting ligands (e.g. small 
molecules, antibodies, aptamers, peptides) that can recognize unique biomarkers (e.g. 
antigens, receptors) on the diseased cell surface, are modified on the surface of the 
vectors to construct functional nanoparticles.  
1.4.4 Endosomal release  
In intracellular condition, inefficient release of the nucleic acid cargo complexes from 
endocytic vesicles into the cytoplasm is one of the primary causes of poor gene delivery. 
After delivery into target cells via endocytosis, the delivery systems should promote the 
endosomal release of siRNA from nanoparticles into the cytoplasm, followed by the 
interaction of siRNA with endogenous RISC in order to be bioactive. In detail, once the 
delivery vectors have been internalized into cells and arrive in an endosomal 
compartment, two essential processes have to occur in order to achieve higher gene 
transfection: one is dissociation of the nucleic acid from the delivery vector; the other is 
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the destabilization of the endosomal membrane to allow the release of the nucleic acid 
into the cytosol where is the site of action for siRNAs, and the release process is also 
critical to make the other nucleic acid cargo (e.g. plasmid DNA) accessible for transport 
to the nucleus for transcription.  
To overcome this obstacle, exogenous agents such as chloroquine
23
 or activated 
adenovirus
24
 were added to affect escape from the endosome and lysosomes, but they 
have cellular toxicity, immunogenicity and other side effects which make them 
impractical for in vivo gene therapy.  
Thus, a variety of stimulus responsive nanoparticle formulations for enhancing drug 
endosomal release and subsequently therapeutic effect, have been designed. Generally, 
several models have been proposed to interpret the possible mechanism of lipid/polymer 
based nanoparticles disrupting the endosome membrane and fleeing from the 
endosome/lysosome. These accepted models include the ion-pairing model (HII phase 
formation), the proton sponge model and the charge-charge destabilization model
22
, 
which will be explained in the following paragraphs in detail.  
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Figure 1.2 Challenges of in vivo siRNA delivery 
1.5 POTENTIAL ADVERSE EFFECTS OF RNA THERAPY 
1.5.1 Induction of immune responses 
siRNA therapy could induce ‘immune stimulation’; this is the recognition of a RNA 
duplex by the innate immune system. GU-rich regions in a particular sequence motif can 
lead to secretion of inflammatory cytokines in a cell-type and sequence-specific 
manner
25
. siRNA-mediated immune induction seems to rely on the TLR receptors located 
in the endosome
26
, such that the mode of delivery and hence compartmentalization of the 
siRNA greatly influences the cellular response. Not all siRNAs could induce immune 
stimulation. The stimulation of innate immune responses by siRNA may be related to a 
specific nucleotide sequence, or motif. The TLR7-mediated interferon-alpha induction by 
siRNA was shown to be sequence specific
27, 28
.  
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1.5.2 Off-target effect 
The ‘off-target’ effect is the inhibition of a gene not intended for silencing. It may occur 
because the gene shares a partial homology with the siRNA. For example, one class of 
siRNA off-target effects involves partial hybridization with the wrong mRNA, or the 
sense strand can cause off-target effects if it hybridizes to an irrelevant mRNA
29
. 
Silencing of an off-target is clearly unwanted as the cellular consequence of altered gene 
activity is unknown and unpredictable
25
. So one of the solutions is to increase the 
selective uptake of the antisense strand and decrease incorporation of the sense strand via 
appropriate siRNA duplex modifications. The undesired silencing of nontarget genes may 
lead to data misinterpretation and toxicity. Thus, the design and selection of a specific 
siRNA may involve consideration of internal repeated sequence, GC content, appropriate 
siRNA length, specific base preference in the sense strand, secondary structure. Some 
studies suggest that some of the off-target gene changes may be due to the delivery 
system itself, e.g. cationic lipids
30, 31
. Above all, off targeting remains a critical issue for 
therapeutic applications of RNAi and tolerable levels of off targeting effect are required 
for siRNA gene therapy.  
1.5.3 Saturation of endogenous silencing pathway 
siRNA relies on the endogenous miRNA machinery in order to achieve potent target 
silencing. The risk of saturating such pathways and hence perturb the natural system has 
been reported
25
. siRNA resembles miRNA precursors before and after Dicer processing, 
so all component of the miRNA pathway might be blocked by high doses of the ectopic 
RNA.  
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1.6 RNA DELIVERY 
Getting siRNA into cells is one of the biggest challenges of any application of RNAi. 
Naked siRNAs appear to be poorly transported into cells, and even there is a little free 
siRNAs that can eventually enter the cells, most of them would remain sequestered 
within endosomal/lysosomal vesicles where it may likely undergo degradation by 
nucleases. Therefore, in order to achieve siRNA-mediated gene silencing in cells, a 
feasible delivery system is required to improve cellular uptake and intracellular 
trafficking of the encapsulated siRNAs, facilitating their binding with the complementary 
mRNA in RISC in cytosolic compartment before gene silencing.  
1.6.1 Physical method 
Multiple physical and mechanical approaches have been used for in vivo gene delivery, 
which are considered the simplest way to deliver gene in vivo for transfection, such as 
hydrodynamic i.v. injection, intraportal injection, electroporation, mechanical liver 
massage, particle bombardment etc.  
1.6.1.1 Hydrodynamic injection  
An efficient gene transfer and expression can be achieved by a rapid injection of a large 
volume of naked DNA solution into animals via the tail vein. This hydrodynamic based 
gene delivery is a simple and highly efficient procedure in gene expression to deliver and 
express exogenous genes to almost all major organs, especially the liver in small animals, 
such as mice and rat. There are two basic requirements for the hydrodynamic injection in 
order to achieve an appropriate hydrodynamic pressure in targeted tissues: one is to inject 
rapidly in 5-7 seconds; the other is to inject a huge volume at one time. This 
hydrodynamic pressure can facilitate DNA solution to transiently permeabilize the 
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endothelium and plasma membrane of parenchyma cells and allow efficient intracellular 
gene transfer. For example, naked DNA in 2 ml volume of saline solution could be 
injected into mice weighing 20 g in just 5-7 seconds. Liu et al
32
 used this hydrodynamic 
procedure to transfect up to 40% of liver cells after a single injection of naked plasmid 
DNA, showing that the level of gene expression in different organs increased with the 
increasing volume of the injected DNA solution, and the optimal transgene expression 
requires an injection volume of approximately 8-12% of the body weight.  
Manual control of the injection speed and strength is hard to standardize, which makes 
the results insufficiently reliable when the experiment is operated by different individual. 
In order to minimize the problem, Suda
33
 developed a computer-controlled injection 
device that uses real-time intravascular pressure as a regulator for the injection and can 
program the computer according to the need. This device can self-adjust the volume 
needed to develop the sufficiently elevated pressure that can thereby help to achieve a 
successful gene transfer. The self-adjustment of the device is base on the size and 
anatomical structure of the selected organ of interest. This device enabled safe and 
effective gene delivery to mouse liver, and kidney and muscle cells in rats with plasmids 
or adenoviral vectors as gene carriers. Gene transfer to the liver of pigs was also 
successful. The study also showed that larger animals tend to require higher pressure for 
successful gene transfer to a given organ, and the liver shows the highest gene delivery 
efficiency probably due to the high elasticity of the liver vasculature and parenchyma 
cells. 
Though the tissue damage caused by the hydrodynamic pressure after injection can 
recover in rodents, rapid injection of large volume of plasmid DNA is invasive and can 
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not be applied to humans. High level of gene expression achieved by this simple method 
may be useful to analyze the function and molecular mechanism of different genes 
involved in many genetic and acquired diseases within the whole animal.   
1.6.1.2 Electroporation  
Electroporation is a simple and convenient way to deliver nucleic acids (e.g. DNA) into 
cells. Cells act as an electrical capacitor which is generally unable to pass current. 
Subjecting the cells to an electric field creates transient permeable structures or 
micropores on the cell membrane, which last long enough after electroporation to allow 
penetration of pharmaceuticals or nucleic acids into the cell. Over time, the micropores 
on the cell membrane close and cell becomes impermeable again. It can be applied, in 
principle, to any types of cells and tissues so long as the target is accessible. The 
advantages of electroporation include controllable tissue or cell damage, flexibility in the 
structure of DNA to be transfected, and the possibility of transfecting cells deep inside a 
specific tissue. The transfection efficiency by electroporation is many times greater than 
that of naked DNA and with reduced inter-individual variability
34, 35
.  
Various devices have been designed for effective electroporation, including electro 
square-wave porator, caliper electrodes, syringe electrode, flow-through electroporation. 
The caliper electrodes consist of a caliper and a pair of adjustable end plates. The 
electrodes sandwich the target area and deliver electric pulses following the injection of 
the molecule of interest. Liu & Huang
36
 invented a syringe electrode device for both 
DNA injection and electroporation. It applies a voltage to the syringe needle, and this 
allows the needle to be used not only for injection but also as an electrode. This is 
particularly advantageous as the electric field is applied to the same area as the injected 
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fluid. And the injected DNA can be confined to the high intensity region of the field, thus 
the required electric field strength can be reduced without compromising the transfection 
efficiency. Tissue damage could be minimized due to the low electric power used. Geng
37
 
introduced a novel flow-through electroporation method for gene delivery into cells at 
high flow rate based on disposable microfluidic chips and a direct current power supply 
that provide a constant voltage. With the optimal parameter design, approximately 75% 
of CHO cells were transfected by this method without apparent toxicity. 
1.6.1.3 Particle bombardment 
Particle bombardment is a commonly used method for genetic transformation to a broad 
range of cell and tissue types. Colloid gold particles coated with DNA (microprojectiles) 
are shot directly into the target cells or tissues by a burst of helium gas using a biolistic 
device or gene gun. The particles or macromolecules can be delivered through 
membranes and extracellular matrices. They can penetrate 100 μm into the skin by this 
method, and transfect some skin Langerhan cells for antigen presentation. Particle 
bombardment is the only reproducible means for delivering DNA to mitochondria
38
. 
Therefore, the method could have a significant impact on the gene expression within the 
cytoplasmic organelles
39
.  
1.6.2 Chemical vectors for RNA delivery 
1.6.2.1 Cationic lipids/liposomes and cationic lipid nanoparticles (lipoplex) 
Various cationic lipids can form complex with negatively charged DNA or siRNA. The 
complex, called lipoplex, at suitable N/P ratios interact with cells in culture by non-
specific charge interaction, followed by endocytosis. Lipofectamine is a commonly used 
cationic liposome reagent for nucleic acid transfection that provides high transfection 
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efficiency and high levels of transgene expression in a range of mammalian cell types in 
vitro. It can transfect siRNA or plasmid DNA into cells in culture by altering the cell 
plasma membrane and allowing nucleic acids to get access into the cytoplasm.  
 
Figure 1.3 Schematic formation of lipoplex (adapted from 
www.google.com/images) 
Liposomes prepared from cationic amphiphiles interact with polyanionic DNA or RNA, 
spontaneously forming lipoplexes driven by electrostatic interaction forces. Lipoplexes 
are efficient nonviral vectors to introduce nucleic acids into the desired target cells. 
Cationic lipids mediated gene transfer has the advantages over viral gene transfer because 
it is less immunogenic, easier to produce and not oncogenic. Most studies have been 
performed on the synthesis and investigation of new cationic lipid for DNA or RNA 
complexing, used either alone or combined with particular helper lipid, such as 
cholesterol and dioleylphosphatidyl-ethanolamine (DOPE) which are neutral lipids and 
can participate in bilayer formation when combined with a cationic lipid
40
. The presence 
of helper lipid affects the association of nucleic acids with lipoplexes
41
 and can help to 
facilitate the release of the cargo from endosome and achieve higher transfection 
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efficiency by promoting the inverted hexagonal HII phase transition. The inverted 
hexagonal phase has a negative spontaneous curvature and the tendency of membranes to 
form inverted micellar structure, which allows to de-stabilize the endosomal membrane 
and de-assemble the lipoplex
42
, resulting in concomitant release of the nucleic acid cargo 
from endosome. For example, cationic lipid DOTAP prefer a bilayer organization, 
however, mixing with helper lipid like DOPE will affect the packing parameter and 
mediate fusion between the liposomes and the endosomal membrane after endocytosis, 
reverting to a HII phase, which results in the destabilization of the endosomal membrane 
and release of the nucleic acid cargo to the cytosol
43-45
. The nonbilayer HII phase structure 
is also formed due to the formation of ion pairs between cationic lipids and the anionic 
phospholipids in the endosome membrane
46
. Several studies have investigated the 
correlation between the structural properties of lipoplexes and their transfection 
efficiency, and revealed that lipoplexes that adopt the HII phase strongly facilitate 
intracellular release of nucleic acid cargo from the endosomal compartment
42
 and display 
the highest transfection efficiency
47
. Cationic lipids with multiple cis double bond, small 
or less hydrophilic head group and unsaturated bulky acyl or alkyl chains favor HII phase 
formation and resulted in higher transfection efficiency
40, 42
. To avoid non-specific 
binding in vivo of the positively charged lipoplex, PEG derivatized lipids are often 
included to decrease the net positive charge
48
, providing stealth properties that stabilize 
the lipoplexes.  
1.6.2.2 Ionizable lipids 
Recently, Alnylam Pharmaceuticals designed some ionizable cationic lipids to formulate 
lipid nanoparticles (LNPs) to deliver siRNA in vivo, such as 1,2-dilinoleyloxy-3-
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dimethylaminopropane (DLinDMA) and other DLinDMA-based lipids. The ionizable 
cationic lipids contain weak basic lipid headgroups, which affect the surface charge of the 
particles in a pH-dependent manner, rendering them positively charged at acidic pH but 
close to neutral charge at physiologic pH
49
. LNPs comprised of different lipid 
compositions and ratios as well as different sizes and structures using different methods, 
which are characterized by very high siRNA encapsulation efficiency, small uniformly 
sized particles as well as superior delivery capacity and therapeutic gene silencing effect. 
One of the newly invented ionizable LNPs termed stable nucleic acid lipid particles 
(SNALP) substantially improved in vivo endogenous gene silencing activity with siRNA 
doses as low as 0.01 mg/kg in rodents and 0.1 mg/kg in nonhuman primates
50
. The 
rational lipid design for SNALP-mediated delivery lies in the pKa of the ionizable 
cationic lipid and the abilities of these lipids to induce the nonbilayer hexagonal HII phase 
structure with anionic phospholipids of endosomal membrane when protonated in acidic 
pH environment in the endosome
50
. The efficient delivery mechanism of these ionizable 
LNPs (iLNPs) involves endogenous apolipoprotein E (apoE) by targeting to the low-
density lipoprotein receptor (LDLR) in the hepatocytes
49
. Briefly, iLNPs behave as 
neutral liposomes in circulation to absorb apoE as an endogenous targeting ligand and 
delivery siRNA to hepatocytes in an endogenous targeting manner. The exogenous 
targeting approach via asialoglycoprotein receptor (ASGPR) expressed on hepatocytes is 
also highly effective
49
. 
1.6.2.3 Lipid-like delivery molecules (lipidoids) 
Akinc et al
51
 developed chemical synthesis methods based on the conjugate addition of 
alkyl-acrylates or alkyl-acrylamides to primary or secondary amines, to rapidly generated 
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substantial and diverse collection of lipid-like molecules, termed lipidoids. They are 
structurally distinct from other classes of lipid delivery vectors since they contained 
multiple protonable amine groups connected to relatively short alkyl chains. Materials 
with good in vitro and in vivo efficacy could be identified within the large library, 
including a lead material 98N12-5 that was shown to be efficacious in primates. In 
addition, the in vivo delivery efficacy of the novel lipid-like material can be affected by 
many parameters, such as the formulation composition, nature of PEGylation on the 
particle, degree of drug loading, particle size, changes in PEG lipids anchor chain length 
and so on
52
, resulting in distinct gene silencing effects. The side chains of the molecule 
can be further altered to obtain different capacities for hydrogen bonding, hydrophobic 
interactions, and protonated states, enabling the exploration of functionalized lipidoids 
for efficient siRNA delivery
53
.  
1.6.2.4 Cationic polymers (polyplexes) 
Cationic polymers include natural DNA-binding proteins, such as histones, synthetic 
polypeptides, poly(ethylenimide) (PEI), cationic dendrimers, carbohydrate-based 
polymers such as chitosan
40
. The self assembly of cationic polymers with nucleic acids in 
solution forms a particulate complex and leads to a strong condensation and large size 
reduction of nucleic acid drug, which is favorable to improve in vivo transfection 
efficiency
54
.  
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Figure 1.4 Schematic formation of polyplexes (Adapted from Nature Reviews 
Drug Discovery 4, 581-593, 2005; Adv Polym Sci 192, 1-8, 2006) 
Polyethylenimine (PEI) has been widely used for non-viral transfection in vitro and in 
vivo. PEI exists as a branched polymer and in linear form as well. It is available in a 
broad range of molecular weights, from less than 1000 Da to 1600 kDa, and the PEIs 
with molecular weight between 5 and 25 kDa are most suitable for gene transfer
55
. Higher 
molecular weights lead to increased cytotoxicity, probably due to aggregation of huge 
clusters of the cationic polymer on the outer cell membrane, which may induce 
necrosis
56
.  
Chitosan is a linear carbohydrate-based polymer comprising β(1,4)-linked D-glucosamine 
and N-acetyl-D-glucosamine. It is widely used in the field of non-viral gene delivery due 
to its good biocompatibility and high positive charge density
57
. The chitosan molecular 
weight, salt form, and the degree of deacetylation affect its gene delivery efficiency. The 
application of chitosan is also limited by its low water solubility, inefficient gene 
unpacking and relatively low gene transfection efficiency. Thus, various chitosan 
derivatives have been synthesized and the structures were further modified to alter its 
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hydrophilicity. Incorporation of negatively charged agents such as hyaluronic acid (HA) 
with chitosan has shown to increase the transfection efficiency significantly due to the 
low density of the HA chain which could improve the DNA release from the condensing 
compact nanoparticles
58
. Jiang
59
 described the chitosan-polyethylenimine (PEI) hybrid 
systems, including chitosan/PEI blend and chitosan-graft-PEI, to enhance the transfection 
efficiency of the cells owing to a proton sponge effect (see below). 
Dendrimers are three-dimensional polymers that can interact with various forms of 
nucleic acids, such as plasmid DNA, antisense oligonucleotides, and RNA, to form 
complexes that protect the nucleic acid from degradation. The cationic dendrimer 
condenses the anionic nucleic acids through electrostatic interaction. The positively 
charged dendrimer/nucleic acid complex can transfect cells by interact with the 
negatively charged cell membranes, though highly cationic systems are also cytotoxic. 
The properties of the dendrimer/nucleic acid complex depend on various factors, such as 
stoichiometry, concentration of dendrimer amines and nucleic acid phosphates, as well as 
solvent properties like pH, salt concentration, buffer strength, and dynamics of mixing. 
Dendrimer based transfection reagents could be used as routine tools for in vitro 
transfection, but in vivo delivery of therapeutic nucleic acids still remains a challenge.  
Bartlett et al
60
 have developed a synthetic delivery system based on a cyclodextrin-
containing polycation (CDP) which can deliver various nucleic acid payloads including 
pDNA, siRNA and ribozyme. The nucleic acid and CDP complexes formed by 
adamantine (AD)-containing molecules and the β-cyclodextrin molecules could be 
attached to the poly (ethylene glycol) (AD-PEG) conjugates for steric stabilization and 
the targeting ligands (AD-PEG-transferrin) for cell-specific targeting. This CDP delivery 
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vehicle can encapsulate large amounts of payload molecules and shows superior 
physicochemical and biological characterizations. 
Generally, the longer the polymer chain or the higher branched polymer leads to better 
condensation of nucleic acids. For example, low branched PEIs with low condensation 
capacity require higher N/P ratios to completely condense nucleic acid payloads 
compared to the highly branched counterparts
56
, most likely because of the lower content 
of primary amines in the low branched polymers. Highly branched PEIs form smaller 
polyplexes and usually achieve higher transfection efficiencies, but also show greater 
toxicity
40
. The complex condensation can confer protection against degradation in the 
extracellular environment and improve cell uptake by electrostatic interactions of the 
polycation with the negatively charged cell surface.  
Unlike cationic lipids, cationic polymers are devoid of hydrophobic domain and hard to 
destabilize the endosome by direct interaction with the endosomal membrane. Instead, the 
cationic polymers, such as PEI, can mediate endosome disruption by the “proton sponge” 
effect to enhance the nucleic acid cargo release
40
. The proton sponge effect arises from a 
large number of weak conjugated bases as proton-buffering groups (e.g. amine groups in 
PEI) with high buffering capabilities at pH 5-6 in acidic organelles, leading to proton 
absorption (sponge) and simultaneously chloride ion accumulation in the endosome, 
which arouses the osmotic pressure buildup in the endosome. This osmotic pressure 
causes swelling and/or rupture of the endosomes and a release of the entrapped drug 
materials into the cytoplasm
61
.  
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In order to achieve higher transfection efficiency, rational design of the polymer structure 
and the systematic structure modification has been developed. The design of the proper 
polymers becomes a sophisticated task in terms of the different applications of polymers 
as gene carrier systems. The molecular weight, the degree of branching, surface charge 
and the composition of the complexes (e.g. the ratio of polymer to nucleic acid payload) 
have to be optimized in order to form stable complexes, and conduct desired in vivo 
release properties as well. Higher charge density and higher molecular weight of 
polymers are usually required to reach high condensation capability. For example, 
polyamidoamine dendrimers have a branched spherical shape and a high surface charge 
density. Their transfection ability depends on the size, shape and the number of primary 
amine groups on the polymer surface
62, 63
.  
Rozema et al
64
 invented a siRNA Dynamic PolyConjugate vehicle for the delivery of 
siRNA to hepatocytes both in vitro and in vivo. They use amphipathic poly(vinyl ether) 
termed PBAVE as a latent endosomolytic agent, whose amine groups are modified with a 
maleic anhydride to create acid-labile maleamate bonds. These bonds reversibly mask the 
activity of this polymer until it reaches the acidic environment of endosomes. These 
bonds can be cleaved in the endosome, exposing the agent’s amines and activating its 
endosome release capacity. The siRNA cargo is attached to PBAVE through a disulfide 
linkage, and the shielding agent PEG and hepatocyte targeting ligand N-
acetylgalactosamine (NAG) are attached to PBAVE by a bifunctional maleamate linkage 
to afford specific targeting to hepatocytes in vivo by i.v. injection. By this delivery 
technology, two endogenous genes apolipoprotein B (apoB) and peroxisome proliferator-
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activated receptor alpha (ppara) in mouse liver were knocked down, consistent with the 
phenotypic changes of the gene functions.  
 
Figure 1.5 Schematic structure of polyconjugates 
1.6.2.5 Core/membrane lipid-based nanoparticles (lipopolyplex) 
The core/membrane nanoparticle Liposome-Polycation-DNA (LPD) was a DNA-
protamine complex subsequently wrapped by cationic liposomes. It is further modified by 
post-insertion of PEG to impart a steric barrier for prolonged circulation time in vivo. Li 
et al.
65
 developed the “LPDI” (Liposome-Polycation-DNA) formulation composed of 
protamine sulfate, DNA, and 1,2-dioleoyl-3-trimethylammonium-propane 
(DOTAP)/cholesterol liposome. The weakly immunogenic protamine sulfate condenses 
DNA or siRNA to form a relatively small and negatively charged complex core about 50 
nm in diameter. The complex core structure has a high efficiency of encapsulation, 
control of particle size, controlled release of nucleic acid in cells
66
, and it can protect the 
nucleic acid cargo from enzymatic degradation by nucleases and other environmental 
assaults as well. The cationic liposome containing DOTAP wraps around the negatively 
charged complex core, and the resulting LPD nanoparticles are slightly less than 100 nm 
in diameter
67
. Lee & Huang
68
 developed a similar LPD gene transfer vector (LPD-II), 
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where DNA was first complexed to polylysine to form a positively charged core. The 
major difference from LPDI is that LPD-II uses pH-sensitive anionic liposomes 
composed of dioleoyl phosphatidylethanolamine (DOPE)/cholesteryl hemisuccinate 
(CHEMS) instead of cationic liposomes. Above all, the liposomes added to the LPD 
complexes are either made of cationic (LPD-I) or anionic (LPD-II) lipids to form 
lipopolyplexes. In order to increase the circulation half-life, PEG was coated outside the 
LPD, and targeting ligands (e.g. anisamide, folate) were also tethered to the distal end of 
the PEG polymer chain to achieve specific internalization, enhanced cellular uptake and 
improved transfection efficiency
69, 70
.  
 
 
Figure 1.6 Structure and preparation scheme of LPD nanoparticles.  
Nakamura et al
66
 developed a multifunctional envelope-type nano device (MEND) as 
non-viral gene delivery for plasmid DNA (pDNA) and oligodeoxynucleotides (ODN), 
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similar to LPD-II
68
. MEND consists of a DNA core condensed by polycation and covered 
with lipid membranes, and the surface of the lipid envelope can be modified with various 
functional devices, such as PEG for prolonged circulation, specific ligand for targeting, or 
fusogenic peptide for endosomal escape
71
. The lipid membrane of MEND was composed 
of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and cholesteryl 
hemisuccinate (CHEMS) without cationic lipids. Since PEG modification on the surface 
of nanoparticle is undesirable for the cellular uptake by interfering the interaction with 
the cell membrane
22
, Hatakeyama
72
 used a biological responsive PEG-peptide-lipid 
ternary conjugate (PEG-peptide-DOPE conjugate (PPD)) to modify the MEND gene 
carrier. The PEG can be removed from the carriers via cleavage by a matrix 
metalloproteinase (MMP) which is specially expressed in tumor tissues. The results show 
MEND modified with PPD is stable in the systemic circulation and can facilitate tumor 
accumulation and transfection.  
 
Figure 1.7 The schematic structure of MEND nanoparticle. (Ref: Advanced 
Drug Delivery Reviews, 2008, 60, 559-571) 
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Figure 1.8 A schematic diagram illustrating the strategy of releasing gene 
cargo in MEND nanoparticles by PPD modification. (Ref: Gene Therapy, 2007, 14, 
68-77)  
  From the xzy confocal microscopy images by Li et al, most of the siRNAs was 
delivered intracellularly in vivo when formulated in anisamide (AA) targeted LPD 
nanoparticles (Fig 1.9c), while siRNAs only remained in extracelluar space when they 
are formulated in non-targeted nanoparticles (Fig 1.9b). Free siRNA and non-targeted 
nanoparticles showed little cellular uptake (Fig 1.9a, 1.9b). However, in Fig 1.9c, the 
siRNA fluorescence was not distributed homogeneously, instead, there were many 
granular dots dispersed in the cytoplasm. The data strongly indicate that the delivered 
siRNA was not completely dissociated from the nanoparticles. Although LPD 
nanoparticles were strikingly successful in delivering siRNA via intravenous 
administration, most of siRNA loaded into the vector is still associated with the cores in 
the cytoplasm such that most of the encapsulated siRNA is not bioavailable.  
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Figure 1.9 A diagram illustrating the limited release of siRNA from LPD 
condensed core. Green fluorescence is FAM-siRNA. Blue arrows indicate the 
extracellular space and pink arrows indicate the intracellular uptake of siRNA. (Ref: 
Molecular Therapy, vol. 16, no. 1, 163-169, 2008) 
In order to solve the problem regarding to the inefficient release of siRNA from LPD 
nanoparticles, Li et al
70
 developed a lipid coated calcium phosphate (LCP) nanoparticle 
formulation for efficient delivery of siRNA to a xenograft tumor model by intravenous 
administration. Comparing to the LPD nanoparticle, the previous DNA-protamine 
complex core was replaced by a biodegradable nano-sized calcium phosphate precipitate 
prepared by using water-in-oil microemulsions, and siRNA was entrapped in the calcium 
phosphate precipitate in the microemulsion. The rationale for the LCP design is that the 
calcium phosphate precipitate in the core of LCP nanoparticles would dissolve and de-
assemble at low pH in the endosome, increase the osmotic pressure, and cause endosome 
swelling and bursting to release the entrapped siRNA. This new formulation improved 
the in vitro silencing effect 3-4 folds comparing to the previous LPD formulation, and 
had decreased immunotoxicity to allow a potential application for clinical trial. The LCP 
nanoparticles can be further optimized by changing the precipitate core and the coating 
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lipids. Fig 1.10 shows the formation process and the entrapped siRNA release mechanism 
of LCP-II nanoparticles. 
 
 
Figure 1.10 The formation process and entrapped siRNA release mechanism 
of LCP nanoparticles                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
1.6.2.6 Aptamer-siRNA chimeras 
Cancer cells usually over-express certain surface markers
73
 which can be exploited for 
targeted delivery of siRNA. Aptamers are ssDNA, RNA, or modified nucleic acids with 
high binding affinity specific to their targets which range from small molecules to 
proteins
74
. They have been isolated and identified for the recognition of molecular targets 
expressed on the surface membranes of specific cancer cells. Dassie et al
75
 and 
McNamara et al
76
 use aptamer-siRNA chimeras to target prostate-specific membrane 
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antigen (PSMA) expressed on prostate cancer cells, triggering cell type-specific gene 
silencing by chimeric RNAs via the RNAi pathway. The aptamer-siRNA chimeras show 
specific tumor inhibition and mediate tumor regression in a xenograft model of prostate 
cancer, which could prove to be useful therapeutics for targeting human prostate cancer 
in the future. The drawback of the vector is the lack of any endosome escape mechanism 
in the chimera.  
 
 
Figure 1.11 Schematic structure of aptamer-siRNA chimeras (Adapted from 
RNAi and small interfering RNAs in human disease therapeutic applications. Trends 
Biotechnol. 28 (11): 570-579, 2010) 
1.7 TARGETING LIGANDS 
1.7.1 Aptamers 
Aptamers are short single-stranded DNA or RNA oligonucleotides ranging in size from 
20 to 80 bases (~6 to 26 kDa) which are able to recognize and bind to their target 
molecules, such as proteins, phospholipids, sugars, nucleic acids, cell surface receptor, 
with high affinity and specificity
11, 77
. Aptamers are derived from a large random 
sequence pool through repeated rounds of in vivo selection for targets on the surface of 
tumor cells and in vitro selection using purified protein target. They can also be obtained 
via a process referred to as SELEX (systemic evolution of ligands by exponential 
enrichment)
78
 to bind to various molecular targets, and even cells, tissues and organisms. 
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Receptor-binding RNA aptamers may help cell receptors to internalize cargos after the 
ligands interact with the receptors. Aptamers are also amenable to a wide variety of 
chemical modifications, such as radioactive or fluorescent reporters, affinity tags for 
molecular recognition, ribose ring modification, which makes aptamers resistant to 
nuclease. Aptamers can also be covalently conjugated to nanomaterials after appropriate 
chemical modification. Another attractive feature of aptamers in biological systems is 
their low toxicity, low immunogenicity
79
 and long circulation half life.  
1.7.2 Cell penetrating peptides  
Cell penetrating peptides (CPPs), also known as protein transduction domain (PTDs), are 
a class of short peptide sequences that can enter cells efficiently, either alone or linked to 
bulky cargos such as peptides, proteins, oligonucleotides, pDNA, or liposomes
80, 81
. 
Linking the cargo macromolecule to CPP can help to overcome the cell membrane 
barrier.  
1.7.3 Antibodies 
Antibodies and antibody fragments have been fused to various drug delivery systems as a 
targeting agent, so that they can selectively deliver their payload to tumor cells. Xu et al
82
 
conjugated a single-chain monoclonal antibody fragment (scFv) that targeted to the 
transferrin receptor to cationic liposomes, and then mixed with plasmid DNA to produce 
scFv-Lip-DNA complex, which enhances the transfection efficiencies both in vitro and in 
vivo in a variety of human tumor models. Chen et al has also conjugated scFv to 
liposome-polycation-hyaluronic acid (LPH) nanoparticles to deliver both siRNA and 
miRNA for therapy in a murine B16F10 melanoma model
83
. The siRNA delivered by the 
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scFv targeted nanoparticles efficiently down-regulated the target genes in the lung 
metastasis and reduced the tumor load in the lung.   
1.7.4 Peptides and Proteins 
Some cancer cells up-regulate certain cell surface receptors that correspond to larger 
protein ligand, such as transferrin which is an iron-transporting serum glycoprotein. The 
transferrin modified drug delivery vectors can be efficiently taken up into cells by 
receptor-mediated endocytosis. Also, small immobilized peptides can be tethered on 
polymers as cell recognition motif which can resist enzymatic degradation and therefore 
exhibit excellent long term stability. In addition, unlike extracellular matrix (ECM) 
proteins that normally contain many different cell recognition motives, the small peptides 
represent only one single motif, so they can selectively address one particular type of cell 
receptors and trigger cell adhesion efficiently. Both linear peptides and cyclic peptides 
can be employed
84
. The Arg-Gly-Asp (RGD) sequence is one of the most effective and 
most often employed peptide sequences for stimulated cell adhesion, targeting to integrin 
family receptors on tumor vasculature, such as αvβ3 which plays a significant role in 
tumor angiogenesis. Peptides containing RGD and RGD-mimetics have been coupled to 
liposomes, polymers, other peptides, small molecule drugs and radiotracers for 
therapeutic, diagnostic imaging of tumor angiogenesis
85
. Many multivalent RGD-
constructs and multimeric cyclic RGD peptides have been used to increase the binding 
affinity and targeting capability to integrin αvβ3
86, 87
. Multivalency not only greatly 
improves affinity but also facilitate internalization via receptor-mediated endocytosis
88
. 
Besides RGD-mediated delivery of small molecule drugs, imaging agents, peptides and 
proteins, RGD-modification of non-viral and viral gene carriers have been successfully 
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exploited as well
89
. Similar to RGD, Asn-Gly-Arg (NGR) is another small peptide 
applied to target to aminopeptidase N (CD13) molecule which is over-expressed on 
certain tumor cells and most tumor endothelial cells
90
. Chen et al
91
 conjugated NGR 
peptide to PEGylated LPD nanoparticles for efficient delivery of siRNA and doxorubicin 
into solid tumors. NGR-hTNF which consists of human tumor necrosis factor (hTNF) 
fused with NGR peptide showed efficient antitumour activity at low doses due to 
selective binding to CD13 over-expressed on tumor blood vessels, and the activity and 
safety of NGR-hTNF was further evaluated in clinical study on colorectal cancer (CRC) 
patients failing standard therapies
92
. The results showed NGR-hTNF was well tolerated 
on CRC patients, and deserves further evaluation in combination with stand 
chemotherapy. Thus, both RGD and NGR have been widely used in many drug delivery 
systems for active tumor targeting and enhanced antitumor therapeutic effect.  
1.7.5 Small molecular weight ligands 
Folate receptors are over-expressed on several types of cancers and diseased cells but are 
expressed in minimal quantity in normal cells except the kidneys
93
. So folate conjugation 
presents an effective method of targeting drug/gene carriers to cancer cells It has been 
successfully applied for the receptor-specific delivery of chemotherapy agents, liposomal 
drug carriers and gene transfer vectors
90
. Anisamide is a high affinity small molecular 
weight ligand for sigma receptors that are highly expressed on many epithelial cancer 
cells. It can be conjugated to lipid nanocarriers to deliver doxorubicin
94
 and siRNA
95, 96 
to 
tumors in animals. Other small molecules such as haloperidol, SA4503, and opipramol 
have also been reported as sigma receptor ligands
97
. Mukherjee et al
98
 reported that 
haloperidol conjugated lipoplexes showed 10-fold greater delivery of DNA to breast 
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carcinoma cells than the control lipoplexes. The advantages of small molecular weight 
ligands are their small size, convenient availability, relatively simple conjugation 
chemistry, and reduced immunogenicity. 
1.8 THERAPEUTIC APPLICATION FOR TREATMENT OF CANCER 
1.8.1 siRNA therapeutic mechanisms 
Many human diseases are often caused by inappropriate endogenous or exogenous gene 
expression that leads to angiogenetic dysfunction. The role of angiogenesis in tumor 
growth is mediated by a balance of activators and inhibitors. siRNA can create new 
inhibitors that down-regulate angiogenesis through post-transcriptional gene silencing, 
such as regulation of VEGF receptor expression
99
. siRNA have already shown 
therapeutic effects from a number of animal disease models, demonstrating that anti-
angiogenesis siRNA may play an important role in the treatment of human diseases in the 
near future
100
. Furthermore, siRNA targeting key elements of proliferation signal 
transduction pathways can prevent the development of specific human cancers. And 
siRNAs specifically down-regulating the expression of the target genes can induce the 
induction of cell cycle arrest, apoptosis and reduced cell proliferation in vitro or tumor 
growth in vivo. In addition, drug resistance in cancer cells can also be overcome by 
delivering c-myc siRNA
101
.  
1.8.2 Examples in cancer treatment by RNA delivery technology 
Clinical trials using RNAi technology to treat human diseases were first launched in 
2004
102
. siRNA is now being evaluated for almost all types of disease and more than 13 
products have entered into clinical trials. Although it is a very promising class of drug, 
the Food and Drug Administration (FDA) has not approved any human gene therapy 
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product to date. Davis et al
103
 has finished the first siRNA clinical trial using targeted 
nanoparticle delivery system invented by Calando Pharmaceuticals. This technology 
applied cyclodextrin polymer carriers to deliver the siRNA
81
. The synthetic delivery 
system tested in clinical trail contained a linear cyclodextrin-based polymer (CDP), a 
human transferrin protein (TF) as the targeting ligand, hydrophilic PEG polymers to 
improve nanoparticle stability in the circulation and siRNA designed to reduce the 
expression of RRM2
103
. This targeted nanoparticles were designed to circulate and then 
to accumulate and permeate in solid tumors after intravenously administration. The 
reduction of the RRM2 mRNA and protein by the RRM2-specific siRNA was observed 
in the tumor biopsies of melanoma patients. The experimental data demonstrated that 
siRNA administered systemically to human can produce a specific gene inhibition by an 
RNAi mechanism of action.  
From this successful example of RNAi clinical trial, it is predictable that cancer treatment 
with siRNAs will be widely applicable in the near future once the challenges of targeting, 
potency, duration of effect, specificity and safety issues are overcome for the effective 
systemic delivery. Table 1.2 summarized some ongoing clinical trials for RNAi based 
therapy to cancers and other wide range of diseases
104-106
.  
 
 
 
 
 
 
 36 
Table 1.2 RNA interference (RNAi) drugs in clinical trials 
Company RNAi agent 
name 
Disease Target RNA delivery 
method 
Route of 
admin. and 
target tissue 
Trial 
phase 
Calando CALAA-01 103 Solid tumors RRM2 Targeted 
nanoparticle 
delivery system 
Intravenous 
injection 
(systemic) 
Phase I 
Alnylam ALN-VSP Liver cancers 
and solid 
tumors 
KSP, VEGF Liposomal 
conjugation 
Intravenous 
infusion 
(systemic) 
Phase I 
Silence 
Therapeutics 
Atu027/ 
Atu093 107 
Lung cancers PKN3 siRNA-lipoplex Intravenous 
injections or 
infusions 
(systemic) 
Phase I 
Quark/ 
Pfizer 
PF-4523655/ 
RTP-801i-14 
AMD, 
diabetic 
macular 
degeneration 
RTP801 Synthetic 
chemically 
modified siRNA 
molecule 
Intravitreal 
injection 
(eye) 
Phase II 
Alnylam ALN-RSV01 108 RSV 
infection 
Nucleocapsid 
(N) gene of 
RSV genome 
Minimally 
modified, 
unencapsulated 
siRNAs 
Intranasal 
(respiratory 
tract) 
Expanded 
Phase II 
Quark AKIi-5 ARF, AKI TP53 Chemically 
modified siRNA 
formulation 
Intravenous 
injection 
(systemic) 
Phase II 
Allergan AGN-211745 
(Sirna-027) 109 
AMD and 
CNV 
infection 
VEGFA, 
VEGFR1 
Sterile siRNA 
buffer or 
nuclease-free 
PBS 
Intravitreal 
injection 
(eye) 
Phase II 
TransDerm TD101 110 Pachyonychia 
congenita 
Keratin 6a 
N171K 
Unmodified 
TD101 siRNA 
Intradermal 
injection 
(skin) 
Phase I 
University 
of Duisburg-
Essen 
BCR-ABL 
siRNA 111 
CML bcr-abl DLS lipid 
solution with 
anionic 
lipoplexes 
Intravenous 
injection 
(systemic) 
Single 
patient 
Duke 
University 
Hospital 
siRNA 
immunotherapy 
Metastatic 
melanoma 
Proteasome Dendritic cell-
based vaccine 
intradermal 
injection 
(skin) 
Phase I 
Opko Health bevasiranib Wet AMD VEGF Direct inject 
siRNA to the eye 
Intravitreal 
injection 
(eye) 
Expanded 
Phase III 
Abbreviations: AKI: Acute kidney injury; AMD: age-related macular degeneration; ARF: 
acute renal failure; CML: Chronic myeloid leukaemia; CNV: choroidal 
neovascularization; KSP: Kinesin spindle protein; PKN3: protein kinase N3; RRM2: M2 
subunit of ribonucleotide reductase; RSV: respiratory syncytial virus; RTP801: hypoxia-
inducible factor 1-responsive gene; TP53: tumor protein p53; VEGF: vascular endothelial 
growth factor; VEGFR-1: vascular endothelial growth factor receptor-1.  
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1.9 CONCLUSION 
Optimal siRNA delivery vectors discussed above are widely applied to improve the 
therapeutic nucleic acid based transfection efficiency with limited toxic side effects. In 
sum, RNAi has rapidly been recognized as an experimental tool and is expected to be 
used as a therapeutic treatment for various diseases. 
 
This literature review leads to the project designs described in Chapter 4 and Chapter 5 of 
this thesis.  
 
2.0  IN VIVO GENE DELIVERY BY NON-VIRAL VECTORS: OVERCOMING 
HURDLES? 
The promise of cancer gene therapeutics is hampered by difficulties in the in vivo 
delivery to the targeted tumor cells, and systemic delivery remains to be the biggest 
challenge to be overcome. Here, we concentrate on systemic in vivo gene delivery for 
cancer therapy using nonviral vectors. In this review, we summarize the existing delivery 
barriers together with the requirements and strategies to overcome these problems. We 
will also introduce the current progress in the design of nonviral vectors, and briefly 
discuss their safety issues. 
2.1 INTRODUCTION 
Gene therapy holds the significance of correcting genetic defects, and there are many 
nucleic acid-based therapeutic strategies that can be used for gene therapy against cancer, 
including antisense and RNA interference (RNAi) mechanisms. Antisense 
oligonucleotides are typically 15-30 nucleotides long and block production of the disease-
causing protein after complementarily hybridizing to their target mRNA and degrading  
 
Reference: Yuan Zhang, Andrew Satterlee, Leaf Huang. In vivo gene delivery by non-
viral vectors: overcoming hurdles? Molecular Therapy (2012); 20 (7), 1298-1304.
the mRNA by activating RNaseH. RNAi is a separate process in which a specific mRNA 
is targeted for degradation in order to inhibit the synthesis of its encoded protein. Two 
types of small RNA molecules – microRNA (miRNA) and small interfering RNA 
(siRNA) – are central to the RNAi function. After delivery into the cytoplasm, the 
antisense strand of RNAi molecules recruits the corresponding mRNA in a sequence-
specific manner to the RNA-induced silencing complex (RISC), which is followed by 
cleavage of the target mRNA, resulting in gene silencing. Both antisense oligonucleotides 
and RNAi-based therapy target mRNA to inhibit transcription of an overexpressing 
endogenous gene or a cancer causing oncogene
112
, resulting in selectively inhibiting the 
expression of an unwanted protein (downregulation or loss of function). Plasmid DNA 
(pDNA) is also widely used to introduce a normal wild-type transgene into specific cells 
of the host where the endogenous gene is underexpressing
112
, resulting in expression of a 
deficient protein (upregulation or gain of function). 
Currently, three different kinds of gene delivery systems have been explored: modified 
naked siRNA, viral vectors, and non-viral vectors. Modified naked siRNAs have 
increased nuclease stability and gene silencing efficiency, as well as reduced immune 
responses and off-target effects, when compared to unmodified RNAs.
113
 Viral vectors 
have high gene transfection efficiency, but their residual viral elements can cause 
insertional mutagenesis and immunological problems. Non-viral vectors are constructed 
with biocompatible materials using innovative fabrication approaches, so that they can 
safely transport gene cargo in vivo, but their transfection efficiencies are not as high as 
viral vectors.  
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Therapeutic nucleic acids are potent in correcting genetic defects in cell and molecular 
levels, but in a real biological environment, their lack of serum stability and rapid 
clearance greatly compromise their in vivo delivery, which retards gene therapy 
application in clinical setting. In this review, we will summarize the existing delivery 
barriers, highlight the strategies to overcome these hurdles, and introduce the current 
progress of non-viral vectors constructed for cancer gene therapy.    
2.2 CHALLENGES OF GENE DELIVERY  
2.2.1 Off-target effect  
siRNAs are capable of reducing expression of non-target genes due to interaction of the 
siRNA guide strand with a partially complementary site on an ‘off-target’ mRNA114. 
Careful selection of siRNA sequences to avoid off-target effects is an important issue, 
and can be minimized by avoiding certain sequence motifs. The design and selection of a 
specific siRNA may involve the consideration of internal repeated sequence, GC content, 
siRNA length, specific base preference, secondary structure, etc. 
115,116
 
2.2.2 Immune stimulation 
Innate immune activation via RNA represents a significant undesirable side effect due to 
the toxicities associated with excessive cytokine release
117
 and inflammatory syndromes 
after systemic administration. The inflammatory response is mediated by Toll-like 
receptors (TLRs) TLR3, TLR7, TLR8 and TLR9, which are located in endosome 
compartments, and recognize unmethylated CpG DNA as well as various moieties in 
double-stranded RNA or their degraded products
118
. A number of parameters affect how 
delivery vehicles potentiate immune stimulation. These include the chemical composition 
of the delivery vehicles, physical properties such as the size and charge of formulated 
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materials, pharmacokinetics and biodistribution of formulated nucleic acids, and routes of 
administration.
117
 TLR-mediated recognition and concomitant immune stimulation can be 
inhibited by chemical modifications, such as introduction of 2’-O-methyl (2’OMe)-
modified nucleotides. 
119
   
2.2.3 Delivery 
The most important—and most difficult—challenge in gene therapy is the issue of 
delivery.  Not only must the therapy evade the reticuloendothelial system as it circulates 
after systemic administration, but it must also cross several barriers before it arrives in the 
cytoplasm or nucleus of its target cells. 
2.2.4 Serum inactivation and enzyme degradation 
Stabilization of RNA is regarded as a prerequisite for in vivo therapeutic applications, 
however, naked RNAs are rapidly degraded by nuclease in serum. Nuclease resistance 
can be enhanced by chemical modification of RNAs. Because the 2’-hydroxyl group of 
the ribose ring is not necessary for potent gene silencing by siRNAs, the most widely 
used RNA modifications are on sugar moieties. Common modifications are 2’-fluoro, 2’-
O-methyl, and 2’-amine conjugations112. The locked nucleic acid (LNA) conformation 
has a 2’-O, 4’-C methylene bridge in the sugar ring. Such LNA molecules have the 
desirable features of increased nuclease stability and silencing potency, as well as 
reduced off-target effects and immune responses. Backbone modification by changing the 
internucleotide phosphate linkage, such as phosphorothioate (P = S) and 
boranophosphonate (P = B) modifications, can be placed in the RNA duplex at any 
desired position to enhance nuclease stability
112
.  
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Though modified RNAs are favorable for in vivo delivery when compared to naked 
RNAs, they lack specific tumor targeting and would be quickly excreted by the kidney 
upon systemic administration, so a large amount of modified RNAs are needed to attain 
desired therapeutic effects
113
. Generally, modified RNAs are delivered by local injection, 
but the local route is only accessible for certain cancers, such as skin cancer or head and 
neck cancer. Thus, most efforts have been concentrated on developing safe and effective 
nanoparticles for systemic gene delivery.  
2.2.5 RES recognition 
In order to condense negatively charged nucleic acids into delivery vehicles, most 
nanoparticles contain polycations such as cationic polymers or lipids. The positive charge 
aids cellular uptake but also promotes non-specific interactions with non-target cells and 
extracellular components such as serum proteins and extracellular matrix
122
. Binding of 
plasma proteins is the primary mechanism for the reticuloendothelial system (RES) to 
recognize circulating nanoparticles
123
, causing the major injected dose (ID) to go to RES 
organs, such as the liver, spleen, and bone marrow, immediately after i.v. injection, with 
little accumulation in tumors.  
The most common way to decrease non-specific interactions is to shield the nanoparticle 
surface with hydrophilic, uncharged polymers such as polyethylene glycol (PEG). 
Surface PEG coating sterically hinders the interaction and binding of blood components 
with the nanoparticle surface and prevents opsonization and recognition by phagocytes of 
the RES
124
, resulting in prolonged nanoparticle circulation in the blood. The nanoparticle 
circulation half-life may vary by changes in PEG chain length, PEG density, surface 
coating, particle size and surface charge of the underlying nanostructure.
125
 PEGylated 
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(aka stealth) nanoparticles with a reduced RES uptake and a prolonged circulation half-
life are a prerequisite for enhanced tumor targeting
123
. 
2.2.6 The EPR effect 
Transport of macromolecules across the tumor endothelium is more efﬁcient than that of 
normal endothelium because of its leaky and discontinuous vascular structures 
(permeation) with poor lymphatic drainage (retention), which is referred to the ‘enhanced 
permeability and retention (EPR) effect’.126 In other words, tumor endothelium allows the 
penetration of macromolecules and most nanoparticles.  The EPR effect can be enhanced 
by PEGylation because the amount of blood that circulates through the tumor is usually 
far less than that of the RES organs, and only those nanoparticles that are not rapidly 
cleared from the circulation will have a chance to encounter the leaky tumor 
vasculature
123
.    
Not all human tumors are equally leaky; for tumors with less leaky vasculatures, 
nanoparticles with small size (less than 30 nm) are desirable
124
, but for most tumors, 
nanoparticles with a mean size around 100 nm are attractive for tumor targeting. Particles 
that are 100 nm in size also allow easier surface modification with PEG arranged in a 
brush mode, a conformation that efficiently prevents serum opsonization. Particles larger 
than 400 nm can not easily enter the capillary gaps in the tumor vasculature, while 
particles smaller than 70 nm are able to access the parenchymal cells in the liver (i.e., 
hepatocytes) after crossing the liver blood vessels (known as the sinusoidal space), since 
the sinusoidal vessels contain fenestrae that have an average diameter of 100 nm
122
. 
Small particles are also prone to renal excretion through the glomeruli in the kidney, and 
their large surface curvature presents difficulties for PEG shielding.   
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2.2.7 Entrance into cells: The PEG dilemma 
PEGylation may protect nanoparticles from protein agglomeration and macrophage 
capture, controlling their biodistribution and tumor accumulation, but the PEG coating 
prevents the formation of essential non-bilayer intermediates
127 
and inhibits fusion with 
the cell and/or the endosomal membrane, thus reducing the potential of nanoparticle 
cellular uptake and cargo release from endosomes, decreasing silencing or transfection 
efficiency. 
To solve this PEG dilemma, labile bonds can be introduced in the PEG chain, so that 
nanoparticles become unPEGylated upon reaching the target cells, leading to increased 
rates of membrane destabilization, transport of the loaded cargo inside the cells, and 
release from the endosome. pH sensitive lipids composed of PEG, an acid-labile linker, 
and a hydrophobic tail can be used to construct fusogenic liposomes
128
, or one can 
conjugate PEG and polycations with acid-sensitive linkers followed by compacting 
nucleic acids into pH-triggered deshielding lipoplexes/polyplexes
129
. Enzyme-sensitive 
linkers can also be applied to conjugate PEG and lipids, followed by entrapping nucleic 
acids in liposome-like vehicles, so that the PEG moiety can be cleaved off in tumor sites 
where the specific enzyme is widespread
130-133
.   
Besides the external stimuli-triggered PEG shedding, conjugates of lipids and hydrophilic 
polymers are generally able to diffuse off of membranes depending on the strength of the 
anchorage or the anchor chain composition
133
. When particles (liposomes or lipoplexes) 
are coated with sheddable stealth PEG-lipid
133
, the spontaneous shedding of the PEG-
lipid from particles (de-PEGylation) 
123,134
 will continuously happen when particles 
circulate in blood, which eventually exposes the shielded cationic lipids and allows 
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membrane fusion for nanoparticle uptake and endosome release
123
. In this case, the 
shedding rate is a crucial parameter that has to be addressed when designing sheddable 
PEG coating. If shedding occurs too quickly, the unprotected carrier will be rapidly 
cleared from circulation by the RES. In other words, RES competes with tumor for the 
uptake of nanoparticles
123
. However, if shedding is incomplete or occurs too slowly, the 
therapeutic efficacy of the loaded cargo might be compromised.  
Targeting ligands are also frequently modified on the nanoparticle surface for enhanced 
cellular uptake by receptor-mediated endocytosis. Commonly used targeting ligands 
include aptamers
135
, cell penetrating peptides (CPPs)
136
, antibodies
137
, peptides or 
proteins
138
, and small molecule ligands
139
. Shixian Huang et al
140
 conjugated the LRP1 
ligand Angiopep-2 to a PAMAM dendrimer using bifunctional PEG, and complexed it 
with plasmid DNA (pORF-TRAIL) to treat brain glioma. Significant apoptosis induction 
and prolonged survival time after systemic administration indicated that the Angiopep-2 
peptide could be exploited as a specific ligand to cross the BBB and target glial tumors. 
Sonsoles Diez et al
141
 constructed an Asialoglycoprotein receptor-targeted lipopolymeric 
vector using the asialofetuin ligand for IL-12 gene transfer in hepatocellular carcinoma in 
vivo.  
2.2.8 Endosome escape 
The delivery of nonviral gene vehicles almost invariably involves endocytosis, and 
escaping from endosomes before they traffic into lysosomes is an essential step for 
nanovectors to avoid enzymatic degradation. 
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Cationic lipid complexes can bind to anionic lipids on the endosome membrane and form 
neutral ion pairs. These ion-pairs destabilize the endosome membrane and promote de-
assembly of the lipoplex through the formation of the inverted hexagonal (HII) phase
142
, 
and finally release nucleic acids to cytoplasm.  
Some protonable groups that are charged at acidic pH but less charged at neutral pH 
could be an alternative choice to designing ionizable cationic lipids that condense nucleic 
acids and promote endosome release
122, 143, 144
. The rational design lies in the pKa of the 
ionizable cationic lipid and the abilities of these lipids to induce the hexagonal HII phase 
structure with anionic lipids of the endosomal membrane when protonated in the acidic 
endosome.  
Acid-responsive mechanisms have been widely used to design delivery carriers in order 
to promote endosome release. Polymers and peptides with high buffer capacity between 
pH 7.2 and 5.0, such as polyethylenimine (PEI)
145
, or peptides containing the cationic 
amino group lysine, arginine, and imidazole group histidine
146
, could buffer the 
endosome.  This would cause more protons to enter into the endosomes, followed by 
chloride ions, leading to increased osmotic pressure and endosome rupture, releasing 
payloads into cytoplasm. This process is called the ‘proton sponge effect’. 
Stimuli other than pH have been used to destabilize endosome membranes as well. Lipid 
or polymer derivatives which are sensitive to sulfhydryl reduction
147-149
 and enzymatic 
cleavage
132, 150
 have been used to construct non-viral gene vectors. Upon exposure to the 
intracellular reducing agents or selective enzymes at the target sites, the vectors become 
destabilized and fuse with the endosome membrane, and finally release the entrapped 
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cargo. Some fusogenic peptides can also be combined with nanoparticles to induce 
membrane fusion in endosomes through their structural changes in acidic conditions as 
compared to physiological pH.
151,152
  
Li and Huang
153
 developed a Lipid-calcium-phosphate nanoparticle (LCP) for efficient 
siRNA delivery. The LCP entraps siRNA in a biodegradable nano-sized calcium 
phosphate precipitate (CaP) core. The LCP de-assembles in endosomes due to the CaP 
core dissolving in acidic conditions, which increases the osmotic pressure, causing the 
endosome to swell and burst to release the entrapped siRNA. 
2.2.9 Nuclear entry 
The final target destination of antisense oligonucleotides, siRNA/miRNA and mRNA, is 
the cytoplasm, whereas pDNA must be transported into the nucleus for gene expression. 
Nuclear transport generally occurs through nuclear pore complexes (NPCs), however, 
nucleic acid condensates are impermeable through NPCs due to their large size.
154
 In 
dividing cells, the nuclear envelope disassembles during mitosis; pDNA transfection can 
only occur at this stage of the cell cycle due to elimination of the permeability barrier. 
The amount of DNA that reaches the nucleus is made lower due to the cytoplasmic 
nuclease that can degrade DNA, such that the majority of DNA that enters the cytoplasm 
never arrives in the nucleus. For non-dividing cells, the mechanisms of DNA nuclear 
transport are of critical importance.  
To facilitate nuclear targeting, many nuclear localization signal (NLS) peptides have been 
developed to allow DNA nuclear entry through NPCs by active transport. NLSs are short 
clusters of amino acids that can bind to cytoplasmic receptors known as importins. NLS 
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peptides can bind to DNA either through non-covalent electrostatic interaction or by 
covalent attachment. The most well-known and popularly used NLS is from the large 
tumor antigen of simian virus 40 (SV40).
155
 Some DNA sequences themselves have 
nuclear import activity based on their ability to bind to cell-specific transcription factors, 
such as the SMGA promoter and flk-1 promoter.
156
  
In summary, in order to elicit superior in vivo therapeutic response to correct genetic 
defects, the non-viral vector must be able to tightly condense and protect nucleic acids to 
avoid enzymatic degradation, accumulate at tumor sites with little RES uptake, target 
specific cells, disrupt the endosomal membrane and release the therapeutic cargo to 
cytoplasm, and translocate the DNA cargo to the nucleus.
154
  (Fig 2.1) 
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Figure 2.1 Representative scheme of in vivo gene delivery barriers. EPR, 
enhanced permeability and retention; mRNA, messenger RNA; PEG, polyethylene glycol; 
RES, reticuloendothelial system; RISC, RNA-induced silencing complex; siRNA, small 
interfering RNA. 
2.3 NON-VIRAL VECTOR DESIGN FOR IN VIVO GENE DELIVERY 
2.3.1 Lipoplex/Polyplex 
Nucleic acids are easily complexed with cationic lipids (e.g. DOTAP), cationic polymers 
(e.g. PEI), biodegradable cationic polysaccharides (e.g. chitosan), and cationic 
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polypeptides (e.g. polylysine, protamine), via electrostatic interactions. By changing the 
charge ratio associated with nucleic acids and condensing agents, the transfection 
efficiency of condensates can be optimized
122
. Cationic polymers and lipids have shown 
superior gene transfection efficiency, but they have dose-dependent toxicity upon 
systemic administration. Among cationic polymers, the polymer chain length and the 
presence or absence of hydroxyl groups play a role in polyplex size and charge in 
addition to transfection efficiency and toxicity. The high gene transfection usually 
correlates with the high cytotoxicity.
157
 Grandinetti et al
158
 reported that direct interaction 
between (PEI-pDNA) polyplexes and mitochondria during PEI transfection causes 
impaired mitochondrial function through membrane depolarization and could be the 
reason for high cytotoxicity in the PEI-based vehicles. This toxicity can be ameliorated 
by conjugation with biocompatible, hydrophilic polymers such as PEG
159, 160
, and some 
pH and enzyme-sensitive linkers are widely used. For example, Walker et al designed 
pH-triggered deshielding polyplexes to enhance endosome release, and Yin et al 
entrapped RNA in poly (β-amine esters) complex nanoparticles that are degradable in the 
reductive environment due to the cleavage of disulfide bonds
129, 161
. Furthermore, some 
synthetic polymers have been optimized using combinatorial chemistry and library 
screening in order to mimic viral functional delivery domains, such as surface ligands for 
cell entry, evasion from endolysosomal compartment, and entry into the cytoplasm of 
target cells. Many defined, precise sequences have been found  to perform potent pDNA 
and siRNA delivery by using solid-phase synthesis.
162
 Since different topologies of the 
defined synthetic polymer structures can influence the complexation and biological 
properties of transfection agents, Schaffert et al
163
 explored the gene delivery efficiency 
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and cytotoxicity of linear polycations with modifications in different areas and found that 
these changes could cause robust differences in biological function.  
2.3.2 Lipopolyplex 
In order to increase serum stability, avoid RES uptake and increase tumor accumulation, 
Li et al
164
 designed a liposome-polycation-DNA nanoparticle (LPD) for siRNA delivery. 
siRNAs were mixed with calf thymus DNA before being condensed with protamine. 
Protamine is a natural arginine-rich cationic polypeptide which is biocompatible, 
biodegradable and nontoxic, so it is more desirable than synthetic polymers. The 
condensed particles were wrapped by cationic liposomes, followed by grafting PEG-lipid 
conjugate (DSPE-PEG) with or without a targeting ligand using a postinsertion method. 
The LPD can deliver a significant fraction of injected siRNA into the tumor after i.v. 
injection with little RES uptake. siRNA formulated in the targeted LPD completely 
silenced oncogenes in tumors, induced tumor cell apoptosis, and achieved superior tumor 
growth inhibition
165,166
. By adjusting the siRNA to protamine ratio, a positively changed 
LPD core can also be attained.  LPD-II was formed by wrapping an anionic liposome 
composed of DOPA around this LPD core, followed by grafting DSPE-PEG
167
. Based on 
the LPD formulation, Chono et al
168
 developed a liposome-polycation-hyaluronic acid (or 
heparin) nanoparticle (LPH). A remarkable advantage for LPH is that it showed very 
little immunotoxicity in a wide dose range compared to LPD. Chen et al
169
 used the scFv 
ligand targeted LPH to effectively deliver siRNAs (c-Myc/MDM2/VEGF) and miRNA-
34a to a B16F10 lung metastasis model. Fig 2.2 shows the structure and preparation 
scheme of LPD (LPD-II)/LPH nanoparticles. 
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Figure 2.2 The structure and preparation scheme of LPD (LPD-II)/LPH 
nanoparticles. LPD, liposome-polycation-DNA; LPH, liposome-polycation-hyaluronic 
acid (or heparin); pDNA, plasmid DNA; PEG, polyethylene glycol; siRNA, small 
interfering RNA. 
mRNA can be loaded in lipopolyplexes (termed LPRs, lipid-polymer-RNA) using the 
similar method of LPDs. Perche et al
170
 reported that MART-1 mRNA lipopolyplexes 
with mannosylated liposomes (Man11-LPR100) targeting dendritic cells can be used as 
an efficient system for anti-B16F10 melanoma mRNA-based vaccines. A great inhibition 
of B16F10 melanoma growth was obtained after mice were intravenously immunized 
with MART-1 Man11-LPR100, indicating that tumor antigen mRNA-loaded Man11-
LPR100 is an efficient system to induce an anticancer immune response.  Although 
mRNA serves as a potential therapy in various medical indications, like other nucleic 
acid molecules, its strong immunogenicity and limited stability hamper clinical 
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applications. To solve these limitations, Kormann et al
171
 designed a combination of 
nucleotide modifications. They found that replacement of only 25% of uridine and 
cytidine with 2-thiouridine and 5-methyl-cytidine synergistically abrogated mRNA 
interaction with TLR3, TLR7, TLR8 and retinoid-inducible gene I (RIG-I), thus 
substantially decreasing activation of the innate immune system. High expression of 
therapeutic proteins were detected in mice after intramuscular administration of double-
modified mRNA, as well as in a congenital surfactant protein B (SP-B) deficiency 
disease model after two intratracheal doses of modified SP-B mRNA.   
Although LPD nanoparticles are successful in the systemic delivery of siRNA, the 
delivered siRNA does not completely dissociate from the nanoparticles, such that most of 
the encapsulated siRNA is not bioavailable. In order to solve the problem regarding the 
inefficient release of siRNA from LPD, Li et al
153
 developed a Lipid-Calcium-Phosphate 
nanoparticle (LCP). The LPD’s DNA-protamine complex core was replaced by a 
biodegradable nano-sized calcium phosphate (CaP) precipitate prepared by water-in-oil 
microemulsions, and siRNA was entrapped in the CaP core. The rationale for the LCP 
design is that the CaP precipitate in the LCP core would dissolve and de-assemble at low 
pH in the endosome, increase the osmotic pressure, and cause endosome swelling and 
bursting to release the entrapped siRNA. The LCP can be further optimized by changing 
the precipitate core and the coating lipids. 
Harashima et al developed a liposomal gene carrier known as multi-functional nano 
device (MEND) for systemic gene delivery. Similar to LPD, MEND consists of a 
nucleotide core condensed with polycations and covered with lipid membranes. The 
surface of the lipid envelope can be modified with various functional devices, such as 
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PEG for prolonged circulation, specific ligands for targeting, or fusogenic peptides for 
endosomal escape.
172
 In order to avoid the PEG dilemma, an enzyme-cleavable PEG 
system, PEG-peptide-DOPE conjugate (PPD), was used to modify MEND
132
. In this 
strategy, the PEG is removed from MEND via the cleavage by a matrix metalloproteinase 
(MMP), which is specifically expressed in tumor tissues.  
Harashima et al
151, 152
 further modified a fusogenic peptide GALA 
(WEAALAEALAEALAEHLAEALAEALEALAA) on MEND for the sake of promoting 
endosome release. The 30 amino acid GALA contains a glutamic acid-alanine-leucine-
alanine sequence that is repeated 4 times. Since the carboxyl groups of glutamic acid are 
negatively charged at physiological pH, electric repulsion between these groups forces 
GALA to be a random coil structure. In contrast, at acidic endosomal pH, protonation of 
the carboxyl group side chains of the glutamic acids dissipates electric repulsion, so the 
GALA structure changes into an α-helix, a structure that tends to induce membrane 
fusion. To avoid the recognition by biomacromolecules in vivo, a shorter version of 
GALA (shGALA) was developed, which was masked by the PEG layer of the MEND. 
The shGALA-modified MEND showed significant gene silencing in the tumor and 
inhibition of tumor growth.   
2.3.3 Aptamer-siRNA chimeras 
Aptamers are three-dimensional single-chain nucleic acid molecules that bind to a 
specific target molecule with high affinity and specificity.
173
 They are selected from a 
combinatorial library of randomized sequences through repeated rounds of selection, 
known as “systematic evolution of ligands by exponential enrichment” (SELEX) 174, and 
the target molecules can be small molecules, nucleic acids, proteins, carbohydrates, 
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whole cells, and even organisms. Aptamers have high diversity and those possessing very 
high affinities to the target molecules can be isolated. In addition, they are relatively 
stable in storage and elicit little immunogenicity in therapeutic applications.  
Most aptamer-siRNA targeted chimeras for cancer therapy are against PSMA, a cell-
surface receptor over-expressed in prostate cancer cells and tumor vascular endothelium. 
McNamara et al
175
 developed aptamer-siRNA chimeric RNAs. The aptamer portion of 
the chimeras mediated binding to PSMA, whereas the siRNA portion targeted the 
expression of tumor survival gene Plk1 and Bcl-2. The chimera effectively delivered 
siRNAs to LNCaP prostate cancer cells expressing PSMA, and triggered apoptosis and 
cell death both in cultured cells and in a prostrate tumor xenograft model
175
. In order to 
enhance silencing activity and specificity of siRNA, Dassie et al
176
 incorporated 
modifications, including adding 2-nucleotide 3’-overhangs and optimizing the 
thermodynamic profile and structure of the duplex, which enabled more efficient 
processing of the siRNA guide strand and reduced the effective concentration of siRNA 
portion. The optimized chimeras resulted in pronounced regression of PSMA-expressing 
tumors after systemic administration. Anti-tumor activity was further enhanced by 
grafting a 20 kDa PEG moiety to the 5’-terminus of the RNA strand, which increased the 
chimeras’ circulating half-life and bioavailability without affecting chimera targeting and 
silencing. The aptamer portion of the chimeras can also be truncated from 71nt to 39nt 
without loss of function, so that large-scale chemical synthesis can be facilitated. In 
principle, the aptamer-siRNA chimera approach can be applied to target reagents to many 
different cell types, provided that a cell-specific receptor exists and that an aptamer 
against the receptor can be selected
176
.  
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2.4 LOCAL  GENE DELIVERY 
Local delivery by external stimulations can avoid or delay RES uptake, reduce systemic 
toxicity, provide organ specificity, and help the delivery system reach the target cells. 
These environment-sensitive nanoparticles have been designed to release their contents 
based on the environmental changes leading to controlled drug release, such as 
temperature, light, ultrasound response, or magnetic stimulus.  
2.4.1 Bubble liposomes by ultrasound exposure 
Ultrasound technology provides an easy, safe, minimally-invasive, and tissue-specific 
method for gene delivery into tumors
177
. The bubble liposome (BL) is one of the most 
favorable ultrasound-aided delivery methods. BLs entrap the ultrasound imaging gas 
perfluoropropane, exploiting the cavitation bubbles produced by the pressure oscillations 
of ultrasound.  This not only transiently enhances the permeability of a tissue or a cell 
membrane, reducing the thickness of the unstirred layer of the cell surface and aiding 
DNA entry into cells
177
, but also affects the intracellular vesicles and trafficking after 
ultrasound exposure, thus enhancing the escape of gene cargo from the endosome to the 
cytoplasm and further transfer to the nucleus
178
. Negishi et al
178
 have used BLs and 
ultrasound exposure to enhance targeted liposome-mediated pDNA gene transfection, 
while Clumakova et al
179
 have demonstrated that their PLGA nanoparticle gene vector 
produced a significantly higher expression of the reporter gene in the tumor after a five-
minute ultrasonic treatment than that without ultrasound.  
2.4.2 Heat and irradiation 
Au nanoparticles (AuNPs) possess vivid optical properties with strong optical resonances 
associated with their surface plasmons. The optical absorption of AuNPs can be tuned 
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from 690nm to 900nm in the near-infrared spectral range by varying the relative 
geometry and size of the core and shell. The plasmon-based optical properties of AuNPs 
assist in the photothermal ablation of solid tumors, providing a light-triggered release of 
short DNA strands conjugated to the surface of AuNPs.
180, 129
 Ni et al
181
 delivered 
DNAPK shRNAs by PSMA-targeting A10-3 RNA aptamers that selectively sensitized 
PSMA-positive cells to ionizing radiation, so that the toxicities to normal tissues were 
reduced. 
2.4.3 Magnetofection 
Liposomal magnetofection potentiates gene transfection by applying a magnetic field. 
Wang et al
182
 constructed magnetic lipoplexes, which are self-assembling complexes of 
cationic lipids with plasmid DNA associated with superparamagnetic iron oxide 
nanoparticles (SPIONs). Liposomal magnetofection provided a threefold improvement in 
transgene expression over lipofection and knocked down the target protein in vitro. In 
vivo, the plasmid delivery efficiency into the tumor was significantly higher via liposomal 
magnetofection than lipofection.  
2.5 CONCLUSION AND PERSPECTIVE  
Various strategies have been developed to deliver gene cargos efficiently into target cells 
by non-viral vectors, which have attracted much attention in recent years. Rationally 
designed non-viral vectors have exhibited improved in vivo stability and 
pharmacokinetics, little RES uptake, high tumor accumulation, target specificity, efficient 
endosome release, and nuclear transcription of the encapsulated therapeutic nucleic acids. 
Even so, we have no doubt that the development of safe, stable, effective, and tumor-
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speciﬁc nanoparticles for systemic administration remains an unmet goal for successful 
clinical applications of cancer gene therapeutics. 
This literature review leads to the project designs described in Chapter 4 and Chapter 5 of 
this thesis.  
 
3.0  SYSTEMIC DELIVERY OF GEMCITABINE TRIPHOSPHATE VIA LCP 
NANOPARTICLES FOR NSCLC AND PANCREATIC CANCER THERAPY 
Nucleoside analogues are a significant class of anticancer agents. As prodrugs, they 
terminate the DNA synthesis upon transforming to their active triphosphate metabolites. 
However, several in vivo delivery hurdles compromise their application in clinical 
settings. To address these delivery problems, we encapsulated the biologically activate 
nucleotide analogue (i.e. gemcitabine triphosphate (GTP)), instead of any form of 
nucleoside (i.e. gemcitabine) derivatives, into a novel Lipid/Calcium/Phosphate 
nanoparticle (LCP) platform. The therapeutic efficacy of LCP-formulated GTP was 
evaluated in a panel of human non-small-cell lung cancer (NSCLC) and human 
pancreatic cancer models after systemic administrations. GTP-loaded LCPs induced cell 
death and arrested the cell cycle in the S phase. In vivo efficacy studies showed that 
intravenously injected GTP-loaded LCPs triggered effective apoptosis of tumor cells, 
significant reduction of tumor cell proliferation and cell cycle progression, leading to 
dramatic inhibition of tumor growth, with little in vivo toxicity. Broadly speaking, the 
current study offers preclinical proof-of-principle that many active nucleotide or 
phosphorylated nucleoside analogues could be encapsulated in the LCP nanoplatform and 
delivered systemically for a wide variety of therapeutic applications.  
Reference: Yuan Zhang, William Y Kim, Leaf Huang. Systemic delivery of gemcitabine 
triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. 
Biomaterials. 2013 Feb 1. doi: 10.1016/j.biomaterials.2013.01.063.
3.1 INTRODUCTION 
Cytotoxic nucleoside analogues have received considerable attention as clinical cancer 
treatments, including treatments for hematological malignancies and solid tumors
183
. 
About 20% of small molecule therapeutics that have been approved by the FDA for 
cancer treatment are nucleoside analogues or related compounds
184
. These drugs act as 
antimetabolites by interfering with nucleic acid synthesis and enzymes of nucleotide 
metabolism
185
.   
Gemcitabine (2’, 2’-difluoro 2’-deoxycytidine) (Gem) is a nucleoside analogue widely 
used in chemotherapy as a first-line treatment of various carcinomas, including non-small 
cell lung cancer (NSCLC) and pancreatic cancer
186
. As a prodrug, Gem relies on 
nucleoside transporters to enter into cells. The overall drug uptake depends on the 
balance of the nucleoside transporters and drug efflux proteins presented on the cell 
membrane. Once in the cells, Gem undergoes sequential phosphorylation into 5’-
triphosphates by deoxycytidine kinase (dCK) before it can be incorporated into DNA and 
cause DNA synthesis inhibition, which leads to DNA damage and cell apoptosis. 
Triphosphates are the active forms of nucleotides in biosynthesis and energy conversions. 
Nucleoside monophosphates are converted into nucleoside triphosphates by two steps. 
First, nucleoside monophosphates are converted into diphosphates by specific nucleoside 
monophosphate kinases that utilize ATP as the phosphoryl-group donor. Second, 
nucleoside diphosphates and triphosphates are interconverted by nucleoside diphosphate 
kinase which has broad specificity. However, processes of mutational resistance readily 
occur in the nucleoside activation process, which makes Gem less efficacious. Examples 
of mutational resistance include down-regulation of nucleoside influx transporters (e.g. 
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ENT1, ENT2, CNT1, CNT3), up-regulation of drug efflux proteins (e.g. MRP, BCRP), 
and inactivation of dCK
187. In addition, Gem is rapidly metabolized to 2’,2’-
difluorodeoxyuridine by the deoxycytidine deaminase and quickly excreted by the kidney 
following in vivo administration. The overall in vivo delivery hurdles of Gem are shown 
in Figure 3.1. 
 
 
Figure 3.1 In vivo delivery hurdles of Gemcitabine. 
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In order to enhance the in vivo delivery efficiency of Gem and overcome the 
aforementioned delivery challenges, our strategy is to entrap the bioactive form of Gem, 
gemcitabine triphosphate (GTP), into a cell-specific, targeted Lipid/Calcium/Phosphate 
nanoparticle (LCP). In this way, the metabolism mechanisms of Gem will be bypassed 
and the bioactive drug will be delivered directly into the cell through receptor-mediated 
endocytosis. Furthermore, LCPs can protect GTP from enzymatic breakdown, preventing 
inactivation within circulation and rapid excretion by the kidney.   
Nanoparticles (NPs) are prone to lysosomal degradation after endocytosis. To avoid the 
degradation of entrapped drugs, NPs must be able to escape from endosomes before 
trafficking to lysosomes. In order to achieve this goal, we used calcium phosphate (CaP) 
precipitate to entrap GTP. The CaP core of the LCPs is dissolvable in endosomes due to 
its low pH
188
. Increase in osmotic pressure in the endosome leads to endosome swelling 
and rupture, releasing the entrapped GTP into the cytoplasm and allowing it to enter into 
the nucleus. A lipid bilayer membrane surrounds the GTP-entrapped CaP core and a high 
density of polyethylene glycol (PEG), either with or without a tethered targeting ligand 
anisamide (AA), was grafted onto the surface. These characteristics increased the tumor 
accumulation of the drug through the enhanced permeability and retention (EPR) effect
189
. 
They also allowed tumor specific targeting and reduced reticuloendothelial system (RES) 
uptake
190
.  
In this study, the feasibility of using the novel LCPs as a nanocarrier for the delivery of 
biologically active GTP was evaluated on human NSCLC and pancreatic cancer models. 
The small molecule ligand anisamide (AA) was modified on the LCP for specific tumor 
targeting via the sigma receptors that are overexpressed in many human cancer cells. 
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Since cytidine triphosphate (CTP) has a similar structure to GTP and does not have any 
therapeutic activity, CTP-loaded LCPs were prepared as control nanoparticles. The 
cytotoxic activity of LCP-formulated GTP was compared with free GTP and its prodrug, 
Gem, both in vitro and in vivo.  
3.2 MATERIALS AND METHODS 
3.2.1 Materials 
Gemcitabine triphosphate tris(triethylammonium) salt was synthesized by Bioduro 
company (Beijing, China). Gemcitabine was purchased from HDH Pharma, Inc. 
(Research Triangle Park, NC). 1，2-Dioleoyl-3-trimethylammonium-propane chloride 
salt (DOTAP), dioleoyl phosphatydic acid (DOPA), and 1,2-distearoryl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethyleneglycol-2000) ammonium salt (DSPE-
PEG2000) were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). DSPE-PEG-
anisamide (AA) was synthesized in our lab as described previously [9]. Other chemicals 
were obtained from Sigma-Aldrich (St. Louis, MO). 
3.2.2 Cell culture 
H460 human NSCLC cells and BxPC-3 human pancreatic cancer cells, originally 
obtained from American Type Culture Collection (ATCC), were cultured in a RPMI-
1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 
100 U/mL penicillin, and 100 µg/mL streptomycin (Invitrogen). Cells were cultivated in 
a humidified incubator at 37°C and 5% CO2.  
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3.2.3 Experimental animals 
Female nude mice that were 6-8 weeks of age were used in all studies. To establish the 
xenograft models, 5×10
6
 cells in 100 µL of PBS were injected subcutaneously into the 
right flank of the mice.  All work performed on animals was approved by the Institutional 
Animal Care and Use Committee at the University of North Carolina at Chapel Hill. 
3.2.4 Preparation of GTP-loaded LCPs 
The LCP cores were prepared by water-in-oil micro-emulsions in the oil phase containing 
cyclohexane/ Igepal CO-520 solution (71/29, v/v)
192
. One hundred and eighty µL of 20 
mM GTP was mixed with 12.5 mM Na2HPO4 (pH=9.0) to the total volume of 600 µL 
before the addition of a 20 mL oil phase with continuous stirring. The calcium micro-
emulsion was prepared by adding 600 µL of 2.5 M CaCl2 to a separate 20 mL oil phase. 
Four hundred µL of 20 mM DOPA in chloroform was added to the phosphate phase and 
then the two separate micro-emulsions were mixed. After stirring for 5 min, another 400 
µL of 20 mM DOPA was added into the emulsion. The emulsion was stirred 
continuously for 20 min before 40 mL of absolute ethanol was added. The ethanol 
emulsion mixture was centrifuged at 9,000 g for 15 min to pellet the LCP core and the 
supernatant was discarded. The LCP core was washed twice with absolute ethanol and 
dried under N2. The LCP core pellets were dissolved in 2 mL chloroform and stored in a 
glass vial at -20ºC for future use. To prepare the final GTP-loaded LCPs (GTP-LCP-PEG) 
with an outer lipid coating, 330 µL LCP core in chloroform was mixed with 38.7 µL of 
10 mg/ml cholesterol, 28 µL of 25 mg/ml DOTAP, 96 µL of 25 mg/ml DSPE-PEG. After 
evaporating the chloroform, the residual lipids were dissolved in 30 µL THF followed by 
50 µL absolute ethanol, and then suspended in 160 µL water. After brief sonication, the 
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solution was dialyzed in distilled water to remove THF and ethanol. The AA-targeted 
GTP-loaded LCPs (GTP-LCP-PEG-AA) were prepared in the same way, except that 20% 
DSPE-PEG was replaced by an equal molar amount of DSPE-PEG-AA.   
3.2.5 Characterization of GTP-loaded LCPs  
The particle size and zeta potential of LCPs were determined by Dynamic light scattering 
(DLS) using a Malvern ZetaSizer Nano series (Westborough, MA). GTP encapsulation 
efficiency was measured by a UV spectrophotometer (Beckman Coulter Inc., DU 800 
spectrophotometer). Transmission electron microscope (TEM) images of GTP-loaded 
LCPs were acquired through the use of JEOL 100CX II TEM (Tokyo, Japan).  Briefly, 4 
µl of LCP solution was dropped onto a 300 mesh carbon coated copper grid (Ted Pella, 
Inc., Redding, CA) for 2 min. Excess fluid was removed with filter paper, and the copper 
grid was dried before observation with TEM. To determine the release kinetics of GTP-
loaded LCP nanoparticles, 250 µL of GTP-loaded nontargeted or targeted particle 
solution was placed in a dialysis bag (MWCO 10,000 Da), and dialysis against 10 mL 
PBS buffer at 37°C with gentle shaking (50 rpm). Aliquots of release medium were 
withdrawn at designated time points, and equal amount of fresh PBS buffer was 
replenished. The GTP concentration was then measured by HPLC, with mobile phase 
containing 10% MeOH/90% 20 mM NH4OAc. The flow rate was 1 mL/min at 20°C and 
the UV detection wavelength was set at 254 nm.   
3.2.6 In vitro cellular uptake 
In the preparation of LCPs, small amount of NBD-labeled phosphatydic acid was used to 
label the LCP cores. H460 cells were seeded in 24-well plates (Corning Inc., Corning, 
NY) with cover glass. Twenty-four h later, cells were treated with NBD labeled LCP 
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formulations at 37°C for 1 h. After washing twice with PBS, cells were fixed with 4% 
paraformaldehyde at room temperature for 10 min, and stained the nuclei with DAPI 
(Vector Lab, Burlingame, CA) before imaging with a Leica SP2 Confocal Laser 
Scanning Microscope (Germany). In the receptor competitive inhibition experiment, cells 
were pre-incubated with 50 µM haloperidol (a sigma receptor agonist) for 1 h prior to the 
incubation with NBD labeled GTP-LCP-PEG-AA for 1 h. To quantify the cellular uptake 
efficiency, H460 cells were seeded in 6-well plates 24 h before the treatment of NBD 
labeled LCPs for 1 h. Then cells were harvested and washed with PBS, and the NBD 
fluorescence intensity in the cells was detected by a FACS Canto flow cytometry (BD 
Biosciences). A total of 10,000 events were acquired for each sample and the mean 
fluorescence intensity of NBD in the cells was analyzed with FACS Diva software (BD 
Biosciences). 
3.2.7 In vitro cytotoxicity assay 
In vitro cytotoxicity of GTP-loaded LCPs and free drugs (GTP, Gem) was determined 
using the 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) assay. 
Cells were seeded in 96-well plates. When cells reached 30% confluence, different 
concentrations of GTP-LCP-PEG-AA, GTP-LCP-PEG, GTP, Gem, and CTP-LCP-PEG-
AA were added to the medium. After 48 h exposure to the LCPs and free drugs at 37ºC, 
MTT (Biosynth Inc.) was added to each well with a final concentration of 0.5 mg/mL, 
and incubated with cells at 37ºC for 4 h. The absorbance at a wavelength of 570 nm was 
measured with a microplate reader. Cell viability was calculated as the percentage of the 
absorbance of the treated cells to that of untreated cells.  
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3.2.8 Cell cycle analysis 
Cells (2×10
5
) were seeded in 6-well plates, and GTP-LCP-PEG-AA, GTP-LCP-PEG, 
GTP, Gem, and CTP-LCP-PEG-AA were added the following day resulting in a final 
concentration of 1.8 µM. After 24 h incubation, cells were trypsinized and washed with 
PBS followed by fixation in pre-cooled 70% ethanol at -20ºC for at least 1 h. Fixed cells 
were washed with PBS staining buffer (BD Pharmingen, San Diego, CA) and incubated 
with RNAase (final concentration 75 µg/mL) at 37ºC for 30 min, followed by incubation 
with 10 µg propidium iodide (PI) at room temperature for 30 min. Finally, cells were 
washed and suspended in PBS, and analyzed with a FACS Canto flow cytometry (BD 
Biosciences) to measure the PI intensity, which correlates with the DNA content in the 
cell cycle. A total of 10,000 events were acquired for each sample and data were analyzed 
with FACS Diva software (BD Biosciences). 
3.2.9 Caspase activation 
Cells (2×10
5
) were seeded in 6-well plates, and treated with GTP-LCP-PEG-AA, GTP-
LCP-PEG, CTP-LCP-PEG-AA, GTP, and Gem with a dose of 1.8 µM for 48 h. For the in 
vivo caspase activation study, H460 and BxPC-3 tumor-bearing mice were given 3 daily 
intravenous (IV) injections of GTP-LCP-PEG-AA, GTP-LCP-PEG, CTP-LCP-PEG-AA, 
GTP, and Gem with a dose of 7.5 µmol/Kg (1.98 mg/Kg in terms of Gem). Twenty-four 
hours after the last injection, mice were sacrificed and tumors were harvested. The cells 
and tumor tissues were lysed with a radioimmunoprecipitation assay (RIPA) buffer that 
was supplemented with a protease inhibitor cocktail (Promega, Madison, WI). Protein 
concentrations were determined using the BCA assay kit (Pierce Biotechnology) 
following the manufacturer’s recommendations. Forty µg protein of each sample was 
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used to detect caspase-3/7 activity of the cell or tumor lysates according to the 
manufacturer’s instructions (Promega).  
3.2.10 Western blot analysis 
Twenty-four h after 3 daily IV injections, H460 and BxPC-3 tumor-bearing mice were 
sacrificed and tumor lysates were prepared as previously described. Forty µg of protein 
per lane was separated by 4%-12% SDS-PAGE electrophoresis (Invitrogen) before being 
transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad). The membranes 
were blocked for 1h with 5% silk milk at room temperature and then incubated with 
mouse monoclonal poly(ADP-ribose) polymerase-1 (PARP-1) antibodies and rabbit 
polyclonal cyclin D1 antibodies (1:500 dilution; Santa Cruz biotechnology, Inc.) 
overnight at 4ºC. β-actin antibody (1:4000 dilution; Santa Cruz biotechnology, Inc.) was 
probed as the loading control. The membranes were washed 3 times and then incubated 
with a secondary antibody (1:4000 dilution; Santa Cruz biotechnology, Inc.) at room 
temperature for 1 h. Finally, the membranes were washed 4 times and developed by an 
enhanced chemiluminescence system according to the manufacturer’s instructions 
(Thermo scientific). 
To confirm sigma receptor expressions on NSCLC and pancreatic cell lines, forty µg 
protein in different cell lysates were probed with sigma receptor antibody (1:500 dilution; 
Santa Cruz biotechnology, Inc.) and β-actin antibody (1:4000 dilution; Santa Cruz 
biotechnology, Inc.) overnight at 4ºC. Goat anti-mouse secondary antibody was used to 
detect sigma receptor and β-actin primary antibody. 
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3.2.11 Immunostaining 
In vivo tumor cell apoptosis after systemic administration was determined by the TdT-
mediated dUTP Nick-End Labeling (TUNEL) assay. H460 and BxPC-3 tumor-bearing 
mice were given 3 daily IV injections of GTP-LCP-PEG-AA, GTP-LCP-PEG, CTP-
LCP-PEG-AA, GTP, and Gem with a GTP dose of 7.5 µmol/Kg. Twenty-four h after the 
final injection, mice were sacrificed and tumors were fixed in 10% formalin for 24 h 
before being embedded in paraffin and sectioned at a thickness of 5 µm. The TUNEL 
staining was performed as recommended by the manufacturer (Promega). DAPI 
mounting medium was dropped on the sections for nucleus staining. Images of TUNEL-
stained tumor sections were captured with a fluorescence microscope (Nikon Corp., 
Tokyo, Japan). The percentage of apoptotic cells was obtained by dividing the number of 
apoptotic cells (TUNEL positive cells shown as green dots in Fig. 5) from the number of 
total cells (blue nuclei stained by DAPI, not shown) in each microscopic field, and 10 
representative microscopic fields were randomly selected in each treatment group (n=3) 
for this analysis.  
Proliferation of tumor cells after the aforementioned treatments and dosing schedule was 
detected by immunohistochemistry, using an antibody against proliferating cell nuclear 
antigen (PCNA) (1:200 dilution, Santa Cruz). The immunohistochemistry was performed 
using a mouse-specific HRP/DAB detection IHC kit as recommended by the 
manufacturer (Abcam, Cambridge, MA). The percentage of proliferation cells was 
obtained by dividing the number of PCNA positive cells (shown as brown dots) from the 
number of total cells (blue nuclei stained by hematoxylin) in each microscopic field, and 
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10 representative microscopic fields were randomly selected in each treatment group 
(n=3) for counting.  
In addition to H460 and BxPC-3 xenograft models, we also tested the therapeutic 
response of GTP-LCP-PEG-AA on a NSCLC A549 xenograft model and a panel of 
pancreatic xenograft models, including Mia PaCa-2, AsPC-1, Capan-1, CFPAC-1, 
PANC-1 and SW1990 in vivo. Results were measured by TUNEL assay and PCNA 
immunohistochemistry.  
3.2.12 Pharmacokinetic profile of GTP-loaded LCPs 
In the preparation of GTP-loaded LCPs, we mixed a trace amount of radioactive cytidine 
5’ triphosphate (CTP) [5-3H] disodium salt (American Radiolabeled Chemicals, Inc., 
1mCi/mL) with GTP. Tritium labeled CTP served as a marker for the entrapped GTP. 
Thus, by measuring the tritium radioactivity, the percentage of GTP-loaded LCPs or free 
GTP circulating in the blood can be calculated. Nude mice bearing H460 tumors were IV 
injected with tritium-labeled, GTP-loaded LCPs or free GTP. At 20 min, 1 h, 2 h, 4 h, 8 h, 
24 h post injection time point, 30 µL blood was drawn from the venous plexus of the eyes 
of the mice, and was mixed with 4 mL scintillation cocktail (Thermo Fisher Scientific 
Inc.). In order to avoid color interference with the scintillation counting, 120 µL of 
hydrogen peroxide (30% in water) was added to samples and vortexed to bleach the 
blood color before measurement. The tritium radioactivity in blood samples was counted 
using a liquid scintillation analyzer (Packard BioScience Co. TRI-CARB 2900TR). The 
percentage of the injected dose (%ID) in the blood was calculated based on the tritium 
DPM (Disintegrations per minute) values using an established standard curve. The initial 
concentration was set as 100% of the injected dose (ID). The post injection time (t) 
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and %ID were fitted with a non-compartment model using the WinNonlin program and 
the key PK parameters were calculated. 
3.2.13 Tumor growth inhibition and toxicity study  
A tumor growth inhibition study was completed on H460 and BxPC-3 subcutaneous 
xenograft mouse models. When the tumor volumes reached about 150-200 mm
3
, the mice 
were randomly assigned into 6 treatment groups (n=5), and intravenously injected 
different formulations, including GTP-LCP-PEG-AA, GTP-LCP-PEG, CTP-LCP-PEG-
AA, GTP, and Gem. IV injections were performed every other day for a total of four 
injections at a GTP dose of 7.5 µmol/Kg. Tumor sizes were measured every other day 
with calipers across their two perpendicular diameters, and the tumor volume was 
calculated using the following formula: 
V=0.5×(W
2
×L), where V = tumor volume, W = the smaller perpendicular diameter and L 
= the larger perpendicular diameter. Body weight of each mouse was recorded every 
other day. Humane sacrifice of mice was performed when tumors reached 20 mm in one 
dimension.  
To test whether GTP-loaded LCPs would induce hepatic and renal dysfunction after 
frequent multiple dosing, mice were given three daily IV injections, and 24 h after the 
final injection, blood was drawn from the venous plexus of the eyes of the mice. Blood 
samples were immediately centrifuged at 3,000 g for 5 min at 4°C, and the supernatant 
blood serums were collected for hematological analysis. Blood urine nitrogen (BUN), 
creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT) values 
were recorded, as indications of hepatic and renal functions.  
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3.2.14 Statistical analysis 
Results were expressed as a mean ± standard deviation (SD). Student’s t-test and one-
way analysis of variance (ANOVA) test were used to evaluate statistical significance. A p 
value of p<0.05 was considered to indicate statistical significance. 
3.3 RESULTS 
3.3.1 Characterization of GTP-loaded LCPs  
The GTP used in this study is gemcitabine triphosphate tris(triethylammonium) salt (Fig 
3.2A) which is synthesized as previously reported
193
. The particle sizes and zeta 
potentials of different LCP formulations were shown in Table 3.1. The GTP-loaded 
LCPs were homogeneous and spherical in shape, as shown in the TEM micrograph (Fig 
3.2B). The encapsulation efficiency of GTP in LCPs was around 25%, as measured by 
UV spectrometry at a wavelength of 288 nm (data not shown). The GTP release profile 
from LCP nanoparticles were shown in Fig 3.2D. About 70-80% GTP was released from 
the particles in 48 h.  
 
Table 3.1 Particle size and zeta potential of LCPs. 
 
  Size (nm) 
Zeta potential 
(mV) 
GTP-LCP-PEG-AA 42.0 ± 9.0  25.4 ± 5.7 
GTP-LCP-PEG 37.7 ± 7.2 7.2 ± 3.1 
CTP-LCP-PEG-AA 33.4 ± 7.7 18.9 ± 5.4 
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Figure 3.2 Physiochemical characterization of GTP-loaded LCPs. (A) The 
chemical structure of GTP (Gemcitabine triphosphate tris(triethylammonium) salt) used 
in this study. (B) TEM image of GTP-loaded LCPs. (C) Particle size distribution 
measured by DLS. (D) In vitro drug release of GTP from LCP nanoparticles in PBS 
buffer at 37 ºC. The error bars were obtained from triplicate samples. Data are shown as 
mean ± SD. 
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3.3.2 In vitro specific tumor cell targeting  
The cellular uptake of GTP-LCP-PEG-AA and GTP-LCP-PEG at 37°C is shown 
in Fig 3.3. It is clear that the cellular endocytosis of AA-modified LCP was higher than 
that of untargeted LCP as shown by confocal images (Fig 3.3A). The addition of 
haloperidol, a known agonist for sigma receptors, significantly reduced the cellular 
uptake of AA-modified LCP, suggesting AA modification on the LCP induce sigma 
receptor-mediated endocytosis. The quantitative flow cytometry also confirmed that the 
AA ligand increased the intracellular uptake of LCPs (Fig 3.3B-3.3C). 
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Figure 3.3 The cellular uptake of GTP-LCP-PEG and GTP-LCP-PEG-AA at 
37°C for 1 h on H460 cells. (A) Confocal images for intracellular uptake. Green: NBD 
labeled LCP nanoparticles; Blue: DAPI stained nuclei. Scale bar, 15 µm. (B) Flow 
cytometry study of cellular uptake. Red: untreated control cells; Blue: GTP-LCP-PEG; 
Green: GTP-LCP-PEG-AA. Gray: GTP-LCP-PEG-AA after haloperidol (50 µM) 
incubation. (C) Quantitative results from flow cytometry by measuring intracellular mean 
fluorescence intensity. Data are shown as mean ± SD.  
 76 
3.3.3 GTP-loaded LCPs reduced the cell viability 
The MTT assay was carried out to determine the cell viabilities after the treatment 
of GTP-loaded LCPs and free drugs. After 48 h incubation, the GTP-loaded LCPs caused 
dramatic reduction of viable H460 (Fig 3.4A) and BxPC-3 (Fig 3.4B) cells in a dose-
dependent manner. Free Gem and GTP also decreased the cell viability in vitro. This 
observation is explained by the facts that Gem can be taken up into cells through 
nucleoside transporters and GTP can be metabolized to Gem by the alkaline phosphatase 
on the cell surface before entering into cells
194
. CTP-loaded LCPs had little effect on cell 
viability. The IC50 concentrations for each of the treatments (GTP-LCP-PEG-AA, GTP-
LCP-PEG, GTP, Gem) were listed in Table 3.2.  
 
 
 
 
 
The figure legend of Figure 3.4 A and B is on the next page. 
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            Figure 3.4 In vitro cell viability and cell cycle arrest of GTP-loaded LCPs. (A-
B) GTP-loaded LCPs induced potent cytotoxicity in vitro on H460 (A) and BxPC-3 (B) 
cells. The cell viabilities of H460 (A) and BxPC-3 (B) cells were measured by MTT 
assay after 48 h exposure to GTP-loaded LCPs, CTP-loaded LCPs and free drugs (GTP, 
Gem). Data are mean ± S.D. (n=3). (C-D) Cell cycle arrest on H460 (C) and BxPC-3 (D) 
cells after 24 h treatment with different formulations and free drugs were analyzed by 
flow cytometry. The cell population of each sample was gated into three cell cycle phases: 
G1, S, G2/M. The percentage of H460 or BxPC-3 cells in different cell cycle phases of 
each sample was shown in the graph, based on the results from FACS software. 
Statistical analysis of cell cycle on (E) H460 and (F) BxPC-3 cells (n=3). *p<0.05, vs 
Untreated. Data are shown as mean ± SD. 
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Table 3.2 IC50 values in each treatment group in MTT assay on H460 and 
BxPC-3 cells (concentration unit: µM, n=3). Data are shown as mean ± SD. 
 
3.3.4 GTP-loaded LCPs arrested the cell cycle in the S phase 
We next evaluated the effect of GTP-loaded LCPs on the cell cycle progression. The 
mechanism of GTP cell-killing is its competition with cytidine triphosphate during DNA 
replication, which results in the inhibition of chain elongation. The termination of DNA 
synthesis impedes the cell cycle progression, leading to cell death. After 24 h incubation 
with GTP-loaded LCPs, the percentage of cells in the S phase increases in H460 and 
BxPC-3 cells (Fig 3.4C-3.4D), indicating the cell cycles were arrested in the S phase. 
GTP-loaded LCPs inhibited DNA synthesis by interfering with the progress toward the 
completion of S-phase in the cell cycle
195
 because the process of incorporating 
nucleotides generally occurs during DNA replication in the S phase of the cell cycle
196
. 
CTP-loaded LCPs had no effect on cell cycle alteration in both cell lines (Fig 3.4C-3.4D). 
The statistical analysis of the cell cycle result was listed in Fig 3.4E-3.4F. 
3.3.5 GTP-loaded LCPs induced caspase activation in vitro and in vivo 
Caspases are activated in cells when cells undergo the apoptotic process. Among them, 
caspase-3 and caspase-7 are primarily responsible for the proteolytic cleavage of a large 
number of substrates during apoptosis
197
. As shown in Fig 3.5, the in vitro caspase-3/7 
activities of GTP-loaded LCPs and free drug (GTP, Gem) treatments were significantly 
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higher than the control in H460 (Fig 3.5A) and BxPC-3 (Fig 3.5B) cells. In vivo caspase 
activation was tested on H460 and BxPC-3 xenograft models. Twenty-four h after 3 daily 
IV injections, the caspase-3/7 activity in tumors after the treatment of GTP-loaded LCPs 
was significantly higher than that of free drugs in H460 (Fig 3.5C) and BxPC-3 (Fig 
3.5D) xenografts, indicating that the LCPs greatly improved the in vivo delivery 
efficiency of GTP to the tumors. Our data suggests that free GTP and Gem were able to 
activate caspase signaling events only in vitro and did not elicit caspase activity in vivo.  
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Figure 3.5 Caspase activation and western blot analysis after different 
treatments. (A-D) GTP-loaded LCPs induced caspase activation in vitro (A, B) and in 
vivo (C, D). (A-B) In vitro caspase activation in H460 (A) and BxPC-3 (B) cells after 48 
h incubation with different formulations. (C-D) In vivo caspase activation in tumors in 
H460 (C) and BxPC-3 (D) xenografts after 3 daily IV injections. Statistics were as 
follows (n=3): **p<0.005 vs. Untreated, *p<0.01 vs. Untreated. Data are shown as mean 
± SD. (E—F) GTP-loaded LCPs induced PARP cleavage and reduced cyclin D1 
expression level in tumors after 3 daily IV injections in H460 (E) and BxPC-3 (F) 
xenografts. Twenty-four h after the last injection, tumor lysates were extracted and 
analyzed by western blots for cleaved PARP, cyclin D1 and ß-actin (loading control). 
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3.3.6 GTP-loaded LCPs triggered PARP cleavage and inhibited cell cycle 
progression in vivo 
PARP is mainly involved in DNA repair induction and apoptosis. During the execution 
phase of apoptosis, intact PARP (116 kDa) is cleaved to its significant segment (85 kDa) 
by members of the caspase family, mainly caspase-3 and caspase-7
197
, reflecting an 
immediate cellular response to DNA damage. Therefore, the cleavage of PARP serves as 
a reliable marker of apoptosis
198
. From the western blots data (Fig 3.5E and 3.5F), the 
cleaved PARP was significantly elevated after the treatment of GTP-loaded LCPs in 
NSCLC and pancreatic tumors. The cleaved PARP expression level of AA-targeted GTP-
loaded LCPs was higher than that of non-targeted LCPs, due to the specific targeting of 
tumor cells. Free GTP and Gem did not induce PARP elevation and did not trigger 
apoptosis in vivo. This was most likely due to the rapid inactivation and excretion of free 
GTP and Gem after systemic administration, which results in little cellular apoptotic 
response. The high expression level of the cleaved PARP coincided with the high 
caspase-3/7 activity after the treatment of GTP-loaded LCPs in vivo, suggesting that the 
induction of apoptosis by GTP-loaded LCPs was due to the activation of the caspase-
dependent pathway
199
. 
Cyclin D1 is involved in regulating cell cycle progression. GTP-loaded LCPs 
dramatically reduced the cyclin D1 expression (Fig 3.5E and 3.5F), while free drugs did 
not show any cell cycle alteration after in vivo treatment. CTP-loaded LCPs did not elicit 
any cellular response in apoptosis induction or cell cycle alteration.   
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3.3.7 GTP-loaded LCPs triggered tumor cell apoptosis and inhibited tumor cell 
proliferation in vivo 
Apoptotic signaling cascades result in DNA fragmentation (DNA damage) that can be 
detected by TUNEL assay. After 3 daily injections, AA-targeted GTP-loaded LCPs 
elicited the most effective killing effects in vivo and triggered a dramatic increase in 
apoptotic cells in H460 (Fig. 3.6A and 3.6E) and BxPC-3 (Fig 3.6B and 3.6F) xenograft 
tumors when compared with the control. Non-targeted GTP-loaded LCPs showed 
medium cell-killing effects. AA-targeted GTP-loaded LCPs displayed higher efficacy 
than the non-targeted group, suggesting that the receptor-mediated endocytosis was 
involved in the in vivo cellular uptake of LCPs. Free drugs caused few apoptotic cells in 
vivo after systemic administration, probably because the majority of the free drugs were 
metabolized and cleared before they encountered the tumor cells. These in vivo apoptosis 
results also agree with the caspase activation and PARP cleavage in tumors shown in Fig 
3.5. 
Next, we detected the inhibition of tumor cell proliferation following different treatments. 
PCNA is expressed in the cell nuclei during DNA synthesis and can be used as a marker 
for cell proliferation
200
. From the results, GTP-loaded LCPs significantly decreased the 
number of PCNA positive cells in H460 (Fig 3.6C and 3.6G) and BxPC-3 (Fig 3.6D and 
3.6H) xenograft tumors compared to the control. However, free drugs and CTP-loaded 
control LCPs had few anti-proliferative effects. This dramatic reduction of the tumor cell 
proliferation also related to the reduced cell cycle progression as illustrated by the 
decreased cyclin D1 protein expression in tumors shown in Fig 3.5E and 3.5F.  
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The figure legend of Figure 3.6 is on the next page. 
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Figure 3.6 GTP-loaded LCPs triggered tumor cell apoptosis and inhibited 
tumor cell proliferation effectively in vivo in H460 and BxPC-3 xenografts. Mice 
were given 3 daily IV injections. Twenty-four h after the last injection, mice were 
sacrificed and tumor tissues were sectioned for TUNEL assay (A, B) and PCNA 
immunohistochemistry (C, D). The immunostaining results of H460 tumors (A, C), 
BxPC-3 tumors (B, D) were shown. (E-F) Percentage of apoptotic cells in H460 (E) and 
BxPC-3 (F) xenograft tumors after the treatment of different formulations. (G-H) 
Percentage of PCNA positive cells in H460 (G) and BxPC-3 (H) xenograft tumors after 
the treatment of different formulations. Statistics were as follows (n=10): (E) *p<0.01: 
GTP-LCP-PEG-AA vs. Untreated; ‡p<0.05: GTP-LCP-PEG vs. Untreated. (F) *p<0.01: 
GTP-LCP-PEG-AA vs. Untreated; ‡p<0.05: GTP-LCP-PEG vs. Untreated. (G) 
**p<0.0005 vs. Untreated. (H) **p<0.0005 vs. Untreated. Data are shown as mean ± SD. 
 
We also tested the anti-tumor potency of AA-targeted GTP-loaded LCPs on a panel of 
NSCLC (A549) and pancreatic cancer (Mia PaCa-2, AsPC-1, Capan-1, CFPAC-1, 
PANC-1 and SW1990) xenograft models by TUNEL assay and PCNA 
immunohistochemistry (Fig 3.7). These NSCLC and pancreatic cancer cells have been 
reported to overexpress sigma receptors
201-203
. Our data suggest that systemic treatment of 
GTP-LCP-PEG-AA induced a significantly higher fraction of apoptotic cells (~4% to 
12%, Fig 3.7B) and decreased the number of proliferating cells (2 to 4 folds lower, Fig 
3.7C) in tumors compared to the corresponding untreated tumors in all NSCLC and 
pancreatic cancer models tested. These data suggest that GTP-loaded LCP delivery 
platform was efficacious in many tumor malignancies.  
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Figure 3.7 AA-targeted and GTP-loaded LCPs triggered tumor cell apoptosis 
and inhibited tumor cell proliferation effectively in vivo in NSCLC A549 tumor and 
a panel of pancreatic tumor xenografts. (A) Twenty-four h after 3 daily IV injections, 
mice were sacrificed and tumor tissues were sectioned for TUNEL assay and PCNA 
immunohistochemistry. Scale bar, 100 µm. (B) Percentage of apoptotic cells in tumors 
after the treatment of GTP-LCP-PEG-AA. (C) Percentage of PCNA positive cells in 
tumors after the treatment of GTP-LCP-PEG-AA. Statistics were as follows (n=10): (B) 
*p<0.01 vs. Untreated; ‡p<0.05 vs. Untreated. (C) **p<0.0005 vs. Untreated; *p<0.001 
vs. Untreated; ‡p<0.01 vs. Untreated. Data are shown as mean ± SD. 
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3.3.8 GTP-loaded LCPs prolonged blood circulation time in vivo 
The pharmacokinetics (PK) experiment (Fig 3.8) indicated that the GTP-loaded LCPs 
have prolonged blood circulation time compared to the free GTP. After bolus 
administration, about 35-40% of the LCPs were retained in the blood circulation after 2 h, 
while the free GTP was quickly excreted within 20 min. The PK data were fitted with a 
non-compartment model using the WinNonlin program and the key PK parameters were 
calculated (Table 3.3). There was no significant difference between the PK profiles of 
AA-targeted and non-targeted LCPs. The results indicated that GTP-loaded LCPs 
increased the area under the curve (AUC) more than 25 fold and decreased the clearance 
more than 25 fold compared to the free GTP. The mean residence time (MRT) increased 
about 7 fold, the steady state volume of distribution (Vss) decreased about 4 fold. Thus, 
compared to free GTP, LCP-formulated GTP had less chance to distribute into tissues, 
leading to an increase in plasma concentration profile. Taken together, incorporation GTP 
in LCPs increased the drug retention in the circulation, and reduced the drug distribution 
and clearance, which results in the effective therapeutic response occurring at a low dose.   
The pharmacokinetic profile of prodrug gemcitabine is expected to be similar to that of 
GTP, because nucleoside analogs are primarily cleared by the kidney after intraveneous 
administration. Nucleoside metabolism or phosphorylation does not contribute 
significantly to the total clearance of the prodrug.
253
    
The systemic clearance of Gem in human is ranged from 29.2 L/h/m
2
 to 92.2 L/h/m
2 
depending on gender and age (renal clearance is 2-7 L/h/m
2
). Clearance appears to 
decrease with age, and clearance for women is lower than the values for men.
254 
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Figure 3.8 Percentage of the GTP injected dose (%ID) in blood after 
intravenous bolus administration of GTP-loaded LCPs and free GTP in H460 
tumor-bearing mice (n=3). 
Table 3.3 The key pharmacokinetic parameters of GTP-loaded LCPs and 
free GTP in H460 xenograft model. Abbreviations: t1/2, elimination half-life; AUC: area 
under the curve; MRT: mean residence time; CL: clearance; Vss: steady state of volume 
distribution.  Data are generated by using WinNonlin program. Three mice were used per 
group for this analysis. 
 
3.3.9 Tumor growth inhibition study 
The tumor growth inhibition was evaluated in nude mice bearing either H460 or BxPC-3 
subcutaneous tumors. As shown in Fig 3.9A and 3.9B, GTP-LCP-PEG-AA treatment 
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group exhibited the most efficient tumor growth inhibition after 4 systemic injections, 
and GTP-LCP-PEG also suppressed tumor growth effectively compared to the control 
and CTP-loaded LCPs. In GTP-LCP-PEG-AA treatment group, the final tumor loads 
were dramatically suppressed by 80% and 50% compared to the control group in H460 
and BxPC-3 xenograft models, respectively. Free GTP and Gem showed limited 
therapeutic effects as compared to GTP-loaded LCPs. No serious toxicity, indicated by 
body weight changes, was observed (Fig 3.9C and 3.9D).  
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Figure 3.9 GTP-loaded LCPs inhibited the tumor growth on H460 (A) and 
BxPC-3 (B) xenografts. The relative body weight changes of H460 (C) and BxPC-3 (D) 
xenografts were calculated. Data are mean ± S.D. (n=5). Statistics were as follows: 
**p<0.0005 vs. Untreated, ‡p<0.001 vs. Untreated, *p<0.005 vs. Untreated. 
 
Hematological parameters were measured 24 h after 3 daily IV treatments (Table 3.4). 
There was little elevation of BUN, creatinine and liver enzymes (AST, ALT) in blood 
serum compared to the control, and all parameter values were in the normal range. Thus, 
GTP-loaded LCPs, at the therapeutic dose, did not elicit any toxicity in kidney and liver 
and there were no significant safety issues.  
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Table 3.4 Serum levels of BUN, creatinine, AST, ALT after 3 daily IV 
injections (n=3). Data are shown as mean ± SD.    
  BUN mg/dL 
Creatinine 
mg/dL 
AST U/L ALT U/L 
Control 24 0.3 111.0 ± 4.2 56.0 ± 2.8 
GTP-LCP-PEG-AA 24.7 ± 1.2 0.3 144.7 ± 12.9 69.3 ± 22.0 
GTP-LCP-PEG 27.0 ± 2.8 0.3 148.5 ± 82.0 74.2 ± 25.5 
CTP-LCP-PEG-AA 27.0 ± 1.4 0.3 134.0 ± 8.5 73.0 ± 12.7 
Normal Range 18--33.7 0.2--0.9 110.5--247 33.4--132 
 
3.4 DISCUSSION 
All nucleoside analogues require transport into the cell and phosphorylation to the 
triphosphate form to be biologically active. Specific nucleoside transporters are 
responsible for the cellular uptake of the principal therapeutic nucleosides (i.e. 
gemcitabine)
196
. Gem mainly works in rapidly dividing cells (i.e. cancer cells) that 
usually grow at uncontrollable rate. It is reported that high dose therapy with nucleoside 
analogs can overcome the mutational deficiency of nucleoside transporters and limiting 
rates of cellular entry by enhancing passive accumulation of the drug within the cell
204
. 
Additionally, due to the rapid enzyme deamination and renal clearance, Gem has a very 
short plasma half-life
205
. In order to achieve therapeutic drug levels, Gem has to be 
administered at a high dose (1,000 mg/m
2
) by intravenous infusion
205
 which causes 
toxicity, particularly kidney and liver dysfunctions. The extensive usage of nucleoside 
analogs also results in the development of drug resistance
185
.  
In order to improve the therapeutic efficiency of nucleoside analogues, some prodrug and 
drug delivery approaches have been developed. Liposomes were used to load nucleoside 
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drugs due to their biphasic (lipophilic/hydrophilic) character. But most nucleoside 
analogues are located exclusively in the aqueous compartment of liposomes because of 
their relatively high solubilities. However, they readily diffuse through the liposome 
bilayer, which limits their stability on storage and reduces the drug concentration 
accumulated inside the tumors
206
. The fabrication of lipophilic nucleoside derivatives 
increased the cell membrane permeability and was expected to bypass the barriers of 
nucleoside transporters
207
. Other studies focused on entrapping the modified lipophilic 
nucleoside derivatives into liposome’s lipid bilayer208 or micelle’s hydrophobic inner 
core
209
. Though these nanocarriers can alleviate the entrapped nucleoside drugs from 
enzymatic degradation, their therapeutic potency is still dependent on the conversion of 
the lipophilic prodrug to the nucleoside drug inside the tumor cells. Besides, the 
lipophilic nucleosides cannot overcome the resistance mutations in the kinases
210
. Thus, 
there is an unmet medical need for the development of new technologies allowing a more 
effective systemic delivery of nucleoside analogues for the treatment of cancer patients.   
In this study, we report a novel systemic delivery platform of nucleoside analogs. 
Gemcitabine triphosphate (GTP), the bioactive form of Gem, was encapsulated into a 
nanoparticle system containing a calcium phosphate precipitate core, i.e. LCP. Such that 
the cellular uptake deficiency and the following requirement of nucleoside kinase 
activation process of Gem can be avoided. Due to the triphosphate structure, GTP can be 
readily co-precipitated in the CaP core of LCP. A lipid bilayer was used to wrap around 
the LCP core to allow a high density of DSPE-PEG being grafted onto the surface. This 
nanoparticle design can protect the GTP from enzymatic degradation and renal clearance 
in vivo. The surface modification with PEG helps shield the cationic charge of the lipid 
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bilayer and may minimize the interaction with circulating blood components
211
. With AA 
as a tumor specific targeting ligand, LCPs can be more effectively taken up into tumor 
cells via sigma-receptor-mediated endocytosis. When LCPs are delivered to acidic 
endosomes, the CaP core of LCPs rapidly dissolves to increase osmotic pressure, 
eventually bursting the endosomes and enabling the entrapped GTP to escape
188
. The 
cationic lipid DOTAP wrapping the LCP core may also promote the release of GTP from 
endosomes to the cytosol by destabilizing the anionic endosome membrane
212
. Altogether, 
the selection of a right drug formulated in a “smart” delivery system is likely to decrease 
the therapeutic dose required and corresponding dose-dependent adverse effects. 
NSCLC and pancreatic cancers are among the top 3 leading causes of cancer death 
worldwide, and pancreatic cancer is particularly deadly. AA-targeted GTP-loaded LCPs 
showed a potent anti-cancer efficacy in NSCLC H460 and pancreatic BxPC-3 models at a 
low dose. In order to further prove the potential therapeutic applications of GTP-loaded 
LCPs in extensive tumor malignancies, we randomly selected 6 additional human 
pancreatic adenocarcinoma cell lines, and established the xenograft tumor models in nude 
mice. All these pancreatic tumor xenografts responded well to systemic treatment with 
AA-targeted GTP-loaded LCPs (Fig 3.6). In addition, Gem is prone to elicit potent 
clinical efficacy in rapidly proliferating cancer cells with high metabolic activity due to 
its impediment of DNA replication
185
. This is probably the reason that H460 xenograft 
with fast growing tumor showed more significant apoptosis induction and proliferation 
inhibition than other cancer models. The different cell-killing effects may also be 
attributed to the extent of the tumors’ vascular abnormalities, which alter the EPR effect. 
The effectiveness of this LCP formulation to gemcitabine-resistant cancer models will 
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under further investigation. Based on our extensive study on multiple NSCLC and 
pancreatic cancer models, we conclude that the targeted GTP-loaded LCPs elicit 
significant anti-cancer efficacy in vivo. This targeted LCP-formulated GTP represents a 
new class of improved nucleoside anticancer drug which should be further investigated 
for potential clinical trials.   
3.5 CONCLUSION 
Encapsulating the bioactive GTP in LCPs holds the advantages of overcoming 
chemoresistance, targeting specifically to tumor, lowering dosages and toxicities. We 
have shown that AA-targeted GTP-loaded LCPs can induce effective cell death and 
enhanced S-phase cell cycle arrest in NSCLC and pancreatic cell lines in vitro. In vivo, 
AA-targeted GTP-loaded LCPs effectively delayed the tumor growth of human NSCLC 
H460 and pancreatic BxPC-3 cancer xenografts, with little toxicity. Molecular analysis 
indicated that this high efficacy of targeted GTP-loaded LCPs was associated with its 
ability to induce dramatic apoptosis of tumor cells, as shown in the TUNEL assay, 
caspase-3/7 activation and the cleaved PARP overexpression in tumor tissues; as well as 
significantly inhibit tumor cell proliferation and cell cycle progression, as indicated in the 
PCNA immunohistochemistry and the cyclin D1 down-regulation in tumor tissues. To the 
best of our knowledge, this is the first report using gemcitabine bioactive form, GTP, 
instead of any forms of gemcitabine prodrug as the delivery cargo for cancer therapy. 
Further, we predict that many chemotherapeutic drugs with phosphate group(s) could be 
entrapped into LCPs and delivered systemically, so that some of the drugs will no longer 
rely on the relative kinase phosphorylation to be bioactive.   
4.0  CO-DELIVERY OF VEGF SIRNA AND GEMCITABINE 
MONOPHOSPHATE IN A SINGLE NANOPARTICLE FORMULATION FOR 
EFFECTIVE TREATMENT OF NSCLC 
 
There is an urgent need for new therapeutics for the treatment of aggressive and 
metastatic refractory human non-small-cell-lung cancer (NSCLC). Anti-angiogenesis 
therapy and chemotherapy are the two major treatment options. Unfortunately, both types 
of therapy are prone to induce resistance. Integrating anti-angiogenesis therapy with 
chemotherapy is expected to target the tumor’s vascular endothelial cells and the tumor 
cells simultaneously. In this study, we co-formulated VEGF siRNA targeting vascular 
endothelial growth factors and gemcitabine monophosphate (GMP) into a single cell-
specific, targeted Lipid/Calcium/Phosphate (LCP) nanoparticle formulation. Anti-tumor 
effect of the combination therapy using LCP loaded with both VEGF siRNA and GMP 
was evaluated in a xenograft model of NSCLC with systemic administration. The 
improved therapeutic response, as compared to either VEGF siRNA or GMP therapy 
alone, was supported by the observation of effective induction of tumor cell apoptosis, 
significant reduction of tumor cell proliferation and tumor microvessel density. The 
combination therapy led to dramatic inhibition of tumor growth, with little in vivo 
toxicity. Additionally, the current studies demonstrated the possibility of incorporating 
multiple nucleic acid molecules and phosphorylated small molecule drugs, targeting to 
different pathways, into a single nanoparticle formulation for profound therapeutic effect. 
4.1 INTRODUCTION 
The combination of chemotherapy and gene therapy could greatly increase their 
therapeutic efficacy in the treatment of many human diseases. The drug resistance 
associated with standard chemotherapy regimens can be alleviated by the addition of 
gene therapy to the treatment plan
216
. Furthermore, the efficacy of gene therapy can be 
bolstered by chemo-agents whose effects are often more potent and widespread. This 
increase in efficacy could be particularly important in the treatment of aggressive human 
cancers whose progression and invasion involves a variety of physiological or 
pathological factors, such as NSCLC.  
Anti-angiogenesis therapy and chemotherapy are important treatment regimens for 
NSCLC. VEGF is over-expressed in malignant tumors and is a major driver of tumor 
angiogenesis. Blocking the VEGF signaling pathway can reduce tumor-associated 
angiogenesis and blood-vessel-dependent metastasis.
217, 218
 VEGF-receptor inhibitors, 
such as small-molecule inhibitors, anti-VEGF monoclonal antibodies, and aptamers that 
strongly antagonize the VEGF-VEGFR binding with high specificity, have been 
developed.
219-221
 However, the efficacy of these inhibitors is often limited by unfavorable 
pharmacokinetics, low tumor accumulation and undesired interaction with the immune 
system. Additional adverse effects also compromise the therapeutic response in 
patients.
222, 223
 siRNA specific to VEGF, if properly delivered to the tumor cells, may 
overcome some shortcomings of the traditional drugs, especially when it is co-delivered 
with an efficient chemodrug. Gemcitabine (2’, 2’-difluoro 2’-deoxycytidine) (Gem) is a 
nucleoside analogue widely used as the first-line chemotherapy of advanced NSCLC. 
Gem relies on nucleoside transporters to enter into cells, sequentially phosphorylated by 
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deoxycytidine kinase (dCK) that forms mono-, di-, and triphosphate derivatives. The 
addition of the first phosphate group to become gemcitabine monophosphate (GMP) is 
the rate-limiting step.
224
 5’-Triphosphate derivative of Gem is then incorporated into the 
DNA strand where it inhibits replication by terminating the DNA chain elongation
224
. 
However, mutational drug resistance readily occurs at the steps of nucleoside transport 
and intracellular nucleoside activation.
225
  
In order to combine the therapeutic advantages of VEGF siRNA and Gem, while also 
avoiding their delivery roadblocks, we entrapped both VEGF siRNA and GMP into a 
single Lipid/Calcium/Phosphate (LCP) nanoparticle formulation. Our aim was to apply 
multiple tumor-killing steps to programmatically inhibit tumor growth and eventually 
eradicate tumor progression. The small molecule ligand, anisamide (AA), was modified 
to the LCP surface to specifically target the sigma receptors that are over-expressed in 
many human cancer cells. The rational design of LCP nanoplatform lies in the fact that 
calcium ions can precipitate both siRNA and GMP. Thus, an anti-angiogenic and a 
chemo agents can be simultaneously delivered to the tumor cells to block different 
mechanisms of tumor cell proliferation (Fig 4.1).
226
 LCPs entrapping only VEGF siRNA 
(VEGF-LCP-AA) and LCPs entrapping only GMP (GMP-LCP-AA) were prepared and 
tested separately to compare with the combination therapy. Cytidine monophosphate 
(CMP), having a chemical structure similar to GMP, but without any cytotoxic effect, 
serves as the surrogate for GMP. LCPs entrapping both CMP and control siRNA 
((CMP+Con)-LCP-AA) were used as control nanoparticles. 
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Figure 4.1 Schematic illustration of the in vivo co-delivery mechanism 
 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
Gemcitabine monophosphate disodium salt (GMP) was synthesized by HDH Pharma, Inc. 
(Research Triangle Park, NC). VEGF siRNA (target sequence: 5’-ACC UCA CCA AGG 
CCA GCA C-3’) and control siRNA (target sequence: 5’-AAU UCU CCG AAC GUG 
TCA CGU-3’) were synthesized by Sigma-Aldrich (St. Louis, MO). 1，2-Dioleoyl-3-
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trimethylammonium-propane chloride salt (DOTAP), dioleoylphosphatydic acid (DOPA), 
and 1,2-distearoryl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol-
2000) ammonium salt (DSPE-PEG2000) were purchased from Avanti Polar Lipids, Inc. 
(Alabaster, AL). DSPE-PEG-AA was synthesized in our lab as described previously.
240
 
DeadEnd Fluorometric TUNEL assay kits and Apo-ONE Homogeneous Caspase-3/7 
assay substrates were obtained from Promega Corporation (Madison, WI). Other 
chemicals were obtained from Sigma-Aldrich (St. Louis, MO). 
4.2.2 Cell culture 
H460 human NSCLC cells, originally obtained from American Type Culture Collection 
(ATCC) (Manassas, VA), were cultured in RPMI-1640 medium (Invitrogen, Carlsbad, 
CA) supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 µg/mL 
streptomycin (Invitrogen). Cells were cultivated in a humidified incubator at 37ºC and 
5% CO2. Cells were harvested with 0.05% trypsin-EDTA before subculture.  
4.2.3 Experimental animals 
Female nude mice 6-8 weeks of age were used in all studies. To establish the xenograft 
models, 5×10
6
 H460 cells in 100 µL of PBS were injected subcutaneously into the right 
flank of mice.  All work performed on animals was approved by the Institutional Animal 
Care and Use Committee at University of North Carolina at Chapel Hill. 
4.2.4 Preparation of VEGF-LCP-AA, GMP-LCP-AA and (GMP+VEGF)-LCP-AA 
LCP cores were prepared using water-in-oil micro-emulsions, with the oil phase 
containing cyclohexane/ Igepal CO-520 solution (71/29, v/v).
241
   To prepare the VEGF-
LCP cores, 48 µg VEGF siRNA was mixed with 600 µL 2.5 M CaCl2 and added into 20 
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mL of oil phase, where the other emulsion contained 600 µL 12.5 mM Na2HPO4 
(pH=9.0). The GMP-LCP core was formulated using 180 µL of 60 mM GMP mixed with 
12.5 mM Na2HPO4 (pH=9.0) (final concentration) to reach a total volume of 600 µL. 
This solution was then added into 20 mL of oil phase. Six-hundred µL 2.5 M CaCl2 was 
added to a separate the 20 mL oil phase. To prepare the (GMP+VEGF)-LCP core, the 
phosphate phase met the same specifications outlined in the preparation of the GMP-LCP 
core. The calcium phase contained 600 µL of 2.5 M CaCl2 mixed with 48 µg of VEGF 
siRNA. Four-hundred µL of 20 mM DOPA in chloroform was added to the phosphate 
phase of the GMP-LCP and (GMP+VEGF)-LCP, whereas only 200 µL of 20 mM DOPA 
was added to the phosphate phase during the preparation of the VEGF-LCP.  
The two separate micro-emulsions were then mixed. After stirring for 5 min, another 400 
µL of 20 mM DOPA was added into the emulsion of GMP-LCP and (GMP+VEGF)-LCP; 
for VEGF-LCP, 200 µL of 20 mM DOPA was added. The emulsion was allowed to 
continually stir for another 20 min before 40 mL of absolute ethanol was added. The 
ethanol emulsion mixture was centrifuged at 10,000 g for 15 min to pellet the LCP core 
and the supernatant was then discarded. The LCP core was washed twice with absolute 
ethanol and dried under N2. The LCP core pellets were suspended in 2 mL chloroform 
and stored in a glass vial at -20ºC for further use.  
To prepare the final VEGF-LCP-AA, GMP-LCP-AA and (GMP+VEGF)-LCP-AA with 
outer lipid outing, 330 µL LCP core in chloroform was mixed with 38.7 µL of 10 mg/ml 
Cholesterol, 28 µL of 25 mg/ml DOTAP, 76.8 µL of 25 mg/ml DSPE-PEG and 19.2 µL 
of 25 mg/ml DSPE-PEG-AA. After evaporating the chloroform, the residual lipids were 
dissolved in 30 µL THF followed by 50 µL absolute ethanol, and then suspended in 160 
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µL water. After brief sonication, the solution was dialyzed in distilled water to remove 
the THF and ethanol. The preparation procedure of (CMP+Con)-LCP-AA was identical 
to that of (GMP+VEGF)-LCP-AA, except that GMP and VEGF siRNA were replaced by 
equal molar amount of CMP and control siRNA.  
4.2.5 Characterization of VEGF-LCP-AA, GMP-LCP-AA and (GMP+VEGF)-
LCP-AA 
The particle size and zeta potential of LCPs were determined by dynamic light scattering 
using a Malvern ZetaSizer Nano series (Westborough, MA). The EE% of GMP or siRNA 
was measured after lysing the LCPs with a THF/1 M HCl (v/v= 70/30) solution. GMP 
EE% was measured using a UV spectrophotometer (Beckman Coulter Inc., DU 800 
spectrophotometer) at a wavelength of 275 nm. The EE% of siRNA was measured by 
mixing a small amount of Texas-red labeled siRNA with VEGF siRNA in LCP cores, and 
the fluorescence intensity of Texas-red was detected at the wavelength of Ex=589 nm and 
Em=615 nm. TEM images of LCP formulations were acquired through the use of JEOL 
100CX II TEM (Tokyo, Japan). Briefly, 4 µl of LCP solution was dropped onto a 300 
mesh carbon coated copper grid (Ted Pella, Inc., Redding, CA) for 2 min. Excess fluid 
was then removed with filter paper, and the copper grid was dried before observation 
using the TEM.   
4.2.6 Western blot analysis 
Twenty-four h after the third injection, mice were sacrificed and tumor lysates were 
prepared with radioimmunoprecipitation assay (RIPA) buffer, supplemented with a 
protease inhibitor cocktail (Promega, Madison, WI). Protein concentrations were 
determined using a BCA assay kit (Pierce Biotechnology) following the manufacturer’s 
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recommendations. Forty µg of protein per lane was separated by 4%-12% SDS-PAGE 
electrophoresis (Invitrogen) before being transferred into polyvinylidene difluoride 
(PVDF) membranes. The membranes were blocked for 1 h with 5% silk milk at room 
temperature and then incubated with rabbit polyclonal VEGF antibody and mouse 
monoclonal poly(ADP-ribose) polymerase-1 (PARP-1) antibody (1:500 dilution; Santa 
Cruz Biotechnology) overnight at 4ºC. ß-actin antibodies (1:4000 dilution; Santa Cruz 
Biotechnology) served as the loading control. The membranes were washed 3 times and 
then incubated with secondary antibodies (1:4000 dilution; Santa Cruz Biotechnology) at 
room temperature for 1 h. Finally, the membranes were washed 4 times and developed by 
an enhanced chemiluminescence system according to the manufacturer’s instructions 
(Thermo Scientific). 
4.2.7 Caspase activation  
Twenty-four h after 3 daily IV injections, forty µg protein of each tumor lysate was used 
to detect caspase-3/7 activity in tumors according to the manufacturer’s instructions 
(Invitrogen, NY). Briefly, 25 µL sample solution containing 40 µg of protein was added 
to a 96-well plate, and 25 µL caspase-3/7 reagent was added to each sample well. The 
contents of the wells were gently mixed at 400 rpm for at least 1 h at room temperature. 
Their fluorescence was measured using a microplate reader at a wavelength of Ex=485 
nm and Em=535 nm. The fluorescence intensity of treatment groups was normalized to 
that of the control group to indicate the extent of caspase activation.    
4.2.8 TUNEL assay 
After predetermined dosing schedule, H460 tumor-bearing mice were sacrificed and 
tumors were fixed in 10% formalin for 24 h before embedded in paraffin and sectioned at 
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a thickness of 5 µm. The TUNEL staining was performed as recommended by the 
manufacturer (Promega, Madison, WI). Then DAPI mounting medium was dropped on 
the sections for nucleus staining. Images of TUNEL-stained tumor sections were captured 
with a fluorescence microscope (Nikon Corp., Tokyo, Japan). The percentage of 
apoptotic cells was obtained by dividing the number of apoptotic cells (TUNEL positive 
cells shown as green dots) from the number of total cells (blue nuclei stained by DAPI, 
not shown) in each microscopic field, and 10 representative microscopic fields were 
randomly selected in each treatment group (n=3) for this analysis.  
4.2.9 Immunohistochemistry 
Paraffin-embedded tumor sections were obtained as mentioned above. The CD31 (1:50 
dilution, Abcam) and PCNA (1:200 dilution, Santa Cruz) immunohistochemistry was 
performed using the HRP/DAB detection IHC kit as recommended by the manufacturer 
(Abcam, Cambridge, MA). Immunostaining images were observed under a light 
microscope (Nikon Corp., Tokyo, Japan). The percentage of proliferation cells was 
obtained by dividing the number of PCNA positive cells (shown as brown dots) from the 
number of total cells (blue nuclei stained by hematoxylin) in each microscopic field, and 
10 representative microscopic fields were randomly selected in each treatment group 
(n=3) for counting.  
4.2.10 Tumor growth inhibition 
Tumor growth inhibition of the nanoparticles system was evaluated in an H460 
subcutaneous xenograft mouse model. When the tumor volumes reached about 150-200 
mm
3
, the mice were randomly assigned into 6 treatment groups, and intravenously 
injected different LCPs, including VEGF-LCP-AA, GMP-LCP-AA, (GMP+VEGF)-
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LCP-AA, (CMP+Con)-LCP-AA and free GMP. The IV injections were performed every 
other day for a total of 4 injections with a dose of 50.4 µmol/Kg GMP and/or 0.2 mg/Kg 
VEGF siRNA. Tumor sizes were measured every other day with calipers across their two 
perpendicular diameters, and the tumor volume was calculated using the following 
formula: V=0.5×(W
2
×L), where V = tumor volume, W = the smaller perpendicular 
diameter and L = the larger perpendicular diameter. Two days after the final injection, the 
mice were sacrificed and the tumors were stripped off. Some tumors were fixed in 10% 
formalin and cut into paraffin-embedded tissue sections for TUNEL assay, 
immunohistochemistry analysis and an H&E stain. Other tumors were arranged and the 
photographs of tumors were taken as a visual comparison of the representative tumor 
sizes in each treatment group.  
4.2.11 In vivo toxicity 
Twenty-four h after 3 daily IV injections, blood was drawn from the venous plexus of the 
eyes of the mice. Blood samples were immediately centrifuged at 3,000 g for 5 min at 
4°C, and the supernatant blood serums were collected for hematological analysis. BUN, 
creatinine, AST, ALT values were recorded, as indications of hepatic and renal functions. 
Organs (heart, liver, spleen, lung, kidney) of mice in different treatment groups were 
fixed and sectioned for H&E stain. 
4.2.12 Statistical analysis 
Results were expressed as a mean ± standard deviation (SD). Student t-tests were used to 
evaluate statistical significance. A result of p<0.05 was considered to be statistically 
significant. 
 104 
4.3 RESULTS 
4.3.1 Characterization of drug-loaded LCPs 
LCP is a membrane/core type nanoparticle. It is composed of a solid calcium phosphate 
precipitate core coated with a single lipid bilayer. The lipid membrane wrapping around 
the core is modified by grafting a high density of polyethylene glycol (PEG) chains, with 
a tethered targeting ligand AA. The preparation scheme of LCP is illustrated in Fig 4.2. 
 
Figure 4.2 Schematic illustration of the preparation procedure of GMP- 
and/or VEGF siRNA- loaded LCP formulations. 
The Transmission electron microscope (TEM) photographs showed that all drug-loaded 
LCP-AAs had a spherical shape and were monodispersed, with a particle size of around 
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20 nm (Fig 4.3). The relatively small size of LCPs renders them better tumor penetration 
capability over large size nanoparticles.
12
 The zeta potentials of VEGF-LCP-AA, GMP-
LCP-AA and (GMP+VEGF)-LCP-AA were 30.2±14.1 mV, 3.4±3.1 mV, and 10.0±4.0 
mV, respectively. The encapsulation efficiency (EE%) of VEGF siRNA and GMP in 
LCP-AA was around 55% and 75%, respectively. The EE% of VEGF siRNA and GMP 
in co-formulated LCP-AA was almost the same as that of the VEGF-LCP-AA or GMP-
LCP-AA single formulation, which indicates that VEGF siRNA and GMP did not 
interfere with each other in the process of co-precipitation with calcium ions within the 
LCP core.  
 
Figure 4.3 TEM pictures of drug-loaded LCPs. (a) VEGF-LCPs, (b) GMP-
LCPs and (c) (GMP+VEGF)-LCPs. Scale bar = 100 nm. 
4.3.2 Drug-loaded LCPs induced VEGF down-regulation and apoptosis in vivo 
Human NSCLC H460 tumor bearing mice  were given three daily IV injections of 
different LCP formulations with a dose of 50.4 µmol/Kg GMP (19.5 mg/Kg GMP, or 
13.2 mg/Kg in terms of Gem) and/or 0.2 mg/Kg VEGF siRNA. Twenty-four h after the 
third injection, mice were sacrificed and tumor lysates were prepared for western blot. 
VEGF-VEGFR signaling in the endothelial cells of tumor blood vessels can be prevented 
by silencing VEGF, which should induce tumor cell apoptosis. PARP is a nuclear protein 
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that performs central roles in the repair of damaged DNA. Cleavage of PARP by caspases 
is considered to be a hallmark of apoptosis.
228
 As shown in Fig 4.4, (GMP+VEGF)-LCP-
AA showed significant knockdown of VEGF, and stimulated the over-expression of 
cleaved PARP. GMP-LCP-AA also activated the cleaved PARP over-expression, but had 
only a minor effect on the VEGF expression level. VEGF-LCP-AA clearly reduced the 
VEGF expression, but had limited effect on PARP cleavage. Compared to the control, 
(CMP+Con)-LCP-AA had no measurable effect on the protein expression level of VEGF, 
and was not able to cleave PARP. VEGF mRNA levels coincided with the VEGF western 
blot results. 
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Figure 4.4 Western blot analysis and VEGF mRNA level after systemic 
treatments. (A) Western blots analysis for VEGF and cleaved PARP expressions in vivo 
after systemic treatment of different LCP formulations. (B)  H460-tumor bearing mice 
were given 4 every other day IV injections, and mice were sacrificed two days after the 
final injection. Tumor VEGF mRNA levels in different treatment groups (n=3) were 
measured by RT-PCR. Data are shown as mean ± SD. 
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4.3.3 Drug-loaded LCPs triggered caspase activation and tumor cell apoptosis in 
vivo 
Caspases are proteolytic enzymes and play an important role in apoptosis as effector 
molecules. Among the caspase enzymes, caspase-3 and caspase-7 are especially 
important, and they are responsible for the proteolytic cleavage of a large number of 
substrates during apoptosis.
229
 Twenty-four h after three daily IV injections, caspase-3/7 
activity in tumors was increased 3-fold in mice injected with (GMP+VEGF)-LCP-AA 
and GMP-LCP-AA and 1.5-fold in mice injected with VEGF-LCP-AA, as compared to 
the control (Fig 4.5A). (CMP+Con)-LCP-AA, free VEGF siRNA, and free GMP 
displayed little caspases elevation (Fig 4.5A). The results indicated that the LCPs greatly 
improved the in vivo delivery efficiency of VEGF siRNA and GMP, and the caspase 
activation was predominantly triggered by GMP rather than VEGF siRNA.  
We also measured the apoptotic induction in tumor tissues using the TdT-mediated dUTP 
Nick-End Labeling (TUNEL) assay. Twenty-four h after 3 daily IV injections, 
(GMP+VEGF)-LCP-AA triggered a dramatic killing effect, inducing 40% apoptotic cells 
in tumors. GMP-LCP-AA and VEGF-LCP-AA led to 22% and 5% apoptotic tumor cells, 
respectively. (CMP+Con)-LCP-AA did not elicit tumor cell apoptosis (Fig 4.5B). The 
tumor cell apoptotic induction of (GMP+VEGF)-LCP-AA was significantly higher than 
GMP-LCP-AA and VEGF-LCP-AA, indicating a profound therapeutic effect of the 
combined LCP. GMP-loaded LCPs were more potent than VEGF-loaded LCP in terms of 
tumor-cell killing effect.  
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The figure legend of Figure 4.5 A and B is on the next page. 
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Figure 4.5 The caspase activation and induction of apoptosis after the 
systemic administration of different LCPs in H460 exnografts. (A) In vivo caspase-
3/7 activity in tumors (n=3). *p<0.01, GMP-LCP-AA vs. control, (GMP+VEGF)-LCP-
AA vs. control, GMP-LCP-AA vs. VEGF-LCP-AA, (GMP+VEGF)-LCP-AA vs. VEGF-
LCP-AA. (B) In vivo tumor apoptosis by TUNEL assay. (C) The percentage (%) of 
apoptotic cells in the TUNEL assay. Statistics of the TUNEL assay in H460 xenografts 
(n=10): **p<0.005, VEGF-LCP-AA vs. control, GMP-LCP-AA vs. control, 
(GMP+VEGF)-LCP-AA vs. control; *p<0.01, GMP-LCP-AA vs. VEGF-LCP-AA, 
(GMP+VEGF)-LCP-AA vs. VEGF-LCP-AA. Data are shown as mean ± SD. 
4.3.4 Drug-loaded LCPs inhibited the formation of tumor vasculature 
Next, we evaluated the effect of different LCP formulations on the formation of tumor 
vasculature. We compared two treatment regimens: a short-term, frequent treatment 
schedule and a long-term, infrequent treatment schedule. The short-term treatment was 
characterized by daily IV injections over 3 consecutive days; the mice were sacrificed 24 
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h after the final injection. The long-term treatment was characterized by IV injections 
given every other day over 8 days, totaling 4 injections. Mice treated with this regimen 
were sacrificed two days after the final injection. Fig 4.6 shows the results of staining 
CD31 antigen, an endothelial cell-specific surface marker. Control tumor showed thick, 
elongated, and disorganized layers of the vascular endothelium. (GMP+VEGF)-LCP-AA 
caused a significant reduction in tumor vasculature in both short-term and long-term 
treatments, indicating an immediate and lasting effect of tumor angiogenesis inhibition. 
VEGF-LCP-AA dramatically shut down the tumor vasculature after long-term treatment, 
but only displayed partial anti-angiogenesis effects with sparsely dispersed microvessels 
after short-term treatments, indicating that VEGF-LCP-AA needs more time to 
effectively impair the tumor vasculature. It seems that GMP co-delivered in the combined 
LCPs sensitized the tumor vasculature for anti-angiogenesis therapy. Indeed, Gem can 
induce apoptosis in tumor-associated endothelial cells, leading to a decrease in 
microvessel density.
230, 231
 GMP-LCP-AA caused minor, partial reduction of tumor vessel 
formation after multiple doses. (CMP+Con)-LCP-AA and free GMP had little effect on 
the alteration of the endothelial cells compared to the control. 
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Figure 4.6 CD31 immunohistochemistry staining of H460 xenograft tumors 
after (A) short term treatment and (B) long term treatment of different LCP 
formulations.  
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4.3.5 Drug-loaded LCPs triggered tumor cell apoptosis and inhibited tumor cell 
proliferation in vivo 
The H460 tumor-bearing mice were given IV injections of different LCP formulations 
every other day for a total of 4 injections. Two days after the final injection, the mice 
were sacrificed and the tumors were sectioned for TUNEL assay, PCNA 
immunohistochemistry and H&E stain. In the TUNEL assay (Fig 4.7A), (GMP+VEGF)-
LCP-AA elicited the most effective killing effects and triggered a significant amount 
(~30%) of apoptotic cells in the tumor, more potent than GMP-LCP-AA which induced 
12% apoptotic cells. The results indicates antiangiogenesis-induced tumor cell starvation 
may augment the intrinsic cytotoxicity and duration of antitumor effects of the co-
formulated GMP.
232
 Treatment with VEGF-LCP-AA was less efficient than with GMP-
LCP-AA, only 3% of tumor cells underwent apoptosis. (CMP+Con)-LCP-AA and free 
GMP had limited ability to induce apoptosis in tumor cells.  
 We also evaluated the anti-proliferation effect of different LCP formulations. PCNA is 
expressed in the cell nuclei during DNA synthesis and can be used as a marker for cell 
proliferation. As shown in Fig 4.7C, (GMP+VEGF)-LCP-AA significantly decreased the 
number of PCNA positive cells in H460 xenograft tumors. VEGF-LCP-AA and GMP-
LCP-AA also caused reductions in the proliferation of tumor cells. The anti-proliferation 
effect of VEGF-LCP-AA indicates that VEGF not only acts as an endothelial-specific 
growth factor, it can also promote proliferation of tumor cells.
233
 However, (CMP+Con)-
LCP-AA and free GMP showed little anti-proliferative effect. From this relatively long-
term and infrequent dosing treatment, we had observed additive tumor-cell-killing and 
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anti-proliferation effects of (GMP+VEGF)-LCP-AA compared to the mono-therapy of 
GMP-LCP-AA or VEGF-LCP-AA. 
4.3.6 Drug-loaded LCPs inhibited mitotic figures in tumors 
As shown in the H&E stain (Fig 4.7E), after long term treatment, the control tumor had 
many mitotic figures, showing a high mitotic activity of tumor cells. Some typical mitotic 
figures were shown by arrows in blue. The chromosomes of the mitotic figures are visible 
as tangled, dark-staining threads or spots. Counting mitotic figures serves as a tool for 
differentiating benign tumors from malignant ones.
234
 The control tumor displayed 
various cell morphologies with dark clumped chromatin, indicating uncontrollable tumor 
growth and poor differentiation, otherwise known as malignancy. Cellular and nuclear 
features also correlated with proliferative activity, with untreated tumors exhibiting 
marked anisocytosis and anisokaryosis (variation in cell and nuclear size), polyploidy, 
and open vesicular nuclei with dispersed chromatin and prominent nucleoli. Tumors that 
were treated with (GMP+VEGF)-LCP-AA experienced a dramatic decrease in mitotic 
figures and exhibited more basophilic and uniform nuclei. However, some chromosome 
condensation remained due to the cytotoxicity induced by the combined therapy. The 
decrease in mitotic figures supported the aforementioned PCNA staining, indicating the 
anti-proliferation effects of (GMP+VEGF)-LCP-AA partially results from the inhibition 
of cell mitosis in tumors. VEGF-LCP-AA and GMP-LCP-AA also triggered a decrease in 
mitotic figures compared to the control. The mitotic figures of tumors in each group are 
shown quantitatively in Fig 4.7F.  
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The figure legend of Figure 4.7A and B is on page 124. 
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The figure legend of Figure 4.7C and D is on page 124. 
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The figure legned of Figure 4.7E and F is on page 124. 
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Figure 4.7 Immunostaining and mitotic figures after long term treatments. 
VEGF-LCP-AA, GMP-LCP-AA, (GMP+VEGF)-LCP-AA, (CMP+Con)-LCP-AA and 
free GMP were administered intravenously every other day for total 4 injections. Two 
days after the last injection, mice were sacrificed and tumor tissues were sectioned for (A, 
B) TUNEL assay and (C, D) PCNA immunohistochemistry. (E) Mitotic figures (MF) in 
tumors were evaluated by H&E stain. (B) Statistics of the TUNEL assay in H460 
xenografts: *p<0.005, VEGF-LCP-AA vs. control, GMP-LCP-AA vs. control, VEGF-
LCP-AA vs. GMP-LCP-AA, VEGF-LCP-AA vs. (GMP+VEGF)-LCP-AA, GMP-LCP-
AA vs. (GMP+VEGF)-LCP-AA; **p<0.001, (GMP+VEGF)-LCP-AA vs. control. (D) 
Statistics of the PCNA immunohistochemistry in H460 xenografts: *p<0.05, VEGF-LCP-
AA vs. control, GMP-LCP-AA vs. control, (GMP+VEGF)-LCP-AA vs. VEGF-LCP-AA, 
(GMP+VEGF)-LCP-AA vs. GMP-LCP-AA; **p<0.01, (GMP+VEGF)-LCP-AA vs. 
control. (F) Statistics of mitotic figures in tumors: *p<0.001, VEGF-LCP-AA vs. control, 
GMP-LCP-AA vs. control; **p<0.0001, (GMP+VEGF)-LCP-AA vs. control.  
4.3.7 Tumor growth inhibition 
The tumor growth inhibition was evaluated in nude mice bearing H460 subcutaneous 
tumors. Mice were treated every other day for a total of 4 IV injections with a dose of 
50.4 µmol/Kg GMP and/or 0.2 mg/Kg VEGF siRNA. As shown in Fig 4.8, 
(GMP+VEGF)-LCP-AA exhibited the most effective tumor growth inhibition; growth 
was almost completely arrested during the combined therapeutic regimen. GMP-LCP-AA 
also suppressed tumor growth effectively, but not as potently as the combined 
nanoparticle treatment. Anti-angiogenic monotherapy with VEGF-LCP-AA was not 
sufficient to obtain long-term tumor suppression. VEGF-LCP-AA stabilized the tumor 
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growth at early stages of treatment, but unfortunately, was associated with insufficient 
anti-cancer activity and tumor progression at later stages. The (CMP+Con)-LCP-AA and 
free GMP had little effect on tumor growth inhibition compared to the control. At the 
treatment end point, representative tumors in each treatment group were harvested (Fig 
4.8B) for visual comparison. Tumors treated with (GMP+VEGF)-LCP-AA were smaller 
than tumors in other treatment groups. Thus, the combined treatment with 
(GMP+VEGF)-LCP-AA was significantly more effective than treatment with GMP-LCP-
AA and VEGF-LCP-AA individually.    
A 
 
 
 
 
 
The figure legend of Figure 4.8A is on the next page. 
 120 
B 
 
Figure 4.8 Tumor growth inhibition of different LCPs after systemic 
treatments. (A) Tumor growth inhibition effects of different LCP formulations on H460-
tumor bearing mice. VEGF-LCP-AA, GMP-LCP-AA, (GMP+VEGF)-LCP-AA, 
(CMP+Con)-LCP-AA and free GMP were administered intravenously every other day 
for total 4 injections. Tumor volume was measured every other day. Data are mean ± S.D. 
Statistics are as follows: *p<0.01, VEGF-LCP-AA vs. control; фp<0.001, GMP-LCP-AA 
vs. control, (GMP+VEGF)-LCP-AA vs. control, (GMP+VEGF)-LCP-AA vs. VEGF-
LCP-AA; ‡p<0.05, (GMP+VEGF)-LCP-AA vs. GMP-LCP-AA. (B) Visual observations 
of the tumor sizes in each treatment group at the end time point. (Scale unit: cm) 
4.3.8  (GMP+VEGF)-LCP-AA reduced the in vivo toxicity  
To test whether GMP and VEGF siRNA loaded LCPs would induce in vivo toxicity, 
especially hepatic and renal dysfunction after frequent multiple dosing, mice were given 
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three daily IV injections. Twenty-four h after the final injection, blood samples were 
obtained for hematological analysis and histopathology of different organs were 
evaluated by H&E stain. As shown in Table 4.1, VEGF-LCP-AA induced a relatively 
high level of blood urine nitrogen (BUN). GMP-LCP-AA led to higher aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) compared to the control. 
However, treatment with (GMP+VEGF)-LCP-AA alleviated the elevations of BUN, AST 
and ALT and kept the parameters of kidney and liver functions within the normal range. 
The administration of chemotherapy to patients with liver impairment may result in 
complicated safety issues, a treatment regimen using the nanoparticles formulated with 
both GMP and VEGF can help alleviate the potential liver toxicity as well as enhance the 
therapeutic response, compared to treatment with a single agent. From the H&E-stained 
tissue sections of heart, liver, spleen, lung and kidney (Fig 4.9), there were no noticeable 
histological changes between the control and (GMP+VEGF)-LCP-AA treatment group, 
which showed no evidence of organ toxicity. 
Table 4.1 Serum levels of BUN, creatinine, AST, ALT after 3 daily IV 
injections in H460 xenograft model.   Data are shown as mean ± SD. 
  BUN mg/dL 
Creatinine 
mg/dL 
AST U/L ALT U/L 
control 15.0 ± 3.0 0.4 ± 0.1 129.5 ± 2.5 45.0 ± 1.0 
VEGF-LCP-AA 33.0 ± 1.0 0.4 158.5 ± 3.5 30.5 ± 8.5 
GMP-LCP-AA 11.0 ± 1.0 0.4 ± 0.1 371.5 ± 31.5 81.0 ± 15.0 
(GMP+VEGF)-LCP-AA 15.0 ± 1.0 0.5 213 ± 95.1 35.0 ± 10.0 
Reference Range 8--33 0.2--0.9 54--298 17--132 
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Figure 4.9 Histopathology of different organs evaluated by H&E stain.  
 
4.4 DISCUSSION 
In this study, we report a novel systemic delivery platform consisting of the co-
formulation of nucleic acid molecules and phosphorylated, small-molecule drugs in a 
single LCP nanoparticle. GMP and VEGF siRNA were co-formulated using LCP 
nanotechnology in order to target two therapeutic pathways of an aggressive human 
cancer malignancy (i.e. NSCLC). Specifically, our delivery system aimed to induce 
apoptosis though GMP chemotherapy and to shut down the tumor neovasculature by 
blocking the VEGF-VEGFR signaling cascade with VEGF RNAi.  
Phosphate groups on the molecules can interact with calcium in a microemulsion, 
enabling the encapsulation of GMP and VEGF siRNA in the nanoparticle system 
containing a calcium phosphate precipitate (CaP) core (i.e. LCP). A lipid bilayer 
surrounds the CaP core to allow a high density of DSPE-PEG to be grafted onto the 
surface. The surface modification with PEG helps shield the cationic charge of the lipid 
bilayer and may minimize the interaction with circulating blood components to prolong 
circulation time of the particle. The prolonged circulation half-life is a prerequisite for 
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enhanced tumor targeting and increases the probability that the LCPs will encounter the 
‘leaky’ tumor vasculature and be exposed to the EPR effect.235 The LCP’s high density 
PEG and small size allow it to evade RES surveillance, which may promote tumor 
accumulation and decrease toxicity in the liver and kidney. With AA as a tumor-specific 
targeting ligand, LCPs can be more effectively taken up into tumor cells via sigma-
receptor-mediated endocytosis. In addition, the design of the CaP core also promotes 
endosomal release of the cargo while preventing lysosomal degradation of the entrapped 
VEGF siRNA and GMP. When LCPs are delivered into acidic endosomes, the CaP core 
of the LCPs rapidly dissolves to increase the osmotic pressure in the endosome, 
eventually bursting the endosomes and enabling the entrapped GMP and VEGF siRNA to 
escape (Fig. 1a).
236
 The cationic lipid, DOTAP, surrounding the LCP core may also 
promote the release of the entrapped cargo by destabilizing the anionic endosome 
membrane.
237
  
Loading Gem derivatives in LCPs can potentially avoid drug efflux proteins (e.g. MRP, 
BCRP) and the deficiency of cellular uptake caused by the mutations of nucleoside 
transporters (e.g. ENT1, ENT2, CNT1, CNT3) in the cell membrane. In our previous 
study, we have validated that the nucleotide analogue Gem triphosphate (GTP)-loaded 
LCP nanoparticle showed significant anti-tumor efficacy on lung and pancreatic 
xenograft models (unpublished data). We later found that comparing to GTP which was 
synthesized in an big organic salt form, GMP (disodium salt form) gave us higher EE% 
and drug loading, such that similar anti-tumor efficacy were attained. So GMP was used 
in the current study. The monophosphate modification on GMP allows it to bypass the 
first rate-limiting phosphorylation step, greatly increasing the conversion rate to 
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biologically active Gem triphosphate derivatives. On the other hand, the down-regulation 
of VEGF expression in tumors leads to blockage of the sequential survival signaling 
initiated by dimerization and autophosphorylation of VEGFR molecules. Blocking 
VEGF/VEGFR signaling by down-regulating VEGF potently inhibits aberrant 
angiogenesis (Fig 4.1). Additionally, LCPs can potentially protect VEGF siRNA and 
GMP from enzymatic degradation (i.e. nuclease and deoxycytidine deaminase, 
respectively) and renal clearance in vivo. 
This study indicates that combining anti-angiogenesis treatment with chemotherapy 
through systemic administrations of LCP nanoparticles containing both VEGF siRNA 
and phosphorylated Gem results in an additive anti-tumor effect. The co-delivered VEGF 
siRNA that can damage existing blood vessels in tumors might influence response to the 
concurrent chemotherapy. Combination therapies are most likely successful because 
damaging the established tumor endothelium has been shown to increase vessel 
permeability and facilitate the delivery of subsequently administered LCPs and the co-
formulated GMP.
238
 The significant knockdown of the pro-angiogenic protein, VEGF, 
caused by the systemic administrations of (GMP+VEGF)-LCP-AA illustrates that this 
treatment regime can lead to decreased tumor angiogenesis (Fig 4.4). Furthermore, 
microvessel density is reduced through the reduction of VEGF/VEGFR interactions and 
the resulting signaling cascades, as indicated by the expression of CD31 antigen in 
vascular endothelial cells (Fig 4.6). These effects of (GMP+VEGF)-LCP-AA modify the 
tumor microenvironment to potentiate the delivery of the chemodrug. GMP entrapped in 
the combined LCP subsequently inhibits the pro-survival program as evidenced by 
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elevated PARP cleavage and caspase activation (Fig 4.4, 4.5), significant induction of 
tumor cell apoptosis and reduction of tumor cell proliferation (Fig 4.4, 4.7). 
The advantages of nanoparticles containing multiple drugs are that they can offer the 
unique features of vehicle uniformity, ratiometric drug loading and temporal drug release, 
while maintaining the ability to unify the pharmacokinetics of different drugs they 
encapsulate. These nanoparticles are thereby able to simultaneously deliver multiple 
gene- and/or chemo- therapeutic agents to the target site.
239
 We have done some 
preliminary work on the comparison of (GMP+VEGF)-LCP-AA and the co-administered 
mixture of GMP-LCP-AA and VEGF-LCP-AA on the anti-tumor therapeutic response. 
The results indicated the combined (GMP+VEGF)-LCP-AA had more potency in 
inducing cell-killing effects compared to the administration of separate LCPs loaded with 
each individual agent (unpublished data). The pharmacokinetic profiles and the 
therapeutic effects of the drug loading ratio are now under investigation. The strategy of 
co-formulating multiple gene therapeutics and phosphorylated chemodrugs in a single 
vector via LCP nanotechnology is expected to lead to superior therapeutic improvement 
in many human diseases, and to modulate multiple therapeutic pathways simultaneously. 
 
 
5.0  CO-DELIVERY OF C-MYC SIRNA AND GEMCITABINE 
MONOPHOSPHATE VIA LCP NANOPARTICLES TO NSCLC 
SUBCUTANEOUS AND ORTHOTOPIC MOUSE MODELS. 
 
There is an urgent need for new therapeutics for the treatment of aggressive and 
metastatic refractory human non-small-lung-cell cancer (NSCLC).  In this study, we 
developed a Lipid/Calcium/Phosphate (LCP) nanoparticle-based lung cancer therapeutic 
regimen which combines the anti-tumor efficacy of a chemodrug gemcitabine 
monophosphate (GMP) with siRNA that is specific for an undruggable oncogene c-Myc, 
while overcoming the in vivo delivery challenges that currently limit their clinical 
application. The combination therapy using LCP loaded with both c-Myc siRNA and 
GMP showed a potent activity in inducing apoptosis and reducing proliferation in both a 
subcutaneous tumor model and an orthotopic model of NSCLC in nude mice with 
systemic administration. The improved therapeutic response, as compared to either c-
Myc siRNA or GMP therapy alone, was supported by the observation of effective 
induction of tumor cell apoptosis, significant reduction of tumor cell proliferation. The 
combination therapy led to dramatic inhibition of tumor growth with little in vivo toxicity. 
Additionally, the current studies demonstrated the possibility of incorporating multiple 
nucleic acid molecules and phosphorylated small molecule drugs, targeting to different 
pathways, into a single nanoparticle formulation. Co-encapsulation of an oncogene-
modulating siRNA and a chemotherapeutic agent will allow simultaneous interruption of 
diverse anti-cancer pathways, leading to increased therapeutic efficacy and reduced 
toxicities.  
 
5.1 INTRODUCTION 
Lung cancer continues to be the leading cause of cancer-related deaths both in the United 
States and throughout the world. Non-small-cell lung carcinoma (NSCLC) is the most 
aggressive type of lung cancer and accounts for up to 80-85% of all lung cancers, while 
SCLC and other more rare histologic subtypes make up the remainder. Many NSCLC 
tumors over-express c-Myc which is a pivotal transcription factor controlling the 
expressions of many proliferation genes. It is one of the most highly amplified 
downstream oncogenes that promote cell growth, proliferation, invasion, expansion and 
angiogenesis.
242, 243
 Although the importance of c-Myc in oncogenesis and maintenance 
of the lung malignancy has long been recognized, no small molecule chemo drugs have 
been approved for clinical use. Thus, c-Myc remains to be an “undruggable” target to 
which alternative approaches must be developed. Myc oncogene family members are 
considered “undruggable” for two reasons. First, Myc genes encode basic helix-loop-
helix transtription factors, which do not provide druggable domains. Second, Myc-
encoded transtription factors carry out so many functions, so their persistant down-
regulation would likely result in severe side effects for patients.
250
 The advent of RNAi 
has brought about a fresh look in controlling any “undruggable” targets. siRNA, although 
very potent and specific in silencing an oncogenic target, has to be protected from 
degradation and efficiently delivered to the cytoplasm of the tumor cells. LCP contains a 
core consisted of amorphous calcium phosphate precipitation which can encapsulate 
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siRNA. The CaP core is further coated with a single lipid bilayer to which PEGylation 
and targeting ligand can be efficiently added for functionalization.  
One of the salient features of LCP is the opportunity to co-encapsulate both siRNA and a 
phosphorylated chemo drug. Gemcitabine is a nucleoside prodrug which must be 
activated intracellularly by phosphorylation. GMP, the first activated species of 
gemcitabine, can be effectively encapsulated in LCP and delivered to tumor cells to 
induce apoptosis. The anticancer potency of GMP was shown in the previous study. In 
this study, GMP was co-encapsulated in LCP together with c-Myc siRNA. Tumor lesions 
were dissected for caspase 3/7 assay. They were tested for TUNEL and PCNA assays, for 
apoptosis and proliferation, respectively. Apoptosis marker PARP was also tested by 
western blot analysis. Hematological, hepatic and renal toxicities of the NP were 
evaluated in immune competent normal mice after repeated injection of NPs at 
therapeutic dose. LCP containing both therapeutic agents showed greater apoptosis 
induction and proliferation reduction activities than either agent alone in the 
subcutaneous and orthotopic xenograft model of human NSCLC. 
5.2 MATERIALS AND METHODS 
5.2.1 Materials 
Gemcitabine monophosphate disodium salt (GMP) was synthesized by HDH Pharma, Inc. 
(Research Triangle Park, NC). c-Myc siRNA (target sequence: 5’- CAG AAA UGU 
CCU GAG CAA UUU-3’) and control siRNA (target sequence: 5’-AAU UCU CCG 
AAC GUG TCA CGU-3’) were synthesized by Sigma-Aldrich (St. Louis, MO). 1，2-
Dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP), dioleoylphosphatydic 
acid (DOPA), and 1,2-distearoryl-sn-glycero-3-phosphoethanolamine-N-
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[methoxy(polyethyleneglycol-2000) ammonium salt (DSPE-PEG2000) were purchased 
from Avanti Polar Lipids, Inc. (Alabaster, AL). DSPE-PEG-AA was synthesized in our 
lab as described previously.
240
 DeadEnd Fluorometric TUNEL assay kits and Apo-ONE 
Homogeneous Caspase-3/7 assay substrates were obtained from Promega Corporation 
(Madison, WI). Other chemicals were obtained from Sigma-Aldrich (St. Louis, MO). 
5.2.2 Cell culture 
H460 and A549 human NSCLC cells, originally obtained from American Type Culture 
Collection (ATCC) (Manassas, VA), were cultured in RPMI-1640 medium (Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 
µg/mL streptomycin (Invitrogen). Cells were cultivated in a humidified incubator at 37ºC 
and 5% CO2. Cells were harvested with 0.05% trypsin-EDTA before subculture.  
5.2.3 Experimental animals 
Female nude mice 6-8 weeks of age were used in all studies. To establish the xenograft 
models, 5×10
6
 H460 cells in 100 µL of PBS were injected subcutaneously into the right 
flank of mice.  All work performed on animals was approved by the Institutional Animal 
Care and Use Committee at University of North Carolina at Chapel Hill. With the 
orthotopic model (Fig 5.1), A549 cells were injected via a 28 g needle about 2 cm up 
from the bottom of the ribcage via the left dorsal side. Mice will be maintained under a 
surgical plane of anesthesia and receive lidocaine at the incision site preoperatively. 
These procedures were conducted by experienced full-time veterinatians at the Animal 
Facility of UNC-Chapel Hill. 
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Figure 5.1 Graphical illustration of the establishment of NSCLC (A549) 
orthotopic model. 
5.2.4 Preparation of cMyc-LCP-AA, GMP-LCP-AA and (GMP+cMyc)-LCP-AA 
LCP cores were prepared using water-in-oil micro-emulsions, with the oil phase 
containing cyclohexane/ Igepal CO-520 solution (71/29, v/v).
241
 To prepare the cMyc-
LCP cores, 48 µg cMyc siRNA was mixed with 600 µL 2.5 M CaCl2 and added into 20 
mL of oil phase, where the other emulsion contained 600 µL 12.5 mM Na2HPO4 
(pH=9.0). The GMP-LCP core was formulated using 180 µL of 60 mM GMP mixed with 
12.5 mM Na2HPO4 (pH=9.0) (final concentration) to reach a total volume of 600 µL. 
This solution was then added into 20 mL of oil phase. Six-hundred µL 2.5 M CaCl2 was 
added to a separate the 20 mL oil phase. To prepare the (GMP+cMyc)-LCP core, the 
phosphate phase met the same specifications outlined in the preparation of the GMP-LCP 
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core. The calcium phase contained 600 µL of 2.5 M CaCl2 mixed with 48 µg of cMyc 
siRNA. Four-hundred µL of 20 mM DOPA in chloroform was added to the phosphate 
phase of the GMP-LCP and (GMP+cMyc)-LCP, whereas only 200 µL of 20 mM DOPA 
was added to the phosphate phase during the preparation of the cMyc-LCP.  
The two separate micro-emulsions were then mixed. After stirring for 5 min, another 400 
µL of 20 mM DOPA was added into the emulsion of GMP-LCP and (GMP+cMyc)-LCP; 
for cMyc-LCP, 200 µL of 20 mM DOPA was added. The emulsion was allowed to 
continually stir for another 20 min before 40 mL of absolute ethanol was added. The 
ethanol emulsion mixture was centrifuged at 10,000 g for 15 min to pellet the LCP core 
and the supernatant was then discarded. The LCP core was washed twice with absolute 
ethanol and dried under N2. The LCP core pellets were suspended in 2 mL chloroform 
and stored in a glass vial at -20ºC for further use.  
To prepare the final cMyc-LCP-AA, GMP-LCP-AA and (GMP+cMyc)-LCP-AA with 
outer lipid outing, 330 µL LCP core in chloroform was mixed with 38.7 µL of 10 mg/ml 
Cholesterol, 28 µL of 25 mg/ml DOTAP, 76.8 µL of 25 mg/ml DSPE-PEG and 19.2 µL 
of 25 mg/ml DSPE-PEG-AA. After evaporating the chloroform, the residual lipids were 
dissolved in 30 µL THF followed by 50 µL absolute ethanol, and then suspended in 160 
µL water. After brief sonication, the solution was dialyzed in distilled water to remove 
the THF and ethanol. The preparation procedure of (CMP+Con)-LCP-AA was identical 
to that of (GMP+cMyc)-LCP-AA, except that GMP and cMyc siRNA were replaced by 
equal molar amount of CMP and control siRNA.  
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5.2.5 Characterization of cMyc-LCP-AA, GMP-LCP-AA and (GMP+cMyc)-LCP-
AA 
The particle size and zeta potential of LCPs were determined by dynamic light scattering 
using a Malvern ZetaSizer Nano series (Westborough, MA). The EE% of GMP or siRNA 
was measured after lysing the LCPs with a THF/1M HCl (v/v= 70/30) solution. GMP 
EE% was measured using a UV spectrophotometer (Beckman Coulter Inc., DU 800 
spectrophotometer) at a wavelength of 275 nm. The EE% of siRNA was measured by 
mixing a small amount of Texas-red labeled siRNA with c-Myc siRNA in LCP cores, and 
the fluorescence intensity of Texas-red was detected at the wavelength of Ex=589 nm and 
Em=615 nm. TEM images of LCP formulations were acquired through the use of JEOL 
100CX II TEM (Tokyo, Japan). Briefly, 4 µl of LCP solution was dropped onto a 300 
mesh carbon coated copper grid (Ted Pella, Inc., Redding, CA) for 2 min. Excess fluid 
was then removed with filter paper, and the copper grid was dried before observation 
using the TEM.   
5.2.6 Western blot analysis 
Twenty-four h after the third injection, mice were sacrificed and tumor lysates were 
prepared with radioimmunoprecipitation assay (RIPA) buffer, supplemented with a 
protease inhibitor cocktail (Promega, Madison, WI). Protein concentrations were 
determined using a BCA assay kit (Pierce Biotechnology) following the manufacturer’s 
recommendations. Forty µg of protein per lane was separated by 4%-12% SDS-PAGE 
electrophoresis (Invitrogen) before being transferred into polyvinylidene difluoride 
(PVDF) membranes. The membranes were blocked for 1 h with 5% silk milk at room 
temperature and then incubated with mouse monoclonal c-Myc antibody and mouse 
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monoclonal poly(ADP-ribose) polymerase-1 (PARP-1) antibody (1:500 dilution; Santa 
Cruz Biotechnology) overnight at 4ºC. ß-actin antibodies (1:4000 dilution; Santa Cruz 
Biotechnology) served as the loading control. The membranes were washed 3 times and 
then incubated with secondary antibodies (1:4000 dilution; Santa Cruz Biotechnology) at 
room temperature for 1 h. Finally, the membranes were washed 4 times and developed by 
an enhanced chemiluminescence system according to the manufacturer’s instructions 
(Thermo Scientific). 
5.2.7 Caspase activation  
Twenty-four h after 3 daily IV injections, forty µg protein of each tumor lysate was used 
to detect caspase-3/7 activity in tumors according to the manufacturer’s instructions 
(Invitrogen, NY). Briefly, 25 µL sample solution containing 40 µg of protein was added 
to a 96-well plate, and 25 µL caspase-3/7 reagent was added to each sample well. The 
contents of the wells were gently mixed at 400 rpm for at least 1 h at room temperature. 
Their fluorescence was measured using a microplate reader at a wavelength of Ex=485 
nm and Em=535 nm. The fluorescence intensity of treatment groups was normalized to 
that of the control group to indicate the extent of caspase activation.    
5.2.8 TUNEL assay 
After predetermined dosing schedule, H460 tumor-bearing mice were sacrificed and 
tumors were fixed in 10% formalin for 24 h before embedded in paraffin and sectioned at 
a thickness of 5 µm. The TUNEL staining was performed as recommended by the 
manufacturer (Promega, Madison, WI). Then DAPI mounting medium was dropped on 
the sections for nucleus staining. Images of TUNEL-stained tumor sections were captured 
with a fluorescence microscope (Nikon Corp., Tokyo, Japan). The percentage of 
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apoptotic cells was obtained by dividing the number of apoptotic cells (TUNEL positive 
cells shown as green dots) from the number of total cells (blue nuclei stained by DAPI, 
not shown) in each microscopic field, and 10 representative microscopic fields were 
randomly selected in each treatment group (n=3) for this analysis.  
5.2.9 Immunohistochemistry 
Paraffin-embedded tumor sections were obtained as mentioned above. The PCNA (1:200 
dilution, Santa Cruz) immunohistochemistry was performed using the HRP/DAB 
detection IHC kit as recommended by the manufacturer (Abcam, Cambridge, MA). 
Immunostaining images were observed under a light microscope (Nikon Corp., Tokyo, 
Japan). The percentage of proliferation cells was obtained by dividing the number of 
PCNA positive cells (shown as brown dots) from the number of total cells (blue nuclei 
stained by hematoxylin) in each microscopic field, and 10 representative microscopic 
fields were randomly selected in each treatment group (n=3) for counting.  
5.2.10 Tumor growth inhibition 
Tumor growth inhibition of the nanoparticles system was evaluated in an H460 
subcutaneous xenograft mouse model. When the tumor volumes reached about 150-200 
mm
3
, the mice were randomly assigned into 6 treatment groups, and intravenously 
injected different LCPs, including cMyc-LCP-AA, GMP-LCP-AA, (GMP+cMyc)-LCP-
AA, (CMP+Con)-LCP-AA and (GMP-LCP-AA)+(cMyc-LCP-AA) mixture with each 
reagent half dose to maintain the same amount of nanoparticles. The IV injections were 
performed every other day for a total of 4 injections with a dose of 25.2 µmol/Kg GMP 
and/or 0.2 mg/Kg c-Myc siRNA. Tumor sizes were measured every other day with 
calipers across their two perpendicular diameters, and the tumor volume was calculated 
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using the following formula: V=0.5×(W
2
×L), where V = tumor volume, W = the smaller 
perpendicular diameter and L = the larger perpendicular diameter. The body weights in 
each treatment group were also measured during the study. Two days after the final 
injection, the mice were sacrificed and the tumor weights were measured.  
5.2.11  In vivo toxicity 
Mice were given every other day IV injections, total 4 injections. Two days after the last 
injection, blood was drawn from the venous plexus of the eyes of the mice. Blood 
samples were immediately centrifuged at 3,000 g for 5 min at 4°C, and the supernatant 
blood serums were collected for hematological analysis. BUN, creatinine, AST, ALT 
values were recorded, as indications of hepatic and renal functions.  
5.2.12 Statistical analysis 
Results were expressed as a mean ± standard deviation (SD). Student t-tests were used to 
evaluate statistical significance. A result of p<0.05 was considered to be statistically 
significant. 
5.3 RESULTS 
5.3.1 Characterization of drug-loaded LCPs 
The Transmission electron microscope (TEM) photographs showed that all drug-loaded 
LCP-AAs had a spherical shape and were monodispersed, with a particle size of around 
30 nm (Fig 5.2). The relatively small size of LCPs renders them better tumor penetration 
capability over large size nanoparticles.
227
 The encapsulation efficiency (EE%) of c-Myc 
siRNA and GMP in LCP-AA was around 55% and 75%, respectively. The EE% of c-
Myc siRNA and GMP in co-formulated LCP-AA was almost the same as that of the 
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cMyc-LCP-AA or GMP-LCP-AA single formulation, which indicates that c-Myc siRNA 
and GMP did not interfere with each other in the process of co-precipitation with calcium 
ions within the LCP core.  
 
Figure 5.2 TEM pictures of (GMP+cMyc)-LCPs. Scale bar = 100 nm. 
5.3.2 Drug-loaded LCPs induced VEGF down-regulation and apoptosis in vivo  
Human NSCLC H460 tumor bearing mice were given three daily IV injections of 
different LCP formulations with a dose of 25.2 µmol/Kg GMP (9.3 mg/Kg GMP, or 6.6 
mg/Kg in terms of Gem) and/or 0.2 mg/Kg c-Myc siRNA. Twenty-four h after the third 
injection, mice were sacrificed and tumor lysates were prepared for western blot. PARP is 
a nuclear protein that performs central roles in the repair of damaged DNA. Cleavage of 
PARP by caspases is considered to be a hallmark of apoptosis.
228
 As shown in Fig 5.3, 
(GMP+cMyc)-LCP-AA showed significant knockdown of the c-Myc oncogene, and 
stimulated the over-expression of cleaved PARP. GMP-LCP-AA also activated the 
cleaved PARP over-expression, but had only a minor effect on the c-Myc expression 
level. cMyc-LCP-AA clearly reduced the c-Myc expression, but had limited effect on 
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PARP cleavage. (GMP-LCP-AA) and (cMyc-LCP-AA) mixture showed partical 
downregulation of the c-Myc oncogene.  
 
Figure 5.3 Western blot analysis for VEGF and cleaved PARP expressions in 
vivo after systemic treatment of different LCP formulations on H460 subcutaneous 
xenograft model.  
5.3.3 Drug-loaded LCPs triggered caspase activation and tumor cell apoptosis in 
vivo 
Caspases are proteolytic enzymes and play an important role in apoptosis as effector 
molecules. Among the caspase enzymes, caspase-3 and caspase-7 are especially 
important, and they are responsible for the proteolytic cleavage of a large number of 
substrates during apoptosis.
229
 Twenty-four h after 3 daily IV injections, caspase-3/7 
activity in A549 lung orthotopic tumor nodules was increased significantly in mice 
injected with (GMP+cMyc)-LCP-AA. The GMP-LCP-AA and cMyc-LCP-AA partically 
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increased the caspase activity (Fig 5.4A). (CMP+Con)-LCP-AA and free GMP displayed 
little caspases elevation (Fig 5.4A).  
We also measured the apoptotic induction in A549 lung orthotopic tumor nodules using 
the TdT-mediated dUTP Nick-End Labeling (TUNEL) assay. Twenty-four h after 3 daily 
IV injections, (GMP+cMyc)-LCP-AA triggered a dramatic killing effect, inducing more 
than 40% apoptotic cells in tumors. GMP-LCP-AA and VEGF-LCP-AA led to about 
10% apoptotic tumor cells. (CMP+Con)-LCP-AA and free GMP did not elicit tumor cell 
apoptosis (Fig 5.4B). The tumor cell apoptotic induction of (GMP+cMyc)-LCP-AA was 
significantly higher than GMP-LCP-AA and VEGF-LCP-AA, indicating a profound 
therapeutic effect of the combined LCP.  
A 
 
 
The figure legend of Figure 5.4A is on the next page. 
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Figure 5.4 The caspase activation and induction of apoptosis after the 
systemic administration of different LCPs in A549 lung orthotopic xenografts (n=4). 
(A) In vivo caspase-3/7 activity in tumors. **p<0.01, *p<0.05. (B) In vivo tumor 
apoptosis by TUNEL assay. (C) The percentage (%) of apoptotic cells in the TUNEL 
assay. **p<0.00001 vs. control, *p<0.0001.  
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5.3.4 Drug-loaded LCPs inhibited tumor cell proliferation in vivo 
The A549 lung orthotopic tumor-bearing mice were given three daily IV injections of 
different LCP formulations. One day after the final injection, the mice were sacrificed 
and the tumor nodules were sectioned for PCNA immunohistochemistry. PCNA is 
expressed in the cell nuclei during DNA synthesis and can be used as a marker for cell 
proliferation. As shown in Fig 5.5, (GMP+cMyc)-LCP-AA significantly decreased the 
number of PCNA positive cells. cMyc-LCP-AA and GMP-LCP-AA also caused 
reductions in the proliferation of tumor cells, but not as potent as the combined therapy. 
(CMP+Con)-LCP-AA and free GMP showed little anti-proliferative effect.  
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Figure 5.5 Tumor cell proliferation after the systemic administration of 
different LCPs in A549 lung orthotopic xenografts. cMyc-LCP-AA, GMP-LCP-AA, 
(GMP+cMyc)-LCP-AA, (CMP+Con)-LCP-AA and free GMP were administered 
intravenously over consecutive three days (n=4). One day after the last injection, mice 
were sacrificed and tumor nodules were sectioned for (A) PCNA immunohistochemistry 
in A549 lung orthotopic tumor nodules. (B) Statistics of the PCNA 
immunohistochemistry in A549 orthotopic xenografts: **p<0.0001 vs. control, *p<0.01.  
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5.3.5 Tumor growth inhibition  
Due to the heterogeneity of tumor formation in the orthotopic model, the tumor growth 
inhibition was evaluated in nude mice bearing H460 subcutaneous tumors. Mice were 
treated every other day for a total of 4 IV injections with a dose of 25.2 µmol/Kg GMP 
and/or 0.2 mg/Kg c-Myc siRNA. As shown in Fig 5.6, (GMP+cMyc)-LCP-AA exhibited 
the most effective tumor growth inhibition; growth was almost completely arrested 
during the combined therapeutic regimen. GMP-LCP-AA, cMyc-LCP-AA and each 
particle mixture also suppressed tumor growth effectively, but not as potently as the 
combined nanoparticle treatment. The (CMP+Con)-LCP-AA had little effect on tumor 
growth inhibition compared to the control. There were no body weight changes among 
different treatment groups. At the treatment end point, the tumor weights in combined 
treatment group were much lower than other groups.  
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Figure 5.6 Tumor growth inhibition after systemic treatment of different 
LCPs. (A) Tumor growth inhibition on H460 xenografts. *p<0.0005 vs. Untreated. 
**p<0.00001 vs. Untreated. ‡p<0.05. (B) The relative body weight changes of H460 
xenografts. Data are mean ± S.D. (n=5). (C) The tumor weights in different treatment 
groups at the end time point. *p<0.005, **p<0.001, ‡p<0.05, ***p<0.01. 
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5.3.6 In vivo toxicity  
To test whether GMP and c-Myc siRNA loaded LCPs would induce in vivo toxicity, 
especially hepatic and renal dysfunction after long term treatment, blood samples were 
obtained for hematological analysis. Long term treatmet was characterized as every other 
day IV injections, total 4 injections, and the blood was drawn two days after the last 
injection from the venous plexus of the eyes of the mice. As shown in Table 5.1, There 
was little elevation of BUN, creatinine and liver enzymes (AST, ALT) in blood serum 
compared to the control, and all parameter values were in the normal range. Thus, GTP-
loaded LCPs, at the therapeutic dose, did not elicit any toxicity in kidney and liver and 
there were no significant safety issues.  
Table 5.1 Serum levels of BUN, creatinine, AST, ALT after long term 
treatment (n=4). Balb/c mice were given every other day IV injections, total 4 injections. 
Two days after the final injection, blood serum were collected for hematological analysis. 
Data are shown as mean ± SD. 
 
5.4 DISCUSSION 
There are now a number of active chemotherapeutic regimens developed for NSCLC, 
including gemcitabine based regimens, these chemotherapeutic treatments provide only 
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modest extensions of life and do not provide curative treatment.  The advent of RNA 
interference has significantly enhanced the possibility of therapeutic intervention for 
cancer. In recent years, significant efforts have been made to identify agents (small 
molecules or biological such as antibodies and small interfering RNA (siRNA)) that 
selectively target cancer cells and/or genes that are expressed mainly in cancer-associated 
pathways. However, some of these targets are pleiotropic or lack an active drug-binding 
site, rendering them “undruggable” (or, at least, have not been successful exploited from 
a pharmaceutical perspective). These targets include cancer-associated protein such as 
transcription factors, which are attractive alternative therapeutic targets. Specifically, 
selective oncogene silencing via siRNA has shown great promise for cancer therapy as 
these have been shown to inhibit the mRNA synthesis that can lead to down-regulation of 
the associated protein
244
. Moreover, such nucleic acid sequences can potentially be 
combined with chemotherapeutics in the same delivery vehicle to strategically disrupt 
tumor progression at protein synthesis level (siRNA) and the at DNA synthesis level 
(chemotherapeutics), which makes the nanoparticle-based co-delivery an efficient 
therapeutic tool for cancer treatment in coordinated fashion, by simultaneously targeting 
unique points in the cancer –signaling cascade. 
Despite being one of the earliest oncogenes identified, the c-Myc transcription factor 
remains “undruggable” by small molecules and/or antibodies. The c-Myc oncogene is 
overexpressed in numerous tumors, such as, lung, breast, pancreatic, gallbladder and 
colon carcinomas, where its downstream target genes promote cell growth, proliferation, 
invasion, expansion and angiogenesis
242, 243, 245
. c-Myc remains a challenging anti-tumor 
drug target for a variety of reasons. The basic helix-loop-helix structure of its 
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transcription factor protein does not possess drug-accessible domains. Also, as with other 
transcription factors, c-Myc carries out a multitude of physiological functions and its 
prolonged down-regulation can adversely affect healthy cells
246
. Nevertheless, c-Myc 
represents a promising target for siRNA-mediated protein down-regulation; several 
reports demonstrate the feasibility of this approach for tumor growth inhibition in 
multiple cancer models
247, 248
.  
While targeted molecular therapy is attractive, there are still many lung cancer patients 
without precise determination of the molecular mutation(s) involved. Gemcitabine 
(Gemzar®) is a commonly used chemotherapeutic drug, especially for non-small cell 
lung carcinoma. It is a nucleoside analog of cytosine transported into mammalian cells 
via the nucleoside transporter and phosphorylated into mono-, di- and tri-nucleotides 
inside the cells. Gemcitabine triphosphate then enters the nucleus to be incorporated into 
cellular DNA during the S phase of the cell cycle and blocks the cell cycle. Thus, 
Gemcitabine is actually a prodrug which requires further cellular metabolism for its 
activity. Furthermore, pharmacokinetics of gemcitabine indicates that it is rapidly 
deaminated in the blood to become inactive difluorouridine and cleared from the blood by 
renal excretion
249
. The amount of intact drug taken up by the tumor is estimated to be less 
than 10%. Nucleotides, such as gemcitabine monophosphate (GMP) are not transported 
by the nucleoside transporter which presents a significant barrier to their use as a drug. 
Using a drug carrier to protect and to bring more gemcitabine to the tumor is an excellent 
strategy to enhance the efficacy and to reduce the toxicity of the drug. 
Thus, taken together, we choose to use c-Myc siRNA as a viable and sound 
“undruggable” candidate, as being the one combination partner to the conventional 
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chemotherapeutic agent gemcitabine derivatives. The combinational therapeutic agents 
were co-delivered via a “smart” LCP nanovector. 
Co-delivery of c-myc siRNA and GMP will obstruct tumor cell progression through two 
independent pathways; one that alters the physiological microenvironment of the tumor 
(c-Myc siRNA), and another that inhibits cell cycle progression through the intracellular 
delivery of GMP.  c-Myc siRNA and GMP can be co-entrapped in ligand targeted LCP 
nanoparticles, delivered and cross the lung tumor cell membrane in vivo through receptor-
mediated up-take, and get released through the acidic pH of the endosome into the 
cytoplasm. Once released in the cytoplasm, c-Myc siRNA can enter the RNA interference 
pathway that guides the sequence-specific mRNA degradation leading to down regulation 
of the c-Myc protein. Simultaneously the nucleotide analog GMP is delivered from the 
cytoplasm to the nucleus of the lung cancer cells where it can induce cellular apoptosis 
through its incorporation into the DNA transcription mechanism. Together, the 
development of a single nanoparticle formulation with multifunctional anti-cancer 
activity will overcome their individual innate limitations; delivery, release, and 
resistance. Additionally co-delivery will expand the potential of each mono-therapeutic 
treatment and facilitate superior efficacy. 
The LCP nanoparticle is composed of a biocompatible and biodegradable amorphous CaP 
precipitation core, which can encapsulate siRNA, plasmid DNA and phosphorylated 
chemodrugs with high affinity.  Moreover, CaP rapidly dissolves at the acidic pH of the 
endosome, increasing endosomal osmotic pressure and releasing the particle cargo into 
the cytoplasm. In LCP, the CaP core is stabilized with dioleoylphoshatic acid (DOPA), a 
phospholipid and further coated with cationic lipid to form an outer-lipid membrane. The 
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resulting NPs possess a spherical hollow core structure with an asymmetric lipid bilayer 
at the surface that can be modified with a polyethylene glycol (PEG)-phospholipid 
conjugate to shield the cationic charge of the lipid bilayer.  Additionally, the NP can be 
augmented with PEGylated targeting ligand, such as PEG-Anisamide which allows for 
more efficient cargo delivery to tumor cells, a prolonged NP circulation time and less 
reticuloendothelial/mononuclear phagocyte system uptake.  
6.0  SUMMARY 
6.1 SUMMARY OF RESEARCH RESULTS  
In this study, our objective was to enhance the activity and expand the therapeutic 
applications of LCP nanoparticles for cancer therapy, aiming for the systemic delivery of 
chemotherapeutics and siRNAs. First, phosphorylated nucleoside or nucleotide analogues 
(i.e. gemcitabine triphosphate (GTP), gemcitabine monophosphate (GMP)) loaded LCP 
nanoparticles were constructed. Our studies demonstrate that LCP can significantly 
improve the in vivo delivery efficiency of GTP and GMP in mice, as evidenced by its 
superior ability relative to gemcitabine to induce tumor cell apoptosis and suppress tumor 
cell proliferation in vivo. Dramatic tumor growth inhibitions were abserved after long 
term treatment, and there were no safety issues raised at the therapeutic dose.  
To further improve the therapeutic efficacy, especially for the refractory human NSCLC, 
we combine angiogenesis therapy together with chemotherapy, by co-delivering GMP 
and VEGF siRNA in a single LCP nanoparticle to eventually eradicate the tumor 
progression in mice. The improved therapeutic response, as compared to either VEGF 
siRNA or GMP therapy alone, was supported by the observation of effective induction of 
tumor cell apoptosis, significant reduction of tumor cell proliferation and tumor 
microvessel density. The combination therapy led to dramatic inhibition of tumor growth, 
with little in vivo toxicity. In the H460 xenograft mouse model, the tumor growth
 was almost completely arrested by the combined LCP. Chemotherapy alone (GMP-LCP) 
also suppressed the tumor growth effectively, but not as potent as the combined 
nanoparticle. Anti-angiogenesis monotherapy (VEGF-LCP) stabilized the tumor growth 
at early stage, but was associated with the tumor progression at later stages, which 
indicated VEGF-LCP alone was not sufficient to obtain long term tumor suppression.   
RNAi provides an alternative approach to knockdown oncogenes, especially some 
undruggable targets, such as c-Myc. The studies conducted herein have validated the 
anticancer potency of GMP. In this study, we co-encapsulate c-Myc siRNA together with 
GMP in a sigle LCP nanoparticle. Our results suggested that LCP co-encapsulating both 
c-Myc siRNA and GMP was more effective than LCP loading each agent individually, in 
terms of apoptosis induction and proliferation inhibition, in both NSCLC subcutaneous 
and orthotropic xenograft models. 
The current studies demonstrated the possibility of incorporating multiple nucleic acid 
molecules and phosphorylated small molecule drugs into a single nanoparticle 
formulation, which leads to superior therapeutic improvement in many human diseases 
(e.g. various animal cancer models), and to modulate multiple therapeutic pathways 
simultaneously. 
Combination therapy is becoming increasingly important in cancer treatment regimen for 
providing long-term effectiveness and prognosis, as well as decreasing side effects.
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Choosing an appropriate target is essential for gene therapy. In this thesis, VEGF siRNA 
and c-Myc siRNA were chosen as therapeutic partners to chemotherapy. VEGF is a key 
regulator of angiogenesis. VEGF overexpression induces microvascular proliferation 
 151 
within the tumor by the VEGF/VEGFR interactions and the following signaling cascades, 
promoting cancer malignancy.VEGF siRNA would kill cancer cells indirectly by 
damaging tumor endothelial cells via VEGF down-regulation, thus, deprived tumors of 
nutrients. NSCLC shows increased levels of c-Myc oncogene which is considered as an 
“undruggable” target, correlating with a poor prognosis for patients. c-Myc is an 
oncogenic transcription factor. Mutated and highly amplified c-Myc leads to the 
disregulation of cell proliferation, differentiation, cell cycle, cellular metabolism and 
genomic stability, resulting in the formation of cancer. c-Myc overexpression can also 
induce DNA damage and compromise the damaging-sensing mechanism of cells.
251
 Since 
down-regulation of c-Myc shows some similar effects as GMP chemotherapy, in order to 
achieve synergistic efficacy and decrease potential toxicity, the dose of GMP in 
(GMP+cMyc)-LCP-AA was reduced to half compared to that of (GMP+VEGF)-LCP-
AA. We need further validation to compare which siRNA serves as a better partner with 
GMP in terms of the anti-tumor efficacy of the combined treatment. 
The advantage of multidrug-containing nanoparticles investigated in this study relative to 
co-administration of multiple different single drug-containing vehicles is that they can 
offer the unique features of vehicle uniformity, ratiometric drug loading and temporal 
drug release, as well as their ability to unify the pharmacokinetics of different drugs by 
simultaneously delivering multiple therapeutic agents to the target site, leading to 
profound therapeutic effects.
6.2 FUTURE DIRECTIONS 
We will further optimize the ratiometric drug loading, including the total drug loading and 
the loading ratio of each indivual agent (i.e. optimal combination ratio of gene and chemo 
therapeutics). The LCP nanoplatform has wide application and can allow various therapeutic 
combinations, including gene therapy (i.e. siRNA, pDNA, mRNA), chemotherapy (i.e. 
phosphorylated nucleosides, antiviral drugs), immunotherapy (i.e. phosphor-modified antigen 
peptide), and their combinations.  
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